Requester

Name: KWON, BRIAN-YONG S <http://es.uspto.gov/emlocator/runEmployeeQry.do?action=ListEmployeeByEmpNo&empNo=
Organization: TC 1600
Art Unit: 1614
Employee Number:
Office Location: REM-3D05
Phone Number: (571)272-0581
Email: brian-yong.kwon@uspto.gov <mailto:brian-yong.kwon@uspto.gov?Subject=1600 Search Request>

Request Detail

Attachment: 10586822.doc <file://\\Nsx-orgshares\PatentsSTIC\Attachments\10586822.doc>

Case/Application number: 10/586822 PALM <http://expoweb1:8001/cgi-bin/expo/GenInfo/snquery.pl?APPL_ID=10/586822>
Priority App. Filing Date: 02/03/2004
Format for Search Results: EMAIL

Identify the novelty:
Claims 37-46, drawn to a method of ehancing bioavailability of drug by coadministering a compoun of the formula in claim 37. Broadly as use of a compound in claim 37 in combination with other drug, namely antitumor or anticancer or chemotherapeutic agent.

INVENTOR SEARCH

```
=> fil hcapl; d que nos l24
FILE 'HCAPLUS' ENTERED AT 16:49:30 ON 29 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 Jan 2010  VOL 152 ISS 6
FILE LAST UPDATED: 28 Jan 2010  (20100128/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Oct 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE


L2              STR
L4          3009 SEA FILE=REGISTRY SSS FUL L2
L5          9000 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L4
L6             1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  US2006-586822/AP
L7         11455 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CHENG Y?/AU
L8         36775 SEA FILE=HCAPLUS SPE=ON  ABB=ON  LEE Y?/AU
L9           285 SEA FILE=HCAPLUS SPE=ON  ABB=ON  YEO H?/AU
L10        28697 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG BIOAVAILABILITY/CT
L11       342049 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG DELIVERY SYSTEMS+NT,OLD/C
                 T
L12       495141 SEA FILE=HCAPLUS SPE=ON  ABB=ON  ANTITUMOR AGENTS+NT,OLD,RTCS/C
                 T
L13        50670 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG INTERACTIONS+OLD/CT
L14        11152 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMB?/OBI(L)PHARMAC?/OBI
L15        45792 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMBINATION CHEMOTHERAPY/CT
L16        12971 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CODRUG#/OBI OR COADMIN?/OBI
                 OR CONCOMITANT?/OBI OR CONCURRENT?/OBI
L17         1784 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CO/OBI(W)(DRUG#/OBI OR
                 ADMIN?/OBI)
L18       203485 SEA FILE=HCAPLUS SPE=ON  ABB=ON  BLEND?/OBI
L19       462118 SEA FILE=HCAPLUS SPE=ON  ABB=ON  MIXTURE#/OBI
L22            3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L7 AND L8 AND L9
L23            7 SEA FILE=HCAPLUS SPE=ON  ABB=ON  ((L7 OR L8 OR L9) AND L5 AND
                 L12 AND (L10 OR L11 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18
```

OR L19)) OR (((L7 AND (L8 OR L9)) OR (L8 AND L9)) AND L5 AND (L10 OR L11 OR L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19))
L24 8 SEA FILE=HCAPLUS SPE=ON ABB=ON (L6 OR L22 OR L23)

=> d ibib abs hitind hitstr l24 1-8

L24 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:639045 HCAPLUS Full-text
DOCUMENT NUMBER: 151:41991
TITLE: α- and β-baicalein crystals and preparation and pharmaceutical composition and application thereof
INVENTOR(S): Du, Guanhua; Lu, Yang; Chang, Ying; Cheng, Yinxia; He, Guorong; Pei, Lixia
PATENT ASSIGNEE(S): Institute of Materia Medica, Chinese Academy of Medical Sciences, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 26pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101434593	A	20090520	CN 2007-10177330	20071114

PRIORITY APPLN. INFO.: CN 2007-10177330 20071114

AB The invention provides X-diffraction characteristics, DSC profile, IR absorption spectrum and m.p. of α-baicalein crystal and β-baicalein crystal. α-baicalein crystal can be prepared by dissolving baicalein in single or mixed solvent system(chloroform, acetonitrile, THF, dioxane, glacial acetic acid, formic acid, dichloromethane, toluene, benzene, n-hexane, DMF, ammonia, water, etc.), recrystg. at 4-250 and relative humidity of <90% for 1-60 days to obtain α-baicalein crystals.β-baicalein crystal can be prepared by solid grinding, pressurizing and heating α-baicalein crystals; or dissolving baicalein in solvent(chloroform, acetonitrile, THF, dioxane, formic acid, Et ether, toluene, benzene, ethanol, isopropanol, acetone, DMF, water, etc.), cold spraying to obtain β-baicalein crystals. The invention also relates to pharmaceutical composition in forms of tablet, capsule, pill, injection, slow-release preparation, controlled-release preparation, which contains α-baicalein and/or β-baicalein, flavone, Chinese herbal medicine and pharmaceutically acceptable carrier. The invention further relates to application of α and/or β-baicalein crystals in preventing/treating nervous system diseases(senile dementia, Parkinson's disease), cardiovascular and cerebrovascular diseases, inflammation, immune system disease, metabolic disease(diabetes mellitus), senile disease, bacterial and viral infections, etc.

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT Anti-inflammatory agents
Antidiabetic agents
Antiparkinsonian agents
Antiviral agents
Cardiovascular disease
Cerebrovascular disease
Controlled-release drug delivery systems
Diabetes mellitus
Immune disease

Inflammation
Natural products, pharmaceutical
Parkinson disease
Pharmaceutical capsules
Pharmaceutical injections
Pharmaceutical tablets
Viral infection
(α- and β-baicalein crystals and preparation and pharmaceutical composition and application thereof)

IT 491-67-8DP, Baicalein, α-and β- crystals
RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(α- and β-baicalein crystals and preparation and pharmaceutical composition and application thereof)

IT 491-67-8DP, Baicalein, α-and β- crystals
RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(α- and β-baicalein crystals and preparation and pharmaceutical composition and application thereof)

RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



L24 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1136053 HCAPLUS Full-text
DOCUMENT NUMBER: 149:524563
TITLE: Impacts of baicalein analogs with modification of the 6th position of A ring on the activity toward NF-κB-, AP-1-, or CREB-mediated transcription
AUTHOR(S): Huang, Sheng-Teng; Lee, Yashang; Gullen, Elizabeth A.; Cheng, Yung-Chi
CORPORATE SOURCE: Department of Pharmacology, Yale University School of Medicine, New Haven, CT, 06510, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2008), 18(18), 5046-5049
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The water extract of Scutellaria baicalensis Georgi (S. baicalensis) has potential anti-tumor and anti-inflammatory activities. A major flavonoid isolated from S. baicalensis, baicalein, was also found to have anti-tumor and anti-inflammatory activities. These biol. activities could be due to their antioxidant action and/or effect on different signal transduction pathways. We investigated the effects of several baicalein analogs with a substitution of hydrogen of the hydroxyl group at the 6th position of A ring on three signal pathway mediated transcription (NF-κB, AP-1, and CREB) associated with inflammation and cancer growth. We found that the analogs with O-alkyl group

of the different carbon chain length or O-benzyl activated NF-κB transcription without TNFα stimulation. Some of the analogs increased TNFα stimulated NF-κB transcription by two- to threefold. None of the analogs studied has major effect on AP-1 signal transduction with or without TPA stimulation. All of the analogs increased CREB transcription with forskolin stimulation up to twofold. However, they did not have a potent effect (less or about twofold activation) on intrinsic CREB signal transduction. The modification of baicalein at the 6th position of A ring was not correlated with change in these signal transduction pathways and cytotoxicity. Though, they are structural analogs, they are not functional analogs. Modification of baicalein at the 6th position could alter the specificity of action toward different cellular targets. Flavonoids could be chemophores in the development of drugs targeted at different signal transcriptional pathway.

CC 1-3 (Pharmacology)

IT Anti-inflammatory agents
Antioxidants
Antitumor agents
Inflammation
Neoplasm
Scutellaria baicalensis
Structure-activity relationship
Transcriptional regulation
(impacts of baicalein analogs with modification of 6th position of A ring on activity toward NF-κB-, AP-1-, or CREB-mediated transcription)

IT 480-11-5 491-67-8 199446-40-7
792923-60-5 792923-65-0 792923-71-8
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(impacts of baicalein analogs with modification of 6th position of A ring on activity toward NF-κB-, AP-1-, or CREB-mediated transcription)

IT 480-11-5 491-67-8 199446-40-7
792923-60-5 792923-65-0 792923-71-8
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(impacts of baicalein analogs with modification of 6th position of A ring on activity toward NF-κB-, AP-1-, or CREB-mediated transcription)

RN 480-11-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-6-methoxy-2-phenyl- (CA INDEX NAME)



RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 199446-40-7 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-6-(phenylmethoxy)- (CA INDEX NAME)



RN 792923-60-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6-(acetyloxy)-5,7-dihydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-65-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-6-propoxy- (CA INDEX NAME)



RN 792923-71-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6-ethoxy-5,7-dihydroxy-2-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:115182 HCAPLUS Full-text
DOCUMENT NUMBER: 148:347386
TITLE: Therapeutic agent comprising baicalein for treating drug abuse
INVENTOR(S): Choi, Gi Hwan; Yoon, Jae Seok; Lee, Yun Hui; Kim, Ju Il; Cho, Dae Hyeon; Oh, Se Gwan; Jung, Su Yeon; Choi, Su Yeong

PATENT ASSIGNEE(S): Korea Food & Drug Administration, S. Korea; Republic of Korea
SOURCE: Repub. Korean Kongkae Taeho Kongbo, 7 pp.
CODEN: KRXXA7
DOCUMENT TYPE: Patent
LANGUAGE: Korean
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2008002374	A	20080104	KR 2006-61176	20060630
KR 804312	B1	20080218		

PRIORITY APPLN. INFO.: KR 2006-61176 20060630

AB The title therapeutic agent comprises baicalein as an active ingredient and pharmaceutically acceptable carriers. The therapeutic agent can inhibit drug dependence resulted from narcotic analgesics or analgesics. The therapeutic agent can be used for treating drug abuse.

CC 1-12 (Pharmacology)
Section cross-reference(s): 63
IT Analgesics
Drug delivery systems
Drug dependence
Narcotics
Substance abuse
(therapeutic agent comprising baicalein for treating drug abuse)
IT 491-67-8, Baicalein
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic agent comprising baicalein for treating drug abuse)
IT 491-67-8, Baicalein
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic agent comprising baicalein for treating drug abuse)
RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



L24 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1367697 HCAPLUS Full-text
DOCUMENT NUMBER: 148:151620
TITLE: Liquid chromatography/mass spectrometry analysis of PHY906, a Chinese medicine formulation for cancer therapy
AUTHOR(S): Ye, Min; Liu, Shwu-Huey; Jiang, Zaoli; Lee, Yashang; Tilton, Robert; Cheng, Yung-Chi
CORPORATE SOURCE: Department of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA
SOURCE: Rapid Communications in Mass Spectrometry (2007), 21(22), 3593-3607
CODEN: RCMSEF; ISSN: 0951-4198
PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal
LANGUAGE: English

AB PHY906 is a Chinese medicine formulation prepared from four medicinal herbs for adjuvant cancer chemotherapy. In this paper, liquid chromatog./electrospray ionization time-of-flight mass spectrometry (LC/ESI-TOFMS) was used to clarify the chemical composition of PHY906. The aqueous extract of PHY906 was separated on a Waters Atlantis C18 column, and was eluted with acetonitrile/0.05% (volume/volume) formic acid. The separated compds. were identified with pure stds., or tentatively characterized by analyzing their mass spectra recorded in both neg. and pos. ion polarity modes. Further structural information was obtained from in-source fragmentation. Based on the LC/MS anal., we proposed the structures for 64 bioactive compds., including flavonoids, triterpene saponins, and monoterpene glycosides. All the compds. identified from PHY906 were further assigned in the four individual herbs, and some of them are reported for the first time.

CC 63-4 (Pharmaceuticals)

IT 149-91-7P, Gallic acid, biological studies 153-18-4P, Rutin 480-11-5P, Oroxylin 480-40-0P, Chrysin 491-67-8P, Baicalein 520-36-5P, Apigenin 529-53-3P, Scutellarein 551-15-5P, Liquiritin 578-86-9P, Liquiritigenin 632-85-9P, Wogonin 1405-86-3P, Glycyrrhizic acid 5041-81-6P, Isoliquiritin 21967-41-9P, Baicalin 23180-57-6P, Paeoniflorin 27740-01-8P, Scutellarin 39011-90-0P, Albiflorin 51059-44-0P, Wogonoside 61276-17-3P, Acteoside 92519-91-0P, Viscidulin III 118325-22-7P, Licorice saponin A3 118441-84-2P, Licorice saponin G2 118441-85-3P, Licorice saponin H2 118525-49-8P, Licorice saponin C2 118536-86-0P, Licorice saponin B2 119417-96-8P, Licorice saponin E2 135815-61-1P, Licoricesaponin K2 172428-47-6P, Viscidulin I 2'-O-glucoside 938042-18-3P, Licoricesaponin J2 1001433-83-5P, Paeoniflorin sulfate
RL: NPO (Natural product occurrence); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(liquid chromatog./mass spectrometry anal. of PHY906 and Chinese medicine formulation for cancer therapy)

IT 480-11-5P, Oroxylin 491-67-8P, Baicalein 529-53-3P, Scutellarein 21967-41-9P, Baicalin 27740-01-8P, Scutellarin
RL: NPO (Natural product occurrence); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(liquid chromatog./mass spectrometry anal. of PHY906 and Chinese medicine formulation for cancer therapy)

RN 480-11-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-6-methoxy-2-phenyl- (CA INDEX NAME)



RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 529-53-3 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 21967-41-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 27740-01-8 HCAPLUS
CN β-D-Glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L24 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:1298715 HCAPLUS Full-text
DOCUMENT NUMBER: 146:149236
TITLE: Simultaneous determination of eight active components

in Chinese medicine 'yiqing' capsule using high-performance liquid chromatography

AUTHOR(S): Qu, Haibin; Ma, Yanhong; Yu, Ke; Cheng, Yiyu
CORPORATE SOURCE: Department of Chinese Medicine Science and Engineering, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310027, Peop. Rep. China

SOURCE: Journal of Pharmaceutical and Biomedical Analysis (2007), 43(1), 66-72
CODEN: JPBADA; ISSN: 0731-7085
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB An effective, accurate and reliable method for the simultaneous separation and determination of eight active components (berberine, aloe-emodin, rhein, emodin, chrysophanol, baicalin, baicalein and wogonin) in Chinese medicine 'yiqing' capsule was developed using reverse phase high-performance liquid chromatog. coupled with diode array detection. The chromatog. separation was performed on a Lichrospher C18 column (250 mm + 4.6 mm i.d. with 5.0 μm particle size) with a simple linear gradient elution program. Due to the different UV characteristic of these components, three detection wavelengths were utilized for the quant. anal. (UV wavelength 254 nm for anthraquinone derivs., 278 nm for flavones compds., and 345 nm for protoberberine alkaloids, resp.). Excellent linear behaviors over the investigated concentration ranges were observed with the values of R 2 higher than 0.99 for all the analytes. The recoveries, measured at three concentration levels, varied from 94.9% to 105.3%. The validated method was successfully applied to the simultaneously determination of these active components in 'yiqing' capsules from different production batches.

CC 64-2 (Pharmaceutical Analysis)
Section cross-reference(s): 63

IT Pharmaceutical capsules
Quality control
Reversed phase HPLC
(eight active components simultaneous determination in Chinese medicine yiqing capsule using high-performance liquid chromatog.)

IT 478-43-3, Rhein 481-72-1, Aloe-emodin 481-74-3, Chrysophanol 491-67-8, Baicalein 518-82-1, Emodin 632-85-9, Wogonin 2086-83-1, Berberine 21967-41-9, Baicalin
RL: ANT (Analyte); NPO (Natural product occurrence); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(eight active components simultaneous determination in Chinese medicine yiqing capsule using high-performance liquid chromatog.)

IT 491-67-8, Baicalein 21967-41-9, Baicalin
RL: ANT (Analyte); NPO (Natural product occurrence); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(eight active components simultaneous determination in Chinese medicine yiqing capsule using high-performance liquid chromatog.)

RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 21967-41-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid,
5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:823682 HCAPLUS Full-text
DOCUMENT NUMBER: 143:211769
TITLE: Preparation of A ring alkylated baicalein analogs with anti-P-glycoprotein activity
INVENTOR(S): Cheng, Yung-Chi; Lee, Yashang; Yeo, Hosup
PATENT ASSIGNEE(S): Yale University, USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005075449	A1	20050818	WO 2005-US2910		20050131
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20070161605	A1	20070712	US 2006-586822		20061013 <--
PRIORITY APPLN. INFO.:			US 2004-541443P	P	20040203
			WO 2005-US2910	W	20050131

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:211769; MARPAT 143:211769
GI



I



II

AB Baicalein analogs of formula I [R1 = H, (substituted) Ph, benzyl, acyl, alkyl, etc.; R2, R3 = H, alkyl, acyl, etc.; R2R3 = (substituted) CH2; R4 = H, OH, acyloxy, alkyl, alkoxy, halo] are prepared which exhibit anti-P-glycoprotein activity. The compds. have enhanced bioavailability by oral administration, and inhibit P-glycoprotein 170 (P-gp 170) and/or CYP450 enzyme, especially CYP450 3A4 enzyme. Pharmaceutical compns. containing I are described. Thus, II was prepared from baicalein and benzyl bromide, and had EC50 value of 1.8 μM against human P-gp 170.

IC ICM C07D311-32
ICS A61K031-352

CC 26-4 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1, 63

IT Drug delivery systems
(oral; preparation of baicalein A ring analogs with anti-P-glycoprotein activity)

IT Antitumor agents
Combination chemotherapy
Drug bioavailability
Human
Neoplasm
(preparation of baicalein A ring analogs with anti-P-glycoprotein activity)

IT 50-07-7, Mitomycin C 50-18-0, Cytoxan
50-76-0, Actinomycin D 53-79-2, Puromycin 57-22-7,
Vincristine 64-86-8, Colchicine 127-07-1, Hydroxyurea
147-94-4, Ara C 483-18-1, Emetine 865-21-4,
Vinblastine 1393-88-0, Gramicidin D 2001-95-8, Valinomycin
7689-03-4, Camptothecin 15663-27-1, cis-Platin
18378-89-7, Mithramycin 20830-81-3, Daunorubicin
23214-92-8, Doxorubicin 23491-52-3, Hoechst 33342
25316-40-9, Adriamycin 33069-62-4, Taxol
33419-42-0, Etoposide 58957-92-9, Idarubicin
62669-70-9, Rhodamine 123 65271-80-9, Mitoxantrone
95058-81-4, Gemcitabine 97682-44-5, Irinotecan
123948-87-8, Topotecan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug; preparation of baicalein A ring analogs with anti-P-glycoprotein activity)

IT 491-67-8, Baicalein
RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(preparation of baicalein A ring analogs with anti-P-glycoprotein activity)

IT 67047-05-6P 110204-45-0P 731817-58-6P

792923-60-5P 792923-65-0P 792923-66-1P
792923-71-8P 792923-72-9P 792923-75-2P
792923-80-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of baicalein A ring analogs with anti-P-glycoprotein activity)

IT 740-33-0P 973-67-1P 67047-06-7P
119120-32-0P 137527-39-0P 199446-40-7P
457601-61-5P 791838-63-6P 792923-61-6P
792923-62-7P 792923-63-8P 792923-64-9P
792923-67-2P 792923-68-3P 792923-69-4P
792923-70-7P 792923-73-0P 792923-74-1P
792923-76-3P 792923-77-4P 792923-78-5P
792923-79-6P 792923-81-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of baicalein A ring analogs with anti-P-glycoprotein activity)

IT 848820-28-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of baicalein A ring analogs with anti-P-glycoprotein activity)

IT 50-07-7, Mitomycin C 50-18-0, Cytoxan
50-76-0, Actinomycin D 57-22-7, Vincristine
127-07-1, Hydroxyurea 147-94-4, Ara C
865-21-4, Vinblastine 7689-03-4, Camptothecin
15663-27-1, cis-Platin 18378-89-7, Mithramycin
20830-81-3, Daunorubicin 23214-92-8, Doxorubicin
25316-40-9, Adriamycin 33069-62-4, Taxol
33419-42-0, Etoposide 58957-92-9, Idarubicin
65271-80-9, Mitoxantrone 95058-81-4, Gemcitabine
97682-44-5, Irinotecan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug; preparation of baicalein A ring analogs with anti-P-glycoprotein activity)

RN 50-07-7 HCAPLUS
CN Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 50-18-0 HCAPLUS
CN 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (CA INDEX NAME)



RN 50-76-0 HCAPLUS
CN Actinomycin D (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 57-22-7 HCAPLUS
CN Vincaleukoblastine, 22-oxo- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 127-07-1 HCAPLUS
CN Urea, N-hydroxy- (CA INDEX NAME)



RN 147-94-4 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-β-D-arabinofuranosyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 865-21-4 HCAPLUS
CN Vincaleukoblastine (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 7689-03-4 HCAPLUS
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,

4-ethyl-4-hydroxy-, (4S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 15663-27-1 HCAPLUS
CN Platinum, diamminedichloro-, (SP-4-2)- (CA INDEX NAME)



RN 18378-89-7 HCAPLUS
CN D-threo-2-Pentulose, 5-deoxy-1-C-[(2S,3S)-7-[[2,6-dideoxy-3-O-(2,6-dideoxy-β-D-arabino-hexopyranosyl)-β-D-arabino-hexopyranosyl]oxy]-3-[(O-2,6-dideoxy-3-C-methyl-β-D-ribo-hexopyranosyl-(1→3)-O-2,6-dideoxy-β-D-lyxo-hexopyranosyl-(1→3)-2,6-dideoxy-β-D-arabino-hexopyranosyl)oxy]-1,2,3,4-tetrahydro-5,10-dihydroxy-6-methyl-4-oxo-2-anthracenyl]-1-O-methyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 20830-81-3 HCAPLUS

CN 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 23214-92-8 HCAPLUS

CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 25316-40-9 HCAPLUS

CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, hydrochloride (1:1), (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 33069-62-4 HCAPLUS

CN Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 33419-42-0 HCAPLUS

CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4,6-O-(1R)-ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 58957-92-9 HCAPLUS

CN 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S,9S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 65271-80-9 HCAPLUS

CN 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]- (CA INDEX NAME)



RN 95058-81-4 HCAPLUS

CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 97682-44-5 HCAPLUS
CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 491-67-8, Baicalein
RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(preparation of baicalein A ring analogs with anti-P-glycoprotein activity)
RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



IT 67047-05-6P 110204-45-0P 731817-58-6P
792923-60-5P 792923-65-0P 792923-66-1P
792923-71-8P 792923-72-9P 792923-75-2P
792923-80-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of baicalein A ring analogs with anti-P-glycoprotein activity)
RN 67047-05-6 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-tris(acetyloxy)-2-phenyl- (CA INDEX NAME)



RN 110204-45-0 HCAPLUS
CN 8H-1,3-Dioxolo[4,5-g][1]benzopyran-8-one, 9-hydroxy-6-phenyl- (CA INDEX NAME)



RN 731817-58-6 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-bis(acetyloxy)-5-hydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-60-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6-(acetyloxy)-5,7-dihydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-65-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-6-propoxy- (CA INDEX NAME)



RN 792923-66-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-2-phenyl-6,7-dipropoxy- (CA INDEX NAME)



RN 792923-71-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6-ethoxy-5,7-dihydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-72-9 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-diethoxy-5-hydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-75-2 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-6,7-bis(pentyloxy)-2-phenyl- (CA INDEX NAME)



RN 792923-80-9 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-dibutoxy-5-hydroxy-2-phenyl- (CA INDEX NAME)



IT 740-33-0P 973-67-1P 67047-06-7P
119120-32-0P 137527-39-0P 199446-40-7P
457601-61-5P 791838-63-6P 792923-61-6P
792923-62-7P 792923-63-8P 792923-64-9P
792923-67-2P 792923-68-3P 792923-69-4P

792923-70-7P 792923-73-0P 792923-74-1P
792923-76-3P 792923-77-4P 792923-78-5P
792923-79-6P 792923-81-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of baicalein A ring analogs with anti-P-glycoprotein activity)

RN 740-33-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-6,7-dimethoxy-2-phenyl- (CA INDEX NAME)



RN 973-67-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trimethoxy-2-phenyl- (CA INDEX NAME)



RN 67047-06-7 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6-bis(acetyloxy)-2-phenyl-7-(phenylmethoxy)- (CA INDEX NAME)



RN 119120-32-0 HCAPLUS
CN 8H-1,3-Dioxolo[4,5-g][1]benzopyran-8-one, 9-methoxy-6-phenyl- (CA INDEX NAME)



RN 137527-39-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6-(acetyloxy)-5,7-dimethoxy-2-phenyl- (CA INDEX NAME)



RN 199446-40-7 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-6-(phenylmethoxy)- (CA INDEX NAME)



RN 457601-61-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-2-phenyl-6,7-bis(phenylmethoxy)- (CA INDEX NAME)



RN 791838-63-6 HCAPLUS
CN 4H-1-Benzopyran-4-one, 8-bromo-5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-61-6 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-bis(acetyloxy)-5-methoxy-2-phenyl- (CA INDEX NAME)



RN 792923-62-7 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-bis(acetyloxy)-2-phenyl-5-(phenylmethoxy)- (CA INDEX NAME)



RN 792923-63-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 7-(acetyloxy)-5-hydroxy-2-phenyl-6-(phenylmethoxy)- (CA INDEX NAME)



RN 792923-64-9 HCAPLUS
CN 8H-1,3-Dioxolo[4,5-g][1]benzopyran-8-one, 9-methoxy-2,2,6-triphenyl- (CA INDEX NAME)



RN 792923-67-2 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-7-methoxy-2-phenyl-6-propoxy- (CA INDEX NAME)



RN 792923-68-3 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dimethoxy-2-phenyl-6-propoxy- (CA INDEX NAME)



RN 792923-69-4 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-methoxy-2-phenyl-6,7-dipropoxy- (CA INDEX NAME)



RN 792923-70-7 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-bis(acetyloxy)-8-bromo-5-hydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-73-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-6,7-bis(octyloxy)-2-phenyl- (CA INDEX NAME)



RN 792923-74-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6-ethoxy-5-hydroxy-7-methoxy-2-phenyl- (CA INDEX NAME)



RN 792923-76-3 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-methoxy-6,7-bis(pentyloxy)-2-phenyl- (CA INDEX NAME)



RN 792923-77-4 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-bis(hexyloxy)-5-hydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-78-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-bis(hexyloxy)-5-methoxy-2-phenyl- (CA INDEX NAME)



RN 792923-79-6 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-diethoxy-5-methoxy-2-phenyl- (CA INDEX NAME)



RN 792923-81-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-dibutoxy-5-methoxy-2-phenyl- (CA INDEX NAME)



IT 848820-28-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of baicalein A ring analogs with anti-P-glycoprotein activity)
RN 848820-28-0 HCAPLUS
CN 8H-1,3-Dioxolo[4,5-g][1]benzopyran-8-one, 9-hydroxy-2,2,6-triphenyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:1141796 HCAPLUS Full-text
DOCUMENT NUMBER: 142:219077
TITLE: Synthesis and Antiviral Activity of Helioxanthin Analogues
AUTHOR(S): Yeo, Hosup; Li, Ying; Fu, Lei; Zhu, Ju-Liang; Gullen, Elizabeth A.; Dutschman, Ginger E.; Lee, Yashang; Chung, Raymond; Huang, Eng-Shang; Austin, David J.; Cheng, Yung-Chi
CORPORATE SOURCE: Department of Pharmacology, Yale University School of Medicine and Department of Chemistry, Yale University, New Haven, CT, 06520, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(2), 534-546
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:219077
GI



I



II

AB A series of natural product analogs based on helioxanthin, with particular attention to modification of the lactone ring and methylenedioxy group, were synthesized and evaluated for their antiviral activities. Among them, lactam derivative I and helioxanthin cyclic hydrazide II exhibited significant in vitro antiviral activity against hepatitis B virus (EC50 = 0.08 and 0.03 μM, resp.). Compound I showed the most potent antiviral activity against hepatitis C virus (55% inhibition at 1.0 μM). An acid-hydrolyzed product of helioxanthin cyclic imide derivative was found to exhibit broad-spectrum antiviral activity against hepatitis B virus (EC50 = 0.8 μM), herpes simplex virus type 1 (EC50 = 0.15 μM) and type 2 (EC50 < 0.1 μM), Epstein-Barr virus (EC50 = 9.0 μM), and cytomegalovirus (EC50 = 0.45 μM). Helioxanthin lactam derivative I also showed marked inhibition of herpes simplex virus type 1 (EC50 = 0.29 μM) and type 2 (EC50 = 0.16 μM). The cyclic hydrazide derivative

of helioxanthin II and its brominated product exhibited moderately potent activities against human immunodeficiency virus (EC50 = 2.7 and 2.5 μM, resp.). Collectively, these mols. represent a novel set of antiviral compds. with unique structural features.

CC 26-9 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1

OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:770227 HCAPLUS Full-text

DOCUMENT NUMBER: 141:405646

TITLE: Increased Anti-P-glycoprotein Activity of Baicalein by Alkylation on the A Ring

AUTHOR(S): Lee, Yashang; Yeo, Hosup; Liu, Shwu-Huey; Jiang, Zaoli; Savizky, Ruben M.; Austin, David J.; Cheng, Yung-chi

CORPORATE SOURCE: Department of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA

SOURCE: Journal of Medicinal Chemistry (2004), 47(22), 5555-5566
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:405646

AB The aqueous extract of Scutellariae baicalensis Georgi has inhibitory activity against P-gp 170, a multiple drug resistant gene product. Baicalein, one of the major flavones, was found to be responsible for this activity. The hydroxyl groups of the A ring of baicalein were systematically alkylated in order to assess the effect of such modifications on the activity against P-gp 170. The impact of the baicalein modifications on activity against the growth of a human nasopharyngeal cancer cell line KB and its P-gp 170 overexpressing cell line KB/MDR were also examined The results indicate that alkylation of R5 of baicalein does not have a major impact on the interaction with P-gp 170, whereas alkylation of R6 or R7 alone or both, could enhance the interaction of baicalein with P-gp 170 as well as the amount of intracellular accumulation of vinblastine, a surrogate marker for the activity of P-gp 170 pump of KB/MDR cells. In this case, the optimal linear alkyl functionality is a Pr side chain. These modifications could also alter the activity of compds. inhibiting cell growth. Among the different compds. synthesized, the most potent mol. against P-gp 170 is 5-methoxy-6,7-dipropyloxyflavone. Its inhibitory activity against P-gp 170 is approx. 40 times better, based on EC50 (concentration of the compound enhancing 50% of the intracellular vinblastine accumulation in the KB/MDR cells) and 3 times higher, based on Amax (the intracellular vinblastine accumulation of the KB/MDR cells caused by the compound) as compared to baicalein. One compound is also a more selective inhibitor than baicalein against P-gp 170, because its cytotoxicity is less than that observed for baicalein. The growth inhibitory IC50 of the compound against KB and KB/MDR cells are about the same, suggesting that compound 23 is unlikely to be a substrate of P-gp 170 pump. Acetylation of R6, R7 or both could also decrease EC50 and increase Amax. Acetylated compds. are more toxic than baicalein, and their potency against cell growth is compromised by the presence of P-gp 170, suggesting that these compds. are substrates of P-gp 170. Benzylation of R6 or R7 but not both also enhanced anti-P-gp170 activity and potency against cell growth; however, the presence of P-gp 170 in cells did not have an impact on their sensitivity to these mols., suggesting that the benzylated compds. are inhibitors but not substrates of P-gp 170, and

perhaps have a different mechanism of action. In conclusion, the substitutions of R6 and R7 hydroxyl groups by alkoxy groups, acetoxy groups, or benzyloxy groups could yield compds. with different modes of action against P-gp 170 with different mechanisms of action against cell growth.

CC 1-3 (Pharmacology)

IT Antitumor agents
(resistance to; increased anti-P-glycoprotein activity of baicalein by alkylation on A ring)

IT 67047-05-6P, 5,6,7-Triac-etoxyflavone 110204-45-0P, 5-Hydroxy-6,7-(methylenedioxy)flavone 731817-58-6P 792923-60-5P 792923-65-0P 792923-66-1P 792923-71-8P 792923-72-9P 792923-75-2P 792923-77-4P 792923-80-9P
RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(increased anti-P-glycoprotein activity of baicalein by alkylation on A ring)

IT 740-33-0P, 5-Hydroxy-6,7-dimethoxyflavone 973-67-1P, 5,6,7-Trimethoxyflavone 67047-06-7P 119120-32-0P, 5-Methoxy-6,7-(methylenedioxy)flavone 137527-39-0P 199446-40-7P 457601-61-5P 791838-63-6P 792923-61-6P 792923-62-7P 792923-63-8P 792923-64-9P 792923-67-2P 792923-68-3P 792923-69-4P 792923-70-7P 792923-73-0P 792923-74-1P 792923-76-3P 792923-78-5P 792923-79-6P 792923-81-0P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(increased anti-P-glycoprotein activity of baicalein by alkylation on A ring)

IT 491-67-8, Baicalein
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(increased anti-P-glycoprotein activity of baicalein by alkylation on A ring)

IT 348820-28-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(increased anti-P-glycoprotein activity of baicalein by alkylation on A ring)

IT 67047-05-6P, 5,6,7-Triac-etoxyflavone 110204-45-0P, 5-Hydroxy-6,7-(methylenedioxy)flavone 731817-58-6P 792923-60-5P 792923-65-0P 792923-66-1P 792923-71-8P 792923-72-9P 792923-75-2P 792923-77-4P 792923-80-9P
RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(increased anti-P-glycoprotein activity of baicalein by alkylation on A ring)

RN 67047-05-6 HCAPLUS

CN 4H-1-Benzopyran-4-one, 5,6,7-tris(acetyloxy)-2-phenyl- (CA INDEX NAME)



RN 110204-45-0 HCAPLUS
CN 8H-1,3-Dioxolo[4,5-g][1]benzopyran-8-one, 9-hydroxy-6-phenyl- (CA INDEX NAME)



RN 731817-58-6 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-bis(acetyloxy)-5-hydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-60-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6-(acetyloxy)-5,7-dihydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-65-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-6-propoxy- (CA INDEX NAME)



RN 792923-66-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-2-phenyl-6,7-dipropoxy- (CA INDEX NAME)



RN 792923-71-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6-ethoxy-5,7-dihydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-72-9 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-diethoxy-5-hydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-75-2 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-6,7-bis(pentyloxy)-2-phenyl- (CA INDEX NAME)



RN 792923-77-4 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-bis(hexyloxy)-5-hydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-80-9 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-dibutoxy-5-hydroxy-2-phenyl- (CA INDEX NAME)



IT 740-33-0P, 5-Hydroxy-6,7-dimethoxyflavone 973-67-1P, 5,6,7-Trimethoxyflavone 67047-06-7P 119120-32-0P, 5-Methoxy-6,7-(methylenedioxy)flavone 137527-39-0P 199446-40-7P 457601-61-5P 791838-63-6P 792923-61-6P 792923-62-7P 792923-63-8P 792923-64-9P 792923-67-2P 792923-68-3P 792923-69-4P 792923-70-7P 792923-73-0P 792923-74-1P 792923-76-3P 792923-78-5P 792923-79-6P 792923-81-0P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(increased anti-P-glycoprotein activity of baicalein by alkylation on A ring)

RN 740-33-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-6,7-dimethoxy-2-phenyl- (CA INDEX NAME)



RN 973-67-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trimethoxy-2-phenyl- (CA INDEX NAME)



RN 67047-06-7 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6-bis(acetyloxy)-2-phenyl-7-(phenylmethoxy)- (CA INDEX NAME)



RN 119120-32-0 HCAPLUS
CN 8H-1,3-Dioxolo[4,5-g][1]benzopyran-8-one, 9-methoxy-6-phenyl- (CA INDEX NAME)



RN 137527-39-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6-(acetyloxy)-5,7-dimethoxy-2-phenyl- (CA INDEX NAME)



RN 199446-40-7 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-6-(phenylmethoxy)- (CA INDEX NAME)



RN 457601-61-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-2-phenyl-6,7-bis(phenylmethoxy)- (CA INDEX NAME)



RN 791838-63-6 HCAPLUS
CN 4H-1-Benzopyran-4-one, 8-bromo-5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-61-6 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-bis(acetyloxy)-5-methoxy-2-phenyl- (CA INDEX

NAME)



RN 792923-62-7 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-bis(acetyloxy)-2-phenyl-5-(phenylmethoxy)- (CA INDEX NAME)



RN 792923-63-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 7-(acetyloxy)-5-hydroxy-2-phenyl-6-(phenylmethoxy)- (CA INDEX NAME)



RN 792923-64-9 HCAPLUS
CN 8H-1,3-Dioxolo[4,5-g][1]benzopyran-8-one, 9-methoxy-2,2,6-triphenyl- (CA INDEX NAME)



RN 792923-67-2 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-7-methoxy-2-phenyl-6-propoxy- (CA INDEX NAME)



RN 792923-68-3 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dimethoxy-2-phenyl-6-propoxy- (CA INDEX NAME)



RN 792923-69-4 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-methoxy-2-phenyl-6,7-dipropoxy- (CA INDEX NAME)



RN 792923-70-7 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-bis(acetyloxy)-8-bromo-5-hydroxy-2-phenyl- (CA INDEX NAME)



RN 792923-73-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-6,7-bis(octyloxy)-2-phenyl- (CA INDEX NAME)



RN 792923-74-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6-ethoxy-5-hydroxy-7-methoxy-2-phenyl- (CA INDEX NAME)



RN 792923-76-3 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5-methoxy-6,7-bis(pentyloxy)-2-phenyl- (CA INDEX NAME)



RN 792923-78-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-bis(hexyloxy)-5-methoxy-2-phenyl- (CA INDEX NAME)



RN 792923-79-6 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-diethoxy-5-methoxy-2-phenyl- (CA INDEX NAME)



RN 792923-81-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 6,7-dibutoxy-5-methoxy-2-phenyl- (CA INDEX NAME)



IT 491-67-8, Baicalein
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(increased anti-P-glycoprotein activity of baicalein by alkylation on A ring)
RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



IT 848820-28-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(increased anti-P-glycoprotein activity of baicalein by alkylation on A ring)
RN 848820-28-0 HCAPLUS
CN 8H-1,3-Dioxolo[4,5-g][1]benzopyran-8-one, 9-hydroxy-2,2,6-triphenyl- (CA INDEX NAME)



OS.CITING REF COUNT:	15	THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
REFERENCE COUNT:	39	THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

STRUCTURE SEARCH

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 16:50:08 ON 29 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 JAN 2010  HIGHEST RN 1204173-70-5
DICTIONARY FILE UPDATES:  28 JAN 2010  HIGHEST RN 1204173-70-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d stat que l4; fil hcapl; d que nos l36; d que nos l43; d que nos l109; d que
nos l45; d que nos l46;d que nos l57; d que nos l63; d que nos l62; d que nos l74;
d que nos l79; s l36,l43,l45,l46,l57,l63,l62,l74,l79,l109 not l24
L2              STR
```




```
VAR G8=H/OH/22/25/26/X
NODE ATTRIBUTES:
NSPEC   IS RC     AT  17
NSPEC   IS RC     AT  21
NSPEC   IS RC     AT  24
CONNECT IS E1  RC AT  25
CONNECT IS E1  RC AT  27
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
```

```
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  28

STEREO ATTRIBUTES: NONE
L4          3009 SEA FILE=REGISTRY SSS FUL L2

100.0% PROCESSED   55925 ITERATIONS                          3009 ANSWERS
SEARCH TIME: 00.00.02



FILE 'HCAPLUS' ENTERED AT 16:51:46 ON 29 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Jan 2010  VOL 152 ISS 6
FILE LAST UPDATED: 28 Jan 2010  (20100128/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Oct 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE


L2              STR
L4          3009 SEA FILE=REGISTRY SSS FUL L2
L5          9000 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L4
L16        12971 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CODRUG#/OBI OR COADMIN?/OBI
                 OR CONCOMITANT?/OBI OR CONCURRENT?/OBI
L17         1784 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CO/OBI(W)(DRUG#/OBI OR
                 ADMIN?/OBI)
L18       203485 SEA FILE=HCAPLUS SPE=ON  ABB=ON  BLEND?/OBI
L36            7 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 AND (L16 OR L17 OR L18)



L2              STR
L4          3009 SEA FILE=REGISTRY SSS FUL L2
L5          9000 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L4
```

```
L10        28697 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG BIOAVAILABILITY/CT
L11       342049 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG DELIVERY SYSTEMS+NT,OLD/C
                 T
L12       495141 SEA FILE=HCAPLUS SPE=ON  ABB=ON  ANTITUMOR AGENTS+NT,OLD,RTCS/C
                 T
L13        50670 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG INTERACTIONS+OLD/CT
L14        11152 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMB?/OBI(L)PHARMAC?/OBI
L15        45792 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMBINATION CHEMOTHERAPY/CT
L16        12971 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CODRUG#/OBI OR COADMIN?/OBI
                 OR CONCOMITANT?/OBI OR CONCURRENT?/OBI
L17         1784 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CO/OBI(W)(DRUG#/OBI OR
                 ADMIN?/OBI)
L18       203485 SEA FILE=HCAPLUS SPE=ON  ABB=ON  BLEND?/OBI
L19       462118 SEA FILE=HCAPLUS SPE=ON  ABB=ON  MIXTURE#/OBI
L40           17 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5(L)L19 AND (L10 OR L11 OR
                 L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18)
L42         1343 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5(L)ANT/RL ANT=ANALYTE
L43           10 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L40 NOT L42


L2                STR
L4           3009 SEA FILE=REGISTRY SSS FUL L2
L5           9000 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L4
L10         28697 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG BIOAVAILABILITY/CT
L13         50670 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG INTERACTIONS+OLD/CT
L14         11152 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMB?/OBI(L)PHARMAC?/OBI
L15         45792 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMBINATION CHEMOTHERAPY/CT
L16         12971 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CODRUG#/OBI OR COADMIN?/OBI
                  OR CONCOMITANT?/OBI OR CONCURRENT?/OBI
L17          1784 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CO/OBI(W)(DRUG#/OBI OR
                  ADMIN?/OBI)
L18        203485 SEA FILE=HCAPLUS SPE=ON  ABB=ON  BLEND?/OBI
L19        462118 SEA FILE=HCAPLUS SPE=ON  ABB=ON  MIXTURE#/OBI
L108          266 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 AND (L13 OR L14 OR L15 OR
                  L16 OR L17 OR L18 OR L19)
L109            9 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L108 AND L10


L2                STR
L4           3009 SEA FILE=REGISTRY SSS FUL L2
L5           9000 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L4
L10         28697 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG BIOAVAILABILITY/CT
L12        495141 SEA FILE=HCAPLUS SPE=ON  ABB=ON  ANTITUMOR AGENTS+NT,OLD,RTCS/C
                  T
L13         50670 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG INTERACTIONS+OLD/CT
L14         11152 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMB?/OBI(L)PHARMAC?/OBI
L15         45792 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMBINATION CHEMOTHERAPY/CT
L16         12971 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CODRUG#/OBI OR COADMIN?/OBI
                  OR CONCOMITANT?/OBI OR CONCURRENT?/OBI
L17          1784 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CO/OBI(W)(DRUG#/OBI OR
                  ADMIN?/OBI)
L18        203485 SEA FILE=HCAPLUS SPE=ON  ABB=ON  BLEND?/OBI
L19        462118 SEA FILE=HCAPLUS SPE=ON  ABB=ON  MIXTURE#/OBI
L42          1343 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5(L)ANT/RL
L45             6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 AND L10 AND (L13 OR L14 OR
                  L15 OR L16 OR L17 OR L18 OR L19) AND L12 NOT L42
```

```
L2              STR
L4          3009 SEA FILE=REGISTRY SSS FUL L2
L5          9000 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L4
L10        28697 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG BIOAVAILABILITY/CT
L11       342049 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG DELIVERY SYSTEMS+NT,OLD/C
                 T
L12       495141 SEA FILE=HCAPLUS SPE=ON  ABB=ON  ANTITUMOR AGENTS+NT,OLD,RTCS/C
                 T
L42         1343 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5(L)ANT/RL
L46           17 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 AND L10 AND L11 AND L12
                 NOT L42


L2              STR
L4          3009 SEA FILE=REGISTRY SSS FUL L2
L5          9000 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L4
L16        12971 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CODRUG#/OBI OR COADMIN?/OBI
                 OR CONCOMITANT?/OBI OR CONCURRENT?/OBI
L17         1784 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CO/OBI(W)(DRUG#/OBI OR
                 ADMIN?/OBI)
L18       203485 SEA FILE=HCAPLUS SPE=ON  ABB=ON  BLEND?/OBI
L19       462118 SEA FILE=HCAPLUS SPE=ON  ABB=ON  MIXTURE#/OBI
L53          298 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L16 AND (L17 OR L18 OR L19)
L54           15 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L17 AND (L18 OR L19)
L57            1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 AND (L53 OR L54)


L2              STR
L4          3009 SEA FILE=REGISTRY SSS FUL L2
L5          9000 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L4
L15        45792 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMBINATION CHEMOTHERAPY/CT
L16        12971 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CODRUG#/OBI OR COADMIN?/OBI
                 OR CONCOMITANT?/OBI OR CONCURRENT?/OBI
L17         1784 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CO/OBI(W)(DRUG#/OBI OR
                 ADMIN?/OBI)
L18       203485 SEA FILE=HCAPLUS SPE=ON  ABB=ON  BLEND?/OBI
L19       462118 SEA FILE=HCAPLUS SPE=ON  ABB=ON  MIXTURE#/OBI
L52         3593 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L15 AND (L16 OR L17 OR L18 OR
                 L19)
L63            5 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 AND L52


L2              STR
L4          3009 SEA FILE=REGISTRY SSS FUL L2
L5          9000 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L4
L14        11152 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMB?/OBI(L)PHARMAC?/OBI
L15        45792 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMBINATION CHEMOTHERAPY/CT
L16        12971 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CODRUG#/OBI OR COADMIN?/OBI
                 OR CONCOMITANT?/OBI OR CONCURRENT?/OBI
L17         1784 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CO/OBI(W)(DRUG#/OBI OR
                 ADMIN?/OBI)
L18       203485 SEA FILE=HCAPLUS SPE=ON  ABB=ON  BLEND?/OBI
L19       462118 SEA FILE=HCAPLUS SPE=ON  ABB=ON  MIXTURE#/OBI
L51         4284 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L14 AND (L15 OR L16 OR L17 OR
                 L18 OR L19)
L62           12 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 AND L51
```

```
L2              STR
L4          3009 SEA FILE=REGISTRY SSS FUL L2
L5          9000 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L4
L14        11152 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMB?/OBI(L)PHARMAC?/OBI
L15        45792 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMBINATION CHEMOTHERAPY/CT
L16        12971 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CODRUG#/OBI OR COADMIN?/OBI
                 OR CONCOMITANT?/OBI OR CONCURRENT?/OBI
L17         1784 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CO/OBI(W)(DRUG#/OBI OR
                 ADMIN?/OBI)
L18       203485 SEA FILE=HCAPLUS SPE=ON  ABB=ON  BLEND?/OBI
L19       462118 SEA FILE=HCAPLUS SPE=ON  ABB=ON  MIXTURE#/OBI
L51         4284 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L14 AND (L15 OR L16 OR L17 OR
                 L18 OR L19)
L52         3593 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L15 AND (L16 OR L17 OR L18 OR
                 L19)
L55         7815 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L18 AND L19
L72          348 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L51 AND (L52 OR L55)
L74            3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L72 AND L5



L2              STR
L4          3009 SEA FILE=REGISTRY SSS FUL L2
L5          9000 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L4
L11       342049 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG DELIVERY SYSTEMS+NT,OLD/C
                 T
L12       495141 SEA FILE=HCAPLUS SPE=ON  ABB=ON  ANTITUMOR AGENTS+NT,OLD,RTCS/C
                 T
L13        50670 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG INTERACTIONS+OLD/CT
L14        11152 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMB?/OBI(L)PHARMAC?/OBI
L15        45792 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMBINATION CHEMOTHERAPY/CT
L16        12971 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CODRUG#/OBI OR COADMIN?/OBI
                 OR CONCOMITANT?/OBI OR CONCURRENT?/OBI
L17         1784 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CO/OBI(W)(DRUG#/OBI OR
                 ADMIN?/OBI)
L18       203485 SEA FILE=HCAPLUS SPE=ON  ABB=ON  BLEND?/OBI
L19       462118 SEA FILE=HCAPLUS SPE=ON  ABB=ON  MIXTURE#/OBI
L42         1343 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5(L)ANT/RL
L48        72117 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L11 AND (L12 OR L13 OR L14 OR
                 L15 OR L16 OR L17 OR L18 OR L19)
L49        38344 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L12 AND (L13 OR L14 OR L15 OR
                 L16 OR L17 OR L18 OR L19)
L50        10606 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L13 AND (L14 OR L15 OR L16 OR
                 L17 OR L18 OR L19)
L51         4284 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L14 AND (L15 OR L16 OR L17 OR
                 L18 OR L19)
L52         3593 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L15 AND (L16 OR L17 OR L18 OR
                 L19)
L55         7815 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L18 AND L19
L69        11425 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L48 AND (L49 OR L50 OR L51 OR
                 L52 OR L55)
L70         7577 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L49 AND (L50 OR L51 OR L52 OR
                 L55)
L71         1622 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L50 AND (L51 OR L52 OR L55)
L76         3135 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L69 AND (L70 OR L71)
L77          633 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L70 AND L71
L79           13 SEA FILE=HCAPLUS SPE=ON  ABB=ON  (L76 OR L77) AND L5 NOT L42
```

```
L115        54 (L36 OR L43 OR L45 OR L46 OR L57 OR L63 OR L62 OR L74 OR L79 OR
               L109) NOT L24  L24=INVENOTR SEARCH ANSWER SET

=> s l115 and patent/dt
      7048795 PATENT/DT
L116        36 L115 AND PATENT/DT

=> s l115 and review/dt
      2338683 REVIEW/DT
L117         1 L115 AND REVIEW/DT

=> s l115 not l116
L118        18 L115 NOT L116

=> s l118 and py<2005
     25160265 PY<2005
L119         6 L118 AND PY<2005

=> s l116 and (PD<20040203 OR AD<20040203 OR PRD<20040203)
     24831906 PD<20040203
                 (PD<20040203)
      4847819 AD<20040203
                 (AD<20040203)
      4321189 PRD<20040203
                 (PRD<20040203)
L120        10 L116 AND (PD<20040203 OR AD<20040203 OR PRD<20040203)

=> s l117,l119,l120
L121        17 (L117 OR L119 OR L120)

=> s l121 not l5(L)ant/rl
      1044212 ANT/RL
         1343 L5(L)ANT/RL
L122        13 L121 NOT L5(L)ANT/RL       ANT=ANALYTE

=> d que nos l105; d que nos l106; d que nos l113; s (l105,l106,l113 not l24) or
l122
L2              STR
L4           3009 SEA FILE=REGISTRY SSS FUL L2
L5           9000 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L4
L13         50670 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG INTERACTIONS+OLD/CT
L14         11152 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMB?/OBI(L)PHARMAC?/OBI
L15         45792 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMBINATION CHEMOTHERAPY/CT
L16         12971 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CODRUG#/OBI OR COADMIN?/OBI
                  OR CONCOMITANT?/OBI OR CONCURRENT?/OBI
L17          1784 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CO/OBI(W)(DRUG#/OBI OR
                  ADMIN?/OBI)
L18        203485 SEA FILE=HCAPLUS SPE=ON  ABB=ON  BLEND?/OBI
L19        462118 SEA FILE=HCAPLUS SPE=ON  ABB=ON  MIXTURE#/OBI
L42          1343 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5(L)ANT/RL
L50         10606 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L13 AND (L14 OR L15 OR L16 OR
                  L17 OR L18 OR L19)
L51          4284 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L14 AND (L15 OR L16 OR L17 OR
                  L18 OR L19)
L90          1214 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 AND PATENT/DT
L91            80 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 AND REVIEW/DT
L92          7786 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 NOT L90
```

```
L93          5065 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L92 AND PY<2005
L94           452 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L90 AND (PD<20040203 OR
                  AD<20040203 OR PRD<20040203)
L95          5105 SEA FILE=HCAPLUS SPE=ON  ABB=ON  (L94 OR L93 OR L91) NOT L42
L105            6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L95 AND (L50 OR L51)



L2                STR
L4           3009 SEA FILE=REGISTRY SSS FUL L2
L5           9000 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L4
L10         28697 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG BIOAVAILABILITY/CT
L11        342049 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG DELIVERY SYSTEMS+NT,OLD/C
                  T
L12        495141 SEA FILE=HCAPLUS SPE=ON  ABB=ON  ANTITUMOR AGENTS+NT,OLD,RTCS/C
                  T
L13         50670 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG INTERACTIONS+OLD/CT
L14         11152 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMB?/OBI(L)PHARMAC?/OBI
L15         45792 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMBINATION CHEMOTHERAPY/CT
L16         12971 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CODRUG#/OBI OR COADMIN?/OBI
                  OR CONCOMITANT?/OBI OR CONCURRENT?/OBI
L17          1784 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CO/OBI(W)(DRUG#/OBI OR
                  ADMIN?/OBI)
L18        203485 SEA FILE=HCAPLUS SPE=ON  ABB=ON  BLEND?/OBI
L19        462118 SEA FILE=HCAPLUS SPE=ON  ABB=ON  MIXTURE#/OBI
L42          1343 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5(L)ANT/RL
L47         22246 SEA FILE=HCAPLUS SPE=ON  ABB=ON  (L10 AND (L11 OR L12 OR L13
                  OR L14 OR L15 OR L16 OR L17 OR L18 OR L19))
L48         72117 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L11 AND (L12 OR L13 OR L14 OR
                  L15 OR L16 OR L17 OR L18 OR L19)
L49         38344 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L12 AND (L13 OR L14 OR L15 OR
                  L16 OR L17 OR L18 OR L19)
L90          1214 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 AND PATENT/DT
L91            80 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 AND REVIEW/DT
L92          7786 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 NOT L90
L93          5065 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L92 AND PY<2005
L94           452 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L90 AND (PD<20040203 OR
                  AD<20040203 OR PRD<20040203)
L95          5105 SEA FILE=HCAPLUS SPE=ON  ABB=ON  (L94 OR L93 OR L91) NOT L42
L106            7 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L95 AND L47 AND (L48 OR L49)



L2                STR
L4           3009 SEA FILE=REGISTRY SSS FUL L2
L5           9000 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L4
L11        342049 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG DELIVERY SYSTEMS+NT,OLD/C
                  T
L12        495141 SEA FILE=HCAPLUS SPE=ON  ABB=ON  ANTITUMOR AGENTS+NT,OLD,RTCS/C
                  T
L13         50670 SEA FILE=HCAPLUS SPE=ON  ABB=ON  DRUG INTERACTIONS+OLD/CT
L14         11152 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMB?/OBI(L)PHARMAC?/OBI
L15         45792 SEA FILE=HCAPLUS SPE=ON  ABB=ON  COMBINATION CHEMOTHERAPY/CT
L16         12971 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CODRUG#/OBI OR COADMIN?/OBI
                  OR CONCOMITANT?/OBI OR CONCURRENT?/OBI
L17          1784 SEA FILE=HCAPLUS SPE=ON  ABB=ON  CO/OBI(W)(DRUG#/OBI OR
                  ADMIN?/OBI)
L18        203485 SEA FILE=HCAPLUS SPE=ON  ABB=ON  BLEND?/OBI
L19        462118 SEA FILE=HCAPLUS SPE=ON  ABB=ON  MIXTURE#/OBI
L42          1343 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5(L)ANT/RL
```

```
L80         3283 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5(L)(THU OR BAC OR PAC OR
                 PKT OR DMA)/RL
L90         1214 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 AND PATENT/DT
L91           80 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 AND REVIEW/DT
L92         7786 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 NOT L90
L93         5065 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L92 AND PY<2005
L94          452 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L90 AND (PD<20040203 OR
                 AD<20040203 OR PRD<20040203)
L95         5105 SEA FILE=HCAPLUS SPE=ON  ABB=ON  (L94 OR L93 OR L91) NOT L42
L108         266 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L5 AND (L13 OR L14 OR L15 OR
                 L16 OR L17 OR L18 OR L19)
L112          42 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L108 AND L12 AND L80 AND L11
L113          20 SEA FILE=HCAPLUS SPE=ON  ABB=ON  L112 AND L95


L123          32 ((L105 OR L106 OR L113) NOT L24) OR L122          L24=INVENTOR SEARCH

=> d ibib abs hitind hitstr l123 1-32; fil hom

L123 ANSWER 1 OF 32  HCAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2009:339147  HCAPLUS  Full-text
DOCUMENT NUMBER:          150:337542
TITLE:                    Inhibitors and enhancers of uridine
                          diphosphate-glucuronosyltransferase 2B
INVENTOR(S):              Oliver, Yoa-Pu Hu; Hsiong, Cheng-Huei; Wang, Mei-Ting;
                          Pao, Li-Heng
PATENT ASSIGNEE(S):       Taiwan
SOURCE:                   U.S. Pat. Appl. Publ., 26pp., Cont.-in-part of U.S.
                          Ser. No. 28,615.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 20090074708        A1    20090319    US 2008-325139          20081128
     US 20060040875        A1    20060223    US 2005-28615           20050105 <--
PRIORITY APPLN. INFO.:                       US 2005-28615        B2 20050105
                                             TW 2004-93100465     A  20040108 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB    A uridine diphosphate-glucuronosyltransferase 2B (UGT2B) inhibitor capable of
      increasing the bio-availability of a drug, is a compound in a free base or a
      pharmaceutically acceptable salt form that is selected from the group
      consisting of: capillarisin, isorhamnetin, β-naphthoflavone, α-naphthoflavone,
      hesperetin, terpineol, (+)-limonene, β-myrcene, swertiamarin, eriodictyol,
      cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alc., puerarin,
      trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin,
      gallic acid, genistein, glycyrrhizin, protocatechuic acid, Et myristate,
      umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20,
      Tween 60, Tween 80, BRIJ 58, BRIJ 76, Pluronic F68, Pluronic F127, and a
      combination thereof.  A UGT2B enhancer capable of enhancing a clearance rate
      of morphine-like analgesic agents, is a compound in a free base or a
      pharmaceutically acceptable salt form that is selected from the group
      consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid,
      baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin,
      narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol,
      formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin,
```

naringenin, daidzin, (-)-epicatechin, luteolin-7-glucoside, ergosterol, rutin, luteolin, Et myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, trans-cinnamaldehyde, and a combination thereof. Thus, nalbuphine was delivered orally and i.v. to control animals, and nalbuphine and capillarisin orally to exptl. animals; 0.3 mL blood samples were taken to analyze the concentration of nalbuphine in the serum; comparing the animals that were orally given inhibitor (experiment group) with those i.v. given drug without inhibitor (control group), the oral absorption is significantly improved with the presence of the inhibitor; its absolute bioavailability increases from 5% to 108%; in addition, the AUC values are similar in both sets of animals, indicating the addition of the inhibitor enhances the oral absorption of nalbuphine.

INCL 424078310; 514456000; 514763000; 514557000; 514724000; 514532000; 514568000; 514033000; 514282000

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

IT Pharmaceutical injections
(i.v. injections; inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B)

IT Combination chemotherapy
Drug bioavailability
Oral drug delivery systems
Pharmacokinetics
(inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B)

IT 57-27-2, (-)-Morphine, biological studies 57-87-4, Ergosterol 62-67-9, Nalorphine 76-41-5, Oxymorphone 76-57-3, Codeine 77-52-1, Ursolic acid 93-35-6, Umbelliferone 99-50-3, Protocatechuic acid 112-53-8, Lauryl alcohol 117-39-5, Quercetin 122-72-5, 3-Phenylpropyl acetate 123-35-3, β-Myrcene 124-06-1, Ethyl myristate 140-10-3, trans-Cinnamic acid, biological studies 149-91-7, Gallic acid, biological studies 153-18-4, Rutin 154-23-4, (+)-Catechin 437-64-9, Genkwanin 446-72-0, Genistein 465-65-6, Naloxone 466-99-9, Hydromorphone 470-82-6, Cineole 480-19-3, Isorhamnetin 480-41-1, Naringenin 485-72-3, Formononetin 486-66-8, Daidzein 490-46-0, (-)-Epicatechin 491-67-8, Baicalein 491-70-3, Luteolin 500-38-9, Nordihydroguaiaretic acid 508-02-1, Oleanolic acid 520-18-3, Kaempferol 520-26-3, Hesperidin 520-33-2, Hesperetin 520-36-5, Apigenin 522-12-3, Quercitrin 551-15-5, Liquiritin 552-58-9, Eriodictyol 552-66-9, Daidzin 604-59-1, α-Naphthoflavone 632-85-9, Wogonin 961-29-5, Isoliquiritigenin 1405-86-3, Glycyrrhizin 3681-99-0, Puerarin 4261-42-1, Homoorientin 5373-11-5, Luteolin-7-glucoside 5989-27-5, (+)-Limonene 6051-87-2, β-Naphthoflavone 8000-41-7, Terpineol 9004-95-9, BRIJ 58 9005-00-9, BRIJ 76 9005-64-5, Tween 20 9005-65-6, Tween 80 9005-67-8, Tween 60 10236-47-2, Naringin 13241-33-3, Neohesperidin 14371-10-9, trans-Cinnamaldehyde 14941-08-3, Poncirin 16590-41-3, Naltrexone 17388-39-5, Swertiamarin 20594-83-6, Nalbuphine 21637-25-2, Isoquercitrin 21967-41-9, Baicalin 23180-57-6, Paeoniflorin 23513-14-6, 6-Gingerol 25322-68-3, PEG 35323-91-2, (+)-Epicatechin 38953-85-4, Isovitexin 56365-38-9, Capillarisin 691397-13-4, Pluronic F68
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B)

IT 480-41-1, Naringenin 491-67-8, Baicalein

21967-41-9, Baicalin
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B)
RN 480-41-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 21967-41-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



L123 ANSWER 2 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1156137 HCAPLUS Full-text
DOCUMENT NUMBER: 149:409732
TITLE: Pharmaceutical compositions and method for treatment of chronic inflammatory diseases
INVENTOR(S): Shapiro, Howard K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 35pp., Cont.-in-part of U.S. Ser. No. 924,945.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080234380	A1	20080925	US 2008-70518	20080220 <--
US 20050090553	A1	20050428	US 2004-924945	20040824 <--
PRIORITY APPLN. INFO.:			US 1992-906909 B2	19920630 <--
			US 1994-241603 B2	19940511 <--
			US 1997-814291 B2	19970310 <--
			US 2000-610073 B2	20000705 <--
			US 2004-924945 A2	20040824

AB This invention defines novel compns. that can be used for clin. treatment of a class of chronic inflammatory diseases. Increased generation of carbonyl substances, namely aldehydes and ketones, occurs at sites of chronic inflammation and is common to the etiologies of all of the clin. disorders addressed herein. Such carbonyl substances are cytotoxic and addnl. serve to perpetuate and disseminate the inflammatory process. This invention defines use of compns., the orally administered required primary agents of which are primary amine derivs. of benzoic acid capable of covalently reacting with the carbonyl substances. P-Aminobenzoic acid is an example of the required primary agent of the present invention. PABA has a small mol. weight, is water-soluble, has a primary amine group which reacts with carbonyl-containing substances and is tolerated by the body in relatively high dosages for extended periods. The method includes administration of a composition comprising: (1) an orally consumed therapeutically effective amount of at least one required primary agent; (2) at least one required previously known medicament co-agent recognized as effective to treat a chronic inflammatory disease addressed herein administered to the mammalian subject via the oral route; and (3) one or more addnl. orally consumed required co-agent selected from the group consisting of antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl co-agents, co-agents which may facilitate glutathione activity and nonabsorbable primary amine polymeric co-agents; so as to-produce an additive or synergistic physiol. effect of an anti-inflammatory nature.

INCL 514565000; 514567000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT Pharmaceutical tablets
(controlled-release; pharmaceutical compns. and method for treatment of chronic inflammatory diseases)
IT Oral drug delivery systems
Pharmaceutical solutions
(oral solns.; pharmaceutical compns. and method for treatment of chronic inflammatory diseases)
IT Oral drug delivery systems
Pharmaceutical suspensions
(oral suspensions; pharmaceutical compns. and method for treatment of chronic inflammatory diseases)
IT Antioxidants
Arthritis
Chronic obstructive pulmonary disease
Colitis
Crohn disease
Drug delivery systems
Epilepsy
Gingivitis
Human
Ileitis

Inflammatory bowel disease
Multiple sclerosis
Opium
Oral drug delivery systems
Periodontitis
Pharmaceutical tablets
Pneumoconiosis
Psoriasis
Quillaja
Reperfusion
Stroke
Systemic lupus erythematosis
(pharmaceutical compns. and method for treatment of chronic inflammatory diseases)

IT Controlled-release drug delivery systems
(tablets; pharmaceutical compns. and method for treatment of chronic inflammatory diseases)

IT 50-02-2, Dexamethasone 50-03-3, Hydrocortisone acetate 50-06-6, Phenobarbital, biological studies 50-14-6, Vitamin D2 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-33-9, Phenylbutazone, biological studies 50-34-0, Propantheline bromide 50-44-2, 6-Mercaptopurine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-53-3, Chlorpromazine, biological studies 50-78-2, Aspirin 51-06-9, Procainamide 51-34-3, Scopolamine 51-83-2, Carbachol 52-53-9, Verapamil 52-67-5, D-Penicillamine 52-90-4, L-Cysteine, biological studies 53-03-2, Prednisone 53-33-8, Paramethasone 53-36-1, Methylprednisolone acetate 53-86-1, Indomethacin 54-05-7, Chloroquine 54-28-4, γ-Tocopherol 54-35-3, Penicillin G procaine 54-47-7, Pyridoxal 5-phosphate 54-85-3, Isoniazid 54-96-6, 3,4-Diaminopyridine 55-63-0, Trinitroglycerin 56-40-6, Glycine, biological studies 57-00-1, Creatine 57-41-0, Phenytoin 57-41-0 57-96-5, Sulfinpyrazone 58-05-9, Folinic acid 58-25-3, Chlordiazepoxide 58-32-2, Dipyridamole 58-73-1, Diphenhydramine 58-85-5, Vitamin H 59-02-9, α-Tocopherol 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-43-8, biological studies 59-43-8D, Thiamine, salt 59-58-5, Thiamine propyl disulfide 59-66-5, Acetazolamide 59-67-6, Nicotinic acid, biological studies 59-96-1, Phenoxybenzamine 60-23-1, Cysteamine 60-54-8, Tetracycline 61-68-7, Mefenamic acid 63-68-3, L-Methionine, biological studies 63-74-1D, Sulfanilamide, polymer with ethylene and 5-aminosalicylic acid 65-22-5, Pyridoxal hydrochloride 66-72-8, Pyridoxal 67-16-3, Thiamine disulfide 67-73-2, Fluocinolone acetonide 67-78-7, Triamcinolone diacetate 67-97-0, Vitamin D3 68-19-9, Vitamin B12 68-26-8, Retinol 69-46-5, Calcium acetylsalicylate 69-72-7, Salicylic acid, biological studies 70-18-8, Glutathione, biological studies 74-31-7, N,N'-Diphenyl-p-phenylenediamine 76-25-5, Triamcinolone acetonide 76-57-3, Codeine 77-37-2, Procyclidine 77-67-8, Ethosuximide 77-92-9, Citric acid, biological studies 79-83-4, Pantothenic acid 80-08-0, Dapsone 81-81-2, Warfarin 83-43-2, Methylprednisolone 83-68-1, Vitamin K6 83-69-2, Vitamin K7 83-70-5, Vitamin K5 83-88-5, Vitamin B2, biological studies 83-89-6, Quinacrine 84-81-1 85-87-0, Pyridoxamine 86-42-0, Amodiaquine 87-33-2, Isosorbide dinitrate 89-57-6D, 5-Aminosalicylic acid, polymer with ethylene and sulfanilamide 91-53-2, Ethoxyquin 91-86-1, η-Tocopherol 92-43-3, Phenidone 98-92-0, Niacinamide 99-66-1, Valproic acid 107-35-7, Taurine 113-98-4, Penicillin G potassium 114-07-8, Erythromycin 116-31-4, Vitamin A aldehyde 117-39-5, Quercetin 118-42-3, Hydroxychloroquine 118-92-3, Vitamin L1 119-13-1, δ-Tocopherol 121-79-9, Propyl gallate 124-94-7,

Triamcinolone 125-33-7, Primidone 127-47-9, Retinyl acetate 128-37-0, Butylated hydroxytoluene, biological studies 129-03-3, Cyproheptadine 129-20-4, Oxyphenbutazone 130-24-5 130-40-5, Riboflavin 5'-phosphate ester monosodium salt 132-17-2, Benztropine mesylate 132-98-9, Penicillin V potassium 137-08-6, Pantothenic acid calcium salt 137-58-6, Lidocaine 138-14-7, Deferoxamine mesylate 144-11-6, Trihexyphenidyl 148-03-8, β-Tocopherol 150-13-0, PABA 153-18-4, Rutin 298-46-4, Carbamazepine 298-50-0, Propantheline 298-81-7, Methoxsalen 302-79-4, Vitamin A acid 303-95-7 303-97-9 303-98-0, Coenzyme Q10 305-03-3, Chlorambucil 309-36-4, Methohexital sodium 315-30-0, Allopurinol 317-34-0, Aminophylline 327-97-9, Chlorogenic acid 352-97-6, Guanidinoacetic acid 356-12-7, Fluocinonide 378-44-9, Betamethasone 404-86-4, Capsaicin 432-70-2, α-Carotene 439-14-5, Diazepam 443-48-1, Metronidazole 444-27-9, Timonacic 446-72-0, Genistein 446-86-6, Azathioprine 458-37-7, Curcumin 462-20-4, Dihydrolipoic acid 472-93-5, γ-Carotene 476-66-4, Ellagic acid 480-16-0, Morin 480-17-1, Leucocyanidol 480-19-3, Isorhamnetin 481-46-9, Ginkgetin 489-35-0, Gossypetin 490-23-3, ε-Tocopherol 493-35-6, ζ2-Tocopherol 498-02-2, Apocynin 500-38-9, Nordihydroguaiaretic acid 501-30-4, Kojic acid 502-65-8, ψ,ψ-Carotene 504-24-5, 4-Aminopyridine 511-28-4, Vitamin D4 514-65-8, Biperiden 520-18-3, Kaempferol 520-36-5, Apigenin 521-32-4, Bilobetin 522-00-9, Ethopropazine 523-68-2 524-36-7, Pyridoxamine dihydrochloride 525-66-6, Propranolol 528-48-3, Fisetin 529-96-4, Pyridoxamine phosphate 530-78-9, Flufenamic acid 532-11-6, Sulfarlem 532-40-1, Thiamine phosphoric acid ester chloride 532-43-4, Thiamine mononitrate 533-31-3, Sesamol 534-13-4, N,N'-Dimethylthiourea 540-05-6 541-15-1, L-Carnitine 548-19-6, Isoginkgetin 548-75-4, Quercetagetin-7-glucoside 552-66-9, Daidzin 552-94-3, Salsalate 564-25-0, Doxycycline 578-36-9 , Potassium salicylate 599-79-1, Sulfasalazine 604-87-5 606-06-4 616-91-1, N-Acetylcysteine 635-97-2, Thiamine phosphoric acid ester phosphate salt 637-07-0, Clofibrate 638-23-3 644-62-2, Meclofenamic acid 652-78-8, Gossypin 674-38-4, Bethanechol 727-81-1 752-56-7, Riboflavin tetrabutyrate 768-94-5, Amantadine 841-73-6, Bucolome 846-49-1, Lorazepam 867-81-2, Pantothenic acid sodium salt 915-30-0, Diphenoxylate 1065-31-2 1077-28-7, Thioctic acid 1115-84-0, Vitamin U 1134-47-0, Baclofen 1143-38-0, Anthralin 1166-52-5, Dodecylgallate 1173-76-8 1398-61-4, Chitin 1424-27-7, Acetazolamide sodium 1505-95-9, Naphthypramide 1508-65-2, Oxybutynin chloride 1524-88-5, Flurandrenolide 1538-09-6 1553-60-2, Ibufenac 1562-74-9, 5-Thiopyridoxine 1597-82-6, Paramethasone 21-acetate 1622-61-3, Clonazepam 1721-51-3, ζ1-Tocopherol 1948-33-0, tert-Butylhydroquinone 1953-02-2, Tiopronin 2016-36-6, Choline salicylate 2055-44-9, Perisoxal 2124-57-4, Vitamin K2(35) 2145-14-4, Paramethasone disodium phosphate 2319-84-8, Thioctic acid sodium salt 2394-68-5 2447-54-3, Sanguinarine 2487-39-0, Vitamin K-S(II) 2766-51-0, Methylmethioninesulfonium bromide 3040-38-8, Acetyl-L-carnitine 3211-76-5, L-Selenomethionine 3286-46-2 3380-34-5, Triclosan 3416-24-8, Glucosamine 3475-65-8, Thiamine triphosphoric acid ester 3570-15-8, Nicotinic acid monoethanolamine salt 3930-20-9, Sotalol 4370-61-0 4370-62-1 4394-00-7, Niflumic acid
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. and method for treatment of chronic inflammatory diseases)

IT 4759-48-2, Isotretinoin 5003-48-5, Benorylate 5011-34-7, Trimetazidine 5034-76-4, Indoxole 5104-49-4, Flurbiprofen 5355-16-8, Diaveridine 5593-20-4, Betamethasone 17,21-dipropionate 5633-20-5, Oxybutynin 5728-52-9, Felbinac 5913-70-2 5934-23-6 5934-25-8, Vitamin K6

dihydrochloride 5934-26-9, Vitamin K7 hydrochloride 5949-29-1, Citric acid monohydrate 6020-87-7, Creatine monohydrate 6027-13-0, Homocysteine 6035-45-6, Folinic acid calcium salt pentahydrate 6054-98-4, Disodium azodisalicylate 6100-05-6 6223-35-4, Sodium guaiazulene-3-sulfonate 6452-71-7, Oxprenolol 6493-05-6, Pentoxifylline 7085-45-2, Biperiden lactate 7235-40-7, β-Carotene 7378-21-4 7512-17-6, N-Acetylglucosamine 7683-59-2, Isoproterenol 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin B6 9002-60-2, Corticotropin, biological studies 9004-34-6D, Cellulose, ethers 9004-57-3, Ethyl cellulose 9005-49-6, Heparin, biological studies 9014-67-9, Aloxiprin 9041-08-1, Heparin sodium 10118-90-8, Minocycline 10236-58-5, L-Selenocysteine 12001-76-2, Vitamin B 12001-79-5, Vitamin K 12192-57-3, Aurothioglucose 12244-57-4, Gold sodium thiomalate 13345-51-2, Prostaglandin B1 13422-55-4, Methyl vitamin B12 13523-86-9, Pindolol 13539-59-8, Azapropazone 13655-52-2, Alprenolol 13710-19-5, Tolfenamic acid 13739-02-1, Diacetylrhein 13993-65-2, Metiazinic acid 14402-89-2, Sodium nitroprusside 15307-86-5, Diclofenac 15475-56-6, Methotrexate sodium 15686-51-8, Clemastine 15687-27-1, Ibuprofen 15722-48-2, Olsalazine 16051-77-7, Isosorbide 5-mononitrate 17969-20-9, Fenclozic acid 18471-20-0, Ditazol 18472-51-0, Chlorhexidine gluconate 18642-10-9, Thiamine disulfide hydrochloride 18694-40-1, Epirizole 18917-89-0, Magnesium salicylate 19771-63-2, L-2-Oxothiazolidine-4-carboxylic acid 19982-08-2, Memantine 20168-99-4, Cinmetacin 20554-84-1, Parthenolide 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22457-89-2, Benfotiamine 22494-42-4, Diflunisal 22760-18-5, Proquazone 23288-49-5, Probucol 23981-47-7, 6-Methoxy-2-naphthylacetic acid 24237-54-5, Tinoridine 24967-94-0, Dermatan sulphate 25013-16-5, Butylated hydroxyanisole 25122-46-7, Clobetasol propionate 25451-15-4, Felbamate 25486-55-9, Vitamin K1 oxide 26171-23-3, Tolmetin 26589-39-9, Eudragit S 26787-78-0, Amoxicillin 26839-75-8, Timolol 27035-30-9, Oxametacin 27470-51-5, Suxibuzone 27686-36-8, Hypolaetin-8-glucoside 27696-41-9, Hypolaetin 28841-62-5, D-myo-Inositol-1,2,6-trisphosphate 29031-19-4, Glucosamine sulfate salt 29098-15-5, Etoclofene 29122-68-7, Atenolol 29679-58-1, Fenoprofen 29908-03-0 30011-11-1, Bimetopyrol 30748-29-9, Feprazone 31793-07-4, Pirprofen 31842-01-0, Indoprofen 32808-51-8, Bucloxic acid 32839-30-8, Eicosapentaenoic acid 33005-95-7, Tiaprofenic acid 34031-32-8, Auranofin 34042-85-8, Sudoxicam 34148-01-1, Clidanac 34334-69-5, Cirsiliol 34461-73-9, Bumadizone calcium 34552-84-6, Isoxicam 34645-84-6, Fenclofenac 36322-90-4, Piroxicam 36330-85-5, Fenbufen 36364-49-5, Imidazole salicylate 36616-52-1, Fenclorac 36740-73-5, Flumizole 36894-69-6, Labetalol 36994-25-9 37270-89-6, Heparin calcium 37517-30-9, Acebutolol 38194-50-2 , Sulindac 38363-40-5, Penbutolol 38957-41-4, Emorfazone 40828-46-4, Suprofen 41340-25-4, Etodolac 42200-33-9, Nadolol 42399-41-7, Diltiazem 42924-53-8, Nabumetone 50270-32-1, 1-Isobutyl-3,4-diphenylpyrazole-5-acetic acid 50270-33-2, Isofezolac 51059-44-0, Oroxindin 51234-28-7, Benoxaprofen 51322-75-9, Tizanidine 51384-51-1, Metoprolol 51484-40-3, Difenpiramide 51579-82-9, Amfenac 51781-06-7, Carteolol 51803-78-2, Nimesulide 52263-84-0, (S)-(+)-Carprofen 52443-21-7, Glucametacin 53123-88-9, Rapamycin 53179-11-6D, Loperamide, diazo derivs. 53527-28-9, Scalaradial 53597-27-6, Fendosal 53716-49-7, Carprofen 54350-48-0, Etretinate 55142-85-3, Ticlopidine 55242-55-2, Propentophylline 55366-56-8, Hibifolin 55453-87-7, Isoxepac 55837-18-8, Butibufen 55985-32-5, Nicardipine 56824-20-5, Amiprilose 57132-53-3, Proglumetacin 58433-11-7, Tilomisole 58456-91-0, 2-Aminomethyl-4-tert-butyl-6-iodophenol 59122-46-2, Misoprostol 59804-37-4, Tenoxicam 59865-13-3, Cyclosporin A 59937-28-9, Malotilate

60142-96-3, Gabapentin 60940-34-3, Ebselen 61177-45-5, Clavulanate potassium 61941-57-9, Ethyl 2-amino-3-benzoylphenylacetate 62571-86-2, Captopril 63329-53-3, Lobenzarit 63659-18-7, Betaxolol 64217-16-9 64224-21-1, Oltipraz 64294-95-7, Setastine 64425-90-7, Choline magnesium trisalicylate 65277-42-1, Ketoconazole 65666-07-1, Silymarin 66734-13-2, Alclometasone dipropionate 66934-18-7, Flunoxaprofen 68291-97-4, ZOnisamide 68506-86-5, Vigabatrin 68767-14-6, Loxoprofen 69425-13-4, 2,6-Di-tert-butyl-4-(2'-thenoyl)phenol 69432-07-1 70360-12-2, Sideritoflavone 71125-38-7, Meloxicam 71320-77-9, Moclobemide 72509-76-3, Felodipine 74103-06-3, Ketorolac 74103-07-4, Ketorolac tromethamine 75060-92-3 75695-93-1, Isradipine 75706-12-6, Leflunomide 75821-71-5, Lonazolac calcium 75847-73-3, Enalapril 76420-72-9, Enalaprilat 76547-98-3, Lisinopril 76584-70-8, Divalproex sodium 76990-56-2, Milacemide 77086-21-6, Dizocilpine 77699-47-9, Herbimycin 80282-49-1 80474-14-2, Fluticasone propionate 80937-31-1 81147-92-4, Esmolol 83919-23-7, Mometasone 17-(2-furoate) 84057-84-1, Lamotrigine 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 88150-42-9, Amlodipine 89149-10-0, 15-Deoxyspergualin 89796-99-6, Aceclofenac 90101-16-9, Droxicam 91418-71-2, Diacetylsplenopentin 98048-97-6, Fosinopril 98320-39-9 100827-28-9, Erbstatin 103475-41-8, Tepoxalin 110101-67-2, Tirilazad mesylate 110952-54-0 111406-87-2, Zileuton 114948-31-1 117279-73-9 120072-59-5 120210-48-2, Tenidap 125697-92-9, Lavendustin A 129424-08-4 131420-91-2 132392-39-3 132392-65-5 133332-08-8 143090-92-0, Anakinra 150977-36-9, Bromelain 151035-57-3, Quinapril-hydrochlorothiazide mixture 226721-96-6 354124-52-0 700346-94-7 762210-30-0 850785-97-6 1061190-73-5 1061190-76-8 1062113-21-6

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. and method for treatment of chronic inflammatory diseases)

IT 50-18-0, Cyclophosphamide 50-44-2, 6-Mercaptopurine 58-05-9, Folinic acid 305-03-3, Chlorambucil 458-37-7, Curcumin 548-75-4, Quercetagetin-7-glucoside 2447-54-3, Sanguinarine 23288-49-5, Probucol 34334-69-5, Cirsiliol 38194-50-2, Sulindac 54350-48-0, Etretinate 65666-07-1, Silymarin 70360-12-2, Sideritoflavone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. and method for treatment of chronic inflammatory diseases)

RN 50-18-0 HCAPLUS

CN 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (CA INDEX NAME)



RN 50-44-2 HCAPLUS

CN 6H-Purine-6-thione, 1,9-dihydro- (CA INDEX NAME)



RN 58-05-9 HCAPLUS
CN L-Glutamic acid, N-[4-[[(2-amino-5-formyl-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 305-03-3 HCAPLUS
CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 458-37-7 HCAPLUS
CN 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-
(CA INDEX NAME)

Double bond geometry as shown.



RN 548-75-4 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-(β-D-glucopyranosyloxy)-3,5,6-trihydroxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 2447-54-3 HCAPLUS
CN [1,3]Benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl- (CA INDEX NAME)



RN 23288-49-5 HCAPLUS
CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)- (CA INDEX NAME)



RN 34334-69-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy- (CA INDEX NAME)



RN 38194-50-2 HCAPLUS
CN 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-, (1Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 54350-48-0 HCAPLUS
CN 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, (2E,4E,6E,8E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 65666-07-1 HCAPLUS
CN Silymarin (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 70360-12-2 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7,8-trimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L123 ANSWER 3 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1100518 HCAPLUS Full-text
DOCUMENT NUMBER: 149:347547
TITLE: Methods using agents modulating thiol compound transport for treatment of thiol compound deficient conditions
INVENTOR(S): Day, Brian J.

PATENT ASSIGNEE(S): Regents of the University of Colorado, USA
SOURCE: U.S. Pat. Appl. Publ., 74pp., Cont.-in-part of U.S. Ser. No. 400,980.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080221029	A1	20080911	US 2007-875811	20071019 <--
US 20040087527	A1	20040506	US 2003-400980	20030327 <--
WO 2009052411	A2	20090423	WO 2008-US80351	20081017
WO 2009052411	A3	20090730		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:	US 2002-422802P	P	20021031 <--
	US 2003-400980	A2	20030327 <--
	US 2007-875811	A	20071019

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Certain embodiments in the invention provide methods for therapy of lung diseases and other conditions, e.g. infection. In certain embodiments, the methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e., ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments can include the use of agents to modulate transport of thiol-containing compds. from the cell, e.g. thiocyanate. In certain embodiments, therapeutic methods involve the administration of such agents to a patient afflicted with an inflammatory condition or infection responsive to stimulation of thiol-containing compound transport.

INCL 514012000; 514352000; 514456000; 514457000; 514311000; 514682000; 514678000; 514044000
CC 1-12 (Pharmacology)
IT Pharmaceutical particles
(bioerodable; thiol compound transport modulators for treatment of thiol compound deficient conditions)
IT Pharmaceutical injections
(i.m. injections; thiol compound transport modulators for treatment of thiol compound deficient conditions)
IT Pharmaceutical injections
(i.p. injections; thiol compound transport modulators for treatment of thiol compound deficient conditions)
IT Pharmaceutical injections
(i.v. injections; thiol compound transport modulators for treatment of thiol compound deficient conditions)
IT Drug delivery systems
(intranodal; thiol compound transport modulators for treatment of thiol compound deficient conditions)
IT Pharmaceutical injections

(s.c. injections; thiol compound transport modulators for treatment of thiol compound deficient conditions)

IT AIDS (disease)
Anti-AIDS agents
Anti-infective agents
Anti-inflammatory agents
Antiasthmatics
Antibacterial agents
Antibiotics
Antitumor agents
Antiviral agents
Asthma
Bacillus anthracis
Bacterial infection
Biological transport
Burkholderia cepacia
Candida
Cardiovascular agents
Central nervous system agents
Cholera
Chronic obstructive pulmonary disease
Combination chemotherapy
Cryptococcus neoformans
Cryptosporidium
Cystic fibrosis
Dermatological agents
Drug delivery systems
Emphysema
Escherichia coli
Francisella tularensis
Fungicides
Gastrointestinal agents
Giardia lamblia
Haemophilus
Helicobacter pylori
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Hepatitis E virus
Hepatitis delta virus
Herpesviridae
Histoplasma capsulatum
Human
Human herpesvirus
Human immunodeficiency virus
Infection
Inflammation
Influenza virus
Inhalation drug delivery systems
Interstitial lung disease
Intratracheal drug delivery systems
Leukemia
Lipid peroxidation
Meningitis
Mitochondria
Molluscum contagiosum virus
Mycosis
Nasal drug delivery systems
Neoplasm
Oral drug delivery systems

Oxidative stress, biological
Pathogen
Plasmodium (malarial genus)
Pneumocystis jirovecii
Prophylaxis
Prostate gland, neoplasm
Protozoacides
Protozoal infection
Pseudomonas aeruginosa
Rectal drug delivery systems
Respiratory system agents
Rotavirus
SARS coronavirus
Secretion (process)
Sepsis
Small intestine
Staphylococcus aureus
Streptococcus pneumoniae
Streptococcus pyogenes
Tinea (genus)
Topical drug delivery systems
Trypanosoma cruzi
Vaginal drug delivery systems
Viral infection
(thiol compound transport modulators for treatment of thiol compound deficient conditions)

IT 50-02-2, Dexamethasone 50-28-2, β-Estradiol, biological studies 52-53-9, Verapamil 53-86-1, Indomethacin 65-49-6, p-Aminosalicylic acid 83-79-4, Rotenone 94-41-7, Chalcone 97-05-2, 5-Sulfosalicylic acid 117-39-5, Quercetin 119-36-8, Methyl salicylate 121-79-9, Propyl gallate 362-05-0, 2-Hydroxyestradiol 362-07-2, 2-Methoxyestradiol 446-72-0, Genistein 458-37-7, Curcumin 480-16-0, Morin 480-40-0, Chrysin 480-41-1, Naringenin 490-46-0, Epicatechin 491-67-8, Baicalein 491-78-1, 5-Hydroxyflavone 491-80-5, Biochanin A 501-36-0, Resveratrol 520-18-3, Kaempferol 520-36-5, Apigenin 525-82-6, Flavone 528-48-3, Fisetin 528-58-5, Cyanidin 529-44-2, Myricetin 548-83-4, Galangin 644-78-0, 2-Hydroxychalcone 2086-83-1, Berberine 2657-25-2, 4'-Hydroxychalcone 6665-86-7, 7-Hydroxyflavone 22395-22-8, 7-Methoxyflavone 33419-42-0, Etoposide 42399-41-7, Diltiazem 115104-28-4, MK-571 223723-79-3
RL: PAC (Pharmacological activity); BIOL (Biological study)
(thiol compound transport modulators for treatment of thiol compound deficient conditions)

IT 458-37-7, Curcumin 480-41-1, Naringenin 491-67-8, Baicalein 491-80-5, Biochanin A 33419-42-0, Etoposide
RL: PAC (Pharmacological activity); BIOL (Biological study)
(thiol compound transport modulators for treatment of thiol compound deficient conditions)

RN 458-37-7 HCAPLUS
CN 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 480-41-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 491-80-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-methoxyphenyl)- (CA INDEX NAME)



RN 33419-42-0 HCAPLUS
CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4,6-O-(1R)-ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L123 ANSWER 4 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:157531 HCAPLUS Full-text
DOCUMENT NUMBER: 148:221361
TITLE: Plant polyphenolics as anti-invasive cancer agents
AUTHOR(S): Bracke, M. E.; Vanhoecke, B. W. A.; Derycke, L.; Bolca, S.; Possemiers, S.; Heyerick, A.; Stevens, C. V.; De Keukeleire, D.; Depypere, H. T.; Verstraete, W.; Williams, C. A.; McKenna, S. T.; Tomar, S.; Sharma, D.; Prasad, A. K.; DePass, A. L.; Parmar, V. S.
CORPORATE SOURCE: Laboratory of Experimental Cancer Research, Department of Radiotherapy, Nuclear Medicine and Experimental Cancer Research, Ghent University Hospital, Ghent, B-9000, Belg.
SOURCE: Anti-Cancer Agents in Medicinal Chemistry (2008), 8(2), 171-185
CODEN: AAMCE4; ISSN: 1871-5206
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Because invasion is, either directly or via metastasis formation, the main cause of death in cancer patients, development of efficient anti-invasive agents is an important research challenge. We have established a screening program for potentially anti-invasive compds. The assay is based on organotypic confronting cultures between human invasive cancer cells and a fragment of normal tissue in three dimensions. Anti-invasive agents appeared to be heterogeneous with regard to their chemical nature, but plant alkaloids, polyphenolics and some of their synthetic congeners were well represented. Even within this group, active compds. were quite diverse: (+)-catechin, tangeretin, xanthohumol and other prenylated chalcones, 3,7-dimethoxyflavone, a pyrazole derivative, an isoxazolylcoumarin and a prenylated desoxybenzoin. The data gathered in this system are now applied in two projects. Firstly, structure-activity relationships are explored with computer models using an artificial neural network approach, based on quant. structural-descriptors. The aim of this study is the prediction and design of optimally efficient anti-invasive compds. Secondly, the metabolism of orally ingested plant polyphenolics by colonic bacteria is studied in a simulator of the human intestinal microbial ecosystem and in human intervention trials. This method should provide information on the final bioavailability of the active compds. in the human body, with regard to microbial metabolism, and the feasibility of designing pre- or probiotics that increase the generation of active principles

for absorption in the gastro-intestinal tract. The final and global aim of all these studies is to predict, synthesize and apply in vivo mols. with an optimal anti-invasive, and hence an anti-metastatic activity against cancer.

CC 63-0 (Pharmaceuticals)
Section cross-reference(s): 1, 11

IT Antitumor agents
(antiinvasive; plant polyphenolics as anti-invasive cancer agents)

IT Colonic bacteria
Drug bioavailability
Drug metabolism
Drug screening
Human
Metastasis
Oral drug delivery systems
(plant polyphenolics as anti-invasive cancer agents)

IT 154-23-4, (+)-Catechin 451-40-1D, Desoxybenzoin, prenylated 481-53-8, Tangeretin 6754-58-1, Xanthohumol 20950-52-1, 3,7-Dimethoxyflavone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(plant polyphenolics as anti-invasive cancer agents)

IT 481-53-8, Tangeretin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(plant polyphenolics as anti-invasive cancer agents)

RN 481-53-8 HCAPLUS

CN 4H-1-Benzopyran-4-one, 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 112 THERE ARE 112 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L123 ANSWER 5 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:758686 HCAPLUS Full-text
DOCUMENT NUMBER: 147:150811
TITLE: Pharmaceutical compositions containing Hops and rosemary extracts and terpenes for regulating inflammatory response
INVENTOR(S): Tripp, Matthew L.; Babish, John G.; Bland, Jeffrey S.; Darland, Gary; Lerman, Robert; Lukaczer, Daniel O.; Liska, Deann J.; Howell, Terrence
PATENT ASSIGNEE(S): Metaproteomics, LLC, USA
SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 464,834.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070160692	A1	20070712	US 2007-532388	20070321 <--
US 20040086580	A1	20040506	US 2003-464410	20030618 <--
US 20040115290	A1	20040617	US 2003-464834	20030618 <--
WO 2004037180	A2	20040506	WO 2003-US33362	20031020 <--
WO 2004037180	A3	20040930		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2008243262	A1	20081204	AU 2008-243262	20081114 <--
PRIORITY APPLN. INFO.:			US 2002-420383P	P 20021021 <--
			US 2003-450237P	P 20030225 <--
			US 2003-400293	B2 20030326 <--
			US 2003-401283	B2 20030326 <--
			US 2003-464410	A2 20030618 <--
			US 2003-464834	A2 20030618 <--
			WO 2003-US33362	W 20031020 <--
			US 2001-885721	A2 20010620 <--
			AU 2002-310484	A3 20020620 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A natural formulation of compds. that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compns. containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivs. or conjugates thereof.

INCL 424745000; 424778000; 514559000; 514548000

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

IT Allergy inhibitors
Alzheimer disease
Anti-inflammatory agents
Antitumor agents
Colon neoplasm
Combination chemotherapy
Human
Humulus lupulus
Inflammation
Irritable bowel syndrome
Joint, anatomical
Macrophage
Nonsteroidal anti-inflammatory drugs
Osteoarthritis
Psoriasis
Rosmarinus officinalis
(pharmaceutical compns. containing hops and rosemary exts. and terpenes for regulating inflammatory response)

IT Drug interactions
(synergistic; pharmaceutical compns. containing hops and rosemary exts. and terpenes for regulating inflammatory response)
IT Pharmaceutical emulsions
Topical drug delivery systems
(topical lotions; pharmaceutical compns. containing hops and rosemary exts. and terpenes for regulating inflammatory response)
IT 76-22-2, Camphor 76-49-3, Bornyl-acetate 79-92-5, Camphene 80-56-8, α-Pinene 80-57-9, Verbenone 83-46-5 87-44-5, Caryophyllene 89-83-8, Thymol 93-15-2, Methyl-eugenol 98-55-5 99-49-0, Carvone 99-85-4 99-86-5, α-Terpinene 99-87-6, p-Cymene 100-51-6, Benzyl-alcohol, biological studies 111-02-4, Squalene 123-35-3, Myrcene 124-07-2, Octanoic acid, biological studies 124-76-5, Isoborneol 127-91-3, β-Pinene 138-86-3, Limonene 327-97-9, Chlorogenic acid 331-39-5, Caffeic acid 470-82-6, 1,8-Cineole 471-53-4, 18-β-Glycyrrhetinic acid 472-15-1, Betulinic acid 473-98-3, Betulin 474-20-4D, Lanostane, derivs. 491-09-8, Piperitenone 491-70-3, Luteolin 495-60-3, Zingiberene 499-75-2, Carvacrol 507-70-0, Borneol 508-01-0, Soyasapogenol A 508-24-7, Tumulosic acid 520-11-6, 6-Methoxyluteolin 520-26-3, Hesperidin 520-34-3, Diosmetin 520-36-5, Apigenin 545-46-0, Uvaol 546-80-5, α-Thujone 559-70-6, β-Amyrin 559-74-0, Friedelin 560-66-7, Eburicoic acid 562-74-3, Terpinen-4-ol 578-74-5 586-62-9, Terpinolene 595-15-3, Soyasapogenol B 638-95-9, α-Amyrin 638-97-1, β-Amyrenone 639-14-5, Gypsogenin 644-30-4, Curcumene 906-33-2, Neo-chlorogenic acid 989-30-0 1139-30-6, Caryophyllene-oxide 1197-07-5, trans-Carveol 1405-86-3, Glycyrrhizin 1449-05-4, 18-α-Glycyrrhetinic acid 3387-41-5, Sabinene 3650-11-1, Rosmaricine 4180-23-8, trans-Anethole 4339-72-4, 3-O-Acetyloleanolic acid 4821-04-9 5373-11-5, Luteolin-7-glucoside 5957-80-2, Carnosol 6246-46-4 6753-98-6, α-Humulene 6822-47-5, Sophoradiol 7372-30-7, 3-O-Acetylursolic acid 10366-91-3, Salicylic acid-2-β-D-glucoside 13849-91-7, 19-α-Hydroxyursolic acid 20283-92-5 23028-17-3, α-Hydroxyhydrocaffeic acid 26707-60-8, 2-β-Hydroxyoleanolic acid 27210-57-7, Rosmariquinone 29070-92-6, Pachymic acid 33880-83-0, β-Elemene 34157-83-0, Celastrol 34334-69-5 34421-27-7, Tetrahydro-isocohumulone 52213-27-1 53527-42-7, Luteolin-3'-O-β-D-glucuronide 53833-85-5, Sabinyl acetate 54556-05-7, Tetrahydro-isohumulone 74285-86-2, Triptophenolide 80225-53-2, Rosmanol 91729-95-2, Rosmaridiphenol 111200-01-2, 7-Ethoxy-rosmanol 113085-62-4, 7-Methoxy-rosmanol 147714-67-8 160598-97-0 160598-98-1 685110-34-3, Hexahydro-isohumulone 685110-35-4, Dihydro-isohumulone 685110-36-5, Tetrahydro-adhumulone 685110-37-6, Hexahydro-isocohumulone 685110-38-7, Hexahydro-adhumulone 685141-03-1, Rosmarinol 790664-64-1, Dihydro-isocohumulone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing hops and rosemary exts. and terpenes for regulating inflammatory response)
IT 520-11-6, 6-Methoxyluteolin 34334-69-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing hops and rosemary exts. and terpenes for regulating inflammatory response)
RN 520-11-6 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxy- (CA INDEX NAME)



RN 34334-69-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy- (CA INDEX NAME)



L123 ANSWER 6 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:606492 HCAPLUS Full-text
DOCUMENT NUMBER: 145:76623
TITLE: Compounds and methods for thiol-containing compound efflux and cancer treatment
INVENTOR(S): Day, Brian J.; Kachadourian, Remy
PATENT ASSIGNEE(S): National Jewish Medical and Research Center, USA
SOURCE: U.S. Pat. Appl. Publ., 62 pp., Cont.-in-part of U.S. Ser. No. 400,980.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060135585	A1	20060622	US 2005-280959	20051115 <--
US 20040087527	A1	20040506	US 2003-400980	20030327 <--
AU 2006327105	A1	20070628	AU 2006-327105	20061115
CA 2669503	A1	20070628	CA 2006-2669503	20061115
WO 2007073518	A2	20070628	WO 2006-US60941	20061115
WO 2007073518	A9	20070823		
WO 2007073518	A3	20071025		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1954681	A2	20080813	EP 2006-848736	20061115
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: US 2002-422802P P 20021031 <--
US 2003-400980 A2 20030327 <--
US 2005-280959 A 20051115
WO 2006-US60941 W 20061115
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 145:76623

AB Methods for therapy of cystic fibrosis and other conditions such as cancer are provided. The methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e.ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments include the use of agents to modulate transport of thiol-containing compds. within the cell. Therapeutic methods involve the administration of such agents to a patient afflicted with cystic fibrosis, cancer and/or another condition responsive to stimulation of thiol-containing compound transport.

INCL 514396000; 548341500; 514374000; 548215000
CC 1-6 (Pharmacology)
IT Drug interactions
(synergistic; thiol-containing compound efflux and cancer treatment)
IT Alkylating agents, biological
Antibacterial agents
Antitumor agents
Bladder, neoplasm
Bone, neoplasm
Brain, neoplasm
Cystic fibrosis
Drug delivery systems
Esophagus, neoplasm
Fever and Hyperthermia
Gallbladder, neoplasm
Head and Neck, neoplasm
Human
Kidney, neoplasm
Lipid peroxidation
Liver, neoplasm
Lung, neoplasm
Lymph node, neoplasm
Mammary gland, neoplasm
Natural products, pharmaceutical
Neoplasm
Ovary, neoplasm
Oxidative stress, biological
Pancreas, neoplasm
Pharynx, neoplasm
Prostate gland, neoplasm
Radiosensitizers, biological
Skin, neoplasm
Stomach, neoplasm
Structure-activity relationship
Thyroid gland, neoplasm
(thiol-containing compound efflux and cancer treatment)
IT 50-02-2, Dexamethasone 50-07-7, Mitomycin C 50-18-0
, Cyclophosphamide 50-28-2, β-Estradiol, biological studies
50-44-2, Mercaptopurine 50-76-0, Dactinomycin
51-21-8, 5-Fluorouracil 52-53-9, Verapamil 53-19-0,
Mitotane 53-86-1, Indomethacin 55-98-1, Busulfan 57-22-7,
Vincristine 59-05-2, Methotrexate 65-49-6, p-Aminosalicylic Acid
83-79-4, Rotenone 94-41-7, Chalcone 97-05-2, 5-Sulfosalicylic Acid
117-39-5, Quercetin 119-36-8, Methylsalicylate 121-79-9, Propyl
Gallate 127-07-1, Hydroxyurea 147-94-4, Cytarabine
148-82-3, Melphalan 153-18-4, Rutin 154-42-7,

Thioguanine 154-93-8, Carmustine 305-03-3,
Chlorambucil 362-05-0, 2-Hydroxyestradiol 446-72-0, Genistein
458-37-7, Curcumin 480-16-0, Morin 480-39-7, Pinocembrin
480-40-0, Chrysin 480-41-1, Naringenin 490-46-0,
(-)-Epicatechin 491-67-8, Baicalein 491-78-1,
5-Hydroxyflavone 491-80-5, Biochanin-A 501-36-0, Resveratrol
520-18-3, Kaempferol 520-36-5, Apigenin 525-82-6, Flavone 528-48-3,
Fisetin 528-58-5, Cyanidin 529-44-2, Myricetin 548-82-3, Pinobanksin
548-83-4, Galangin 599-79-1, Sulfasalazine 644-78-0, 2-Hydroxychalcone
671-16-9, Procarbazine 865-21-4, Vinblastine
1214-47-7, 2'-HydroxyChalcone 1482-74-2, 2',3',4'-Trihydroxychalcone
1776-30-3, 2',4'-Dihydroxychalcone 1818-12-8, 2-Methylestradiol
2086-83-1, Berberine 2657-25-2, 4'-Hydroxychalcone 3033-92-9,
3'-Hydroxychalcone 4342-03-4, Dacarbazine 6665-86-7,
7-Hydroxyflavone 10540-29-1, Tamoxifen 11056-06-7,
Bleomycin 13010-47-4, Lomustine 13323-66-5, 2',4-Dihydroxychalcone
13745-20-5, 2',4',4-Trihydroxychalcone 15131-80-3 15663-27-1
, Cisplatin 18378-89-7, Plicamycin 18883-66-4,
Streptozocin 19312-13-1, 2',5'-Dihydroxychalcone 20426-12-4,
4-Hydroxychalcone 20830-81-3, Daunorubicin 22395-22-8,
7-Methoxyflavone 23214-92-8, Doxorubicin 29767-20-2
, Teniposide 33419-42-0, Etoposide 36574-83-1,
2',3-Dihydroxychalcone 42399-41-7, Diltiazem 115104-28-4, MK-571
RL: PAC (Pharmacological activity); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)
(thiol-containing compound efflux and cancer treatment)

IT 50-07-7, Mitomycin C 50-18-0, Cyclophosphamide
50-44-2, Mercaptopurine 50-76-0, Dactinomycin
51-21-8, 5-Fluorouracil 53-19-0, Mitotane
57-22-7, Vincristine 127-07-1, Hydroxyurea
147-94-4, Cytarabine 148-82-3, Melphalan
154-42-7, Thioguanine 154-93-8, Carmustine
305-03-3, Chlorambucil 458-37-7, Curcumin
480-41-1, Naringenin 491-67-8, Baicalein
491-80-5, Biochanin-A 671-16-9, Procarbazine
865-21-4, Vinblastine 4342-03-4, Dacarbazine
10540-29-1, Tamoxifen 11056-06-7, Bleomycin
15663-27-1, Cisplatin 18378-89-7, Plicamycin
18883-66-4, Streptozocin 20830-81-3, Daunorubicin
23214-92-8, Doxorubicin 29767-20-2, Teniposide
33419-42-0, Etoposide
RL: PAC (Pharmacological activity); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)
(thiol-containing compound efflux and cancer treatment)

RN 50-07-7 HCAPLUS
CN Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione,
6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-
5-methyl-, (1aS,8S,8aR,8bS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 50-18-0 HCAPLUS
CN 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (CA INDEX NAME)



RN 50-44-2 HCAPLUS
CN 6H-Purine-6-thione, 1,9-dihydro- (CA INDEX NAME)



RN 50-76-0 HCAPLUS
CN Actinomycin D (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 51-21-8 HCAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-fluoro- (CA INDEX NAME)



RN 53-19-0 HCAPLUS
CN Benzene, 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]- (CA INDEX NAME)



RN 57-22-7 HCAPLUS

CN Vincaleukoblastine, 22-oxo- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 127-07-1 HCAPLUS
CN Urea, N-hydroxy- (CA INDEX NAME)



RN 147-94-4 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-β-D-arabinofuranosyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 148-82-3 HCAPLUS
CN L-Phenylalanine, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 154-42-7 HCAPLUS
CN 6H-Purine-6-thione, 2-amino-1,9-dihydro- (CA INDEX NAME)



RN 154-93-8 HCAPLUS
CN Urea, N,N'-bis(2-chloroethyl)-N-nitroso- (CA INDEX NAME)



RN 305-03-3 HCAPLUS
CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 458-37-7 HCAPLUS
CN 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-
(CA INDEX NAME)

Double bond geometry as shown.



RN 480-41-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-,
(2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 491-80-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-methoxyphenyl)- (CA INDEX NAME)



RN 671-16-9 HCAPLUS
CN Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazinyl)methyl]- (CA INDEX NAME)



RN 865-21-4 HCAPLUS
CN Vincaleukoblastine (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 4342-03-4 HCAPLUS
CN 1H-Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazen-1-yl)- (CA INDEX

NAME)



RN 10540-29-1 HCAPLUS
CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 11056-06-7 HCAPLUS
CN Bleomycin (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 15663-27-1 HCAPLUS
CN Platinum, diamminedichloro-, (SP-4-2)- (CA INDEX NAME)



RN 18378-89-7 HCAPLUS
CN D-threo-2-Pentulose, 5-deoxy-1-C-[(2S,3S)-7-[[2,6-dideoxy-3-O-(2,6-dideoxy-β-D-arabino-hexopyranosyl)-β-D-arabino-hexopyranosyl]oxy]-3-[(O-2,6-dideoxy-3-C-methyl-β-D-ribo-hexopyranosyl-(1→3)-O-2,6-dideoxy-β-D-lyxo-hexopyranosyl-(1→3)-2,6-dideoxy-β-D-arabino-hexopyranosyl)oxy]-1,2,3,4-tetrahydro-5,10-dihydroxy-6-methyl-4-oxo-2-anthracenyl]-1-O-methyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 18883-66-4 HCAPLUS
CN D-Glucose, 2-deoxy-2-[[(methylnitrosoamino)carbonyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 20830-81-3 HCAPLUS
CN 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 23214-92-8 HCAPLUS

CN 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 29767-20-2 HCAPLUS

CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-[(R)-2-thienylmethylene]-β-D-glucopyranosyl]oxy]-, (5R,5aR,8aR,9S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 33419-42-0 HCAPLUS
CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4,6-O-(1R)-ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L123 ANSWER 7 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:342625 HCAPLUS Full-text
DOCUMENT NUMBER: 144:386807
TITLE: Extraction of γ-butyrolactones from Bupleurum scorzonerifolium for use in antitumor pharmaceutical compositions
INVENTOR(S): Lin, Shinn-Zong; Harn, Horng-Jyh
PATENT ASSIGNEE(S): Buddhist Tzu Chi General Hospital, Taiwan
SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 690,992.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20060079575	A1	20060413	US 2005-186705		20050720	<--
TW 315985	B	20091021	TW 2003-92119380		20030716	<--
US 20050013879	A1	20050120	US 2003-690992		20031021	<--
US 7348032	B2	20080325				
AT 416765	T	20081215	AT 2003-450241		20031028	<--
PRIORITY APPLN. INFO.:			TW 2003-92119380	A	20030716	<--
			US 2003-690992	A2	20031021	<--
			EP 2003-450241	A	20031028	<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 144:386807
GI



I

AB γ-Butyrolactones, such as chaihulactone (I), were isolated from Bupleurum scorzonerifolium extract and formulated for therapeutic use in the treatment of cancer. These γ-butyrolactones alone or in combination with other antitumor agents have inhibitory effects on hepatoma, ovarian cancer, breast cancer, lung cancer, malignant glioblastoma or colorectal carcinoma, and are cytotoxic with high specificity to inhibit Paclitaxel-resistant tumor cells at later stage of chemotherapy without any damage on normal cells.

INCL 514464000; 549320000

CC 11-1 (Plant Biochemistry)
Section cross-reference(s): 1, 63

IT Antitumor agents
Bupleurum scorzoneraefolium
Combination chemotherapy
Drug delivery systems
Human
(extraction of γ-butyrolactones from Bupleurum scorzonerifolium for use in antitumor pharmaceutical compns.)

IT 480-11-5P, Oroxylin A 480-34-2P, Eugenin 632-85-9P, Wogonin 6258-43-1P, Chaihunaphthone 17187-79-0P, Chaihulactone 22804-52-0P, 1,2,3,7-Tetramethoxyxanthone 40456-50-6P, Yatein 53965-06-3P, Chinensinaphthol 57096-02-3P, Isoscutellarein 8-methyl ether 75590-33-9P 126574-52-5P, Isokaerophyllin 132624-99-8P, Saikochromone A 652143-70-9P, Isochaihulactone
RL: BMF (Bioindustrial manufacture); NPO (Natural product occurrence); PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(extraction of γ-butyrolactones from Bupleurum scorzonerifolium for use in antitumor pharmaceutical compns.)

IT 480-11-5P, Oroxylin A
RL: BMF (Bioindustrial manufacture); NPO (Natural product occurrence); PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(extraction of γ-butyrolactones from Bupleurum scorzonerifolium for use in antitumor pharmaceutical compns.)

RN 480-11-5 HCAPLUS

CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-6-methoxy-2-phenyl- (CA INDEX NAME)



L123 ANSWER 8 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:340113 HCAPLUS Full-text
DOCUMENT NUMBER: 144:376495
TITLE: Formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases
INVENTOR(S): Jia, Qi; Zhao, Yuan
PATENT ASSIGNEE(S): Unigen Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 932,571.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060079467	A1	20060413	US 2005-254433	20051019 <--
US 20030216481	A1	20031120	US 2003-427746	20030430 <--
US 7514469	B2	20090407		
EP 2108370	A1	20091014	EP 2009-167112	20030430 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR				
US 20030232763	A1	20031218	US 2003-462030	20030613 <--
US 20040186062	A1	20040923	US 2004-785704	20040224 <--
US 7531521	B2	20090512		
US 20050096281	A1	20050505	US 2004-932571	20040901 <--
AU 2005295190	A1	20060427	AU 2005-295190	20051019
CA 2584124	A1	20060427	CA 2005-2584124	20051019
WO 2006045056	A2	20060427	WO 2005-US37936	20051019
WO 2006045056	A3	20070201		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1804787	A2	20070711	EP 2005-810437	20051019
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101083981	A	20071205	CN 2005-80043644	20051019
JP 2008517069	T	20080522	JP 2007-538073	20051019
BR 2005018218	A	20081104	BR 2005-18218	20051019
US 20060177528	A1	20060810	US 2006-279925	20060417 <--
US 20070135359	A1	20070614	US 2007-676528	20070220 <--
MX 2007004471	A	20070618	MX 2007-4471	20070413
IN 2007KN01579	A	20070727	IN 2007-KN1579	20070503
PRIORITY APPLN. INFO.:			US 2002-377168P P	20020430 <--
			US 2003-450922P P	20030226 <--
			US 2003-427746 A2	20030430 <--
			US 2003-462030 A2	20030613 <--

US 2003-499742P	P	20030902	<--
US 2004-785704	A2	20040224	
US 2004-932571	A2	20040901	
US 2004-620163P	P	20041019	
US 2002-91362	A2	20020301	<--
US 2002-104477	A2	20020322	<--
WO 2003-US6098	W	20030228	<--
EP 2003-726548	A3	20030430	<--
US 2003-469275	A1	20030827	<--
WO 2005-US37936	W	20051019	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 144:376495

AB The present invention provides a novel composition comprised of a mixture of 2 specific classes of compds, free-B-Ring flavonoids and flavans, for use in the prevention and treatment of diseases and conditions associated with mouth, gums and teeth. This composition of matter simultaneously inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymic activity and reduces cytokine production at the mRNA level in normal, aged and damaged periodontal cells and tissues. This invention further provides a method for the prevention and treatment of diseases and conditions of the mouth, gums and teeth. The method for preventing and treating diseases and conditions of the mouth, teeth and gums is comprised of administering to a host in need thereof a therapeutically effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants, preferably in the Scutellaria, Oroxylum, Acacia or Uncaria genus of plants and pharmaceutically and/or cosmetically acceptable carriers. Finally the present invention provides a method for the prevention and treatment of diseases and conditions of the mouth, teeth or gums, including but not limited to periodontal diseases, such as gingivitis, periodontitis, pulpitis, periodontal conditions caused by the phys. implantation of oral dentures, trauma, injuries, bruxism, neoplastic and other degenerative processes; material alba, pellicles, dental plaques, calculus, and stains. Use of the composition described herein also affords the benefit of maintaining optimum saliva production and pH, minimizing bacterial growth, reducing the formation of pellicles and plaque, inhibiting tooth decalcification and tooth caries (decay), promoting remineralization, which yields healthy gums, whitening teeth, maintaining healthy oral hygiene and reducing oral malodor (halitosis).

INCL 514027000; 514456000

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 62

IT Drug delivery systems
(aerosols; formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases)

IT Drug delivery systems
(chewing gums; formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases)

IT Acacia
Acacia catechu
Achyrocline
Actinodaphne
Adiantaceae
Alpinia
Anaphalis
Annonaceae
Artocarpus
Asteraceae
Baccharis
Beverages
Bignoniaceae

Centaurea
Chewing gum
Colebrookea
Combretaceae
Cotula
Cytokine inhibitors
Dentifrices
Derris (genus)
Desmos
Discoloration
  Drug bioavailability
Eupatorium
Euphorbiaceae
Fabaceae
Ficus (plant)
Flower
Gingiva, disease
Glycyrrhiza
Gnaphalium
Helichrysum
Human
Lamiaceae
Laurencia
Lindera
Millettia
Moraceae
Mouth, disease
  Mouthwashes
Notholaena
Origanum
Oroxylum
Oroxylum indicum
Periodontium, disease
Pinaceae
Pinus
Pityrogramma
Pongamia
Pteridaceae
Sapium
Scutellaria
Scutellaria baicalensis
Scutellaria lateriflora
Scutellaria orthocalyx
Skin
Stachys
Tephrosia
Terminalia
Tooth, disease
Ulmaceae
Ulmus
Uncaria
Uncaria gambier
Uncaria hirsuta
Uncaria sinensis
Uncaria tomentosa
Zingiberaceae
Ziziphora
   (formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases)

IT Drug delivery systems

(gels; formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases)

IT Drug delivery systems
(injections, i.m.; formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases)

IT Drug delivery systems
(injections, i.v.; formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases)

IT Drug delivery systems
(ointments; formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases)

IT Drug delivery systems
(suppositories; formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases)

IT Drug delivery systems
(tinctures; formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases)

IT Drug delivery systems
(topical; formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases)

IT 21967-41-9, Baicalin
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases)

IT 154-23-4, Catechin 480-11-5, Oroxylin A 480-40-0, Chrysin 490-46-0, EpiCatechin 491-67-8, Baicalein 494-12-2D, Flavan, derivs. 632-85-9, Wogonin 4443-09-8, Norwogonin 27740-01-8, Scutellarin 29550-13-8, 5,6-Dihydroxy-7-methoxyflavone 35775-49-6, Chrysin-7-glucuronide 36948-76-2 38183-03-8, 7,8-Dihydroxyflavone 51059-44-0, Wogonin-7-glucuronide 123549-16-6 882527-46-0, UP 676
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases)

IT 21967-41-9, Baicalin
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases)

RN 21967-41-9 HCAPLUS

CN β-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



IT 480-11-5, Oroxylin A 491-67-8, Baicalein 27740-01-8, Scutellarin 29550-13-8, 5,6-Dihydroxy-7-methoxyflavone 36948-76-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulation of dual eicosanoid and cytokine system inhibitors for treatment of oral diseases)

RN 480-11-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-6-methoxy-2-phenyl- (CA INDEX NAME)



RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 27740-01-8 HCAPLUS
CN β-D-Glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 29550-13-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6-dihydroxy-7-methoxy-2-phenyl- (CA INDEX NAME)



RN 36948-76-2 HCAPLUS
CN β-D-Glucopyranosiduronic acid, 5-hydroxy-6-methoxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

L123 ANSWER 9 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:164629 HCAPLUS Full-text
DOCUMENT NUMBER: 144:239871
TITLE: Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b)
INVENTOR(S): Oliver, Yoa-Pu Hu; Hsiong, Cheng-Huei; Wang, Mei-Ting; Pao, Li-Heng
PATENT ASSIGNEE(S): National Defense Medical Center, Taiwan; National Defense University
SOURCE: U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060040875	A1	20060223	US 2005-28615	20050105 <--
TW 287990	B	20071011	TW 2004-93100465	20040108 <--
CA 2593140	A1	20060713	CA 2005-2593140	20051213
WO 2006072203	A1	20060713	WO 2005-CN2167	20051213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CN 1820743	A	20060823	CN 2005-10130486	20051213
JP 2008526788	T	20080724	JP 2007-549784	20051213
US 20090074708	A1	20090319	US 2008-325139	20081128

PRIORITY APPLN. INFO.:
TW 2004-93100465 A 20040108 <--
US 2005-28615 A 20050105
WO 2005-CN2167 W 20051213

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A UGT2B inhibitor capable of increasing the bioavailability of a drug, being a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin, β-naphthoflavone, α-naphthoflavone, hesperetin, terpineol, (+)-limonene, β-

myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alc., puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, Et myristate, umbelliferone, and a combination thereof. A UGT2B enhancer capable of enhancing the liver detoxification function in a subject, being a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: mordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+) epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (-)epicatechin, luteolin-7-glucoside, ergosterol, rutin, luteolin, Et myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, trans-cinnamaldehyde, and a combination thereof. Rat were administered with both 100 mg/Kg nalbuphine and 4 mg/Kg capillarisin orally. The Tmax and Cmax for nalurphin was 25 min, and 2582 ng/mL resp., as compared with 97 min and 79 ng/mL for the control group which did not receive capillarsisin.

INCL 514027000; 514169000; 514026000; 514033000; 514548000; 514724000; 514282000

CC 63-5 (Pharmaceuticals)

IT Drug bioavailability
Liver, disease
(inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b))

IT Drug delivery systems
(injections, i.v.; inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b))

IT Drug delivery systems
(oral; inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b))

IT 57-27-2, (-)-Morphine, biological studies 57-87-4, Ergosterol 62-67-9, Nalorphine 76-41-5, Oxymorphone 76-57-3, Codeine 77-52-1, Ursolic acid 93-35-6, Umbelliferone 99-50-3, Protocatechuic acid 112-53-8, Lauryl alcohol 117-39-5, Quercetin 122-72-5, 3-Phenylpropyl acetate 123-35-3, -Myrcene 124-06-1, Ethyl myristate 140-10-3, trans-Cinnamic acid, biological studies 149-91-7, Gallic acid, biological studies 153-18-4, Rutin 154-23-4, (+)-Catechin 437-64-9, Genkwanin 446-72-0, Genistein 465-65-6, Naloxone 466-99-9, Hydromorphone 470-82-6, Cineole 480-19-3, Isorhamnetin 480-41-1, Naringenin 485-72-3, Formononetin 486-66-8, Daidzein 490-46-0, (-)-Epicatechin 491-67-8, Baicalein 491-70-3, Luteolin 500-38-9, Nordihydroguaiaretic acid 508-02-1, Oleanolic acid 509-60-4, Dihydromorphine 520-18-3, Kaempferol 520-26-3, Hesperidin 520-33-2, Hesperetin 520-36-5, Apigenin 522-12-3, Quercitrin 551-15-5, Liquiritin 552-58-9, Eriodictyol 552-66-9, Daidzin 604-59-1, α-Naphthoflavone 632-85-9, Wogonin 961-29-5, Isoliquiritigenin 1405-86-3, Glycyrrhizin 3681-99-0, Puerarin 4261-42-1, Homoorientin 5373-11-5, Luteolin-7-glucoside 5989-27-5, (+)-Limonene 8000-41-7, Terpineol 10236-47-2, Naringin 13241-33-3, Neohesperidin 14371-10-9, trans-Cinnamaldehyde 14941-08-3, Poncirin 16590-41-3, Naltrexone 17388-39-5, Swertiamarin 20594-83-6, Nalbuphine 21637-25-2, Isoquercitrin 21967-41-9, Baicalin 23180-57-6, Paeoniflorin 23513-14-6, 6-Gingerol 35323-91-2, (+)Epicatechin 38953-85-4, Isovitexin 52485-79-7, Buprenorphine 56365-38-9, Capillarisin 111555-53-4, Naltrindole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b))

IT 480-41-1, Naringenin 491-67-8, Baicalein

21967-41-9, Baicalin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (ugt2b))
RN 480-41-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 21967-41-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



L123 ANSWER 10 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:394807 HCAPLUS Full-text
DOCUMENT NUMBER: 142:423869
TITLE: Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
INVENTOR(S): Jia, Qi; Burnett, Bruce; Zhao, Yuan
PATENT ASSIGNEE(S): Unigen Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 427,746.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20050096281	A1	20050505	US 2004-932571		20040901	<--
US 20030165588	A1	20030904	US 2002-91362		20020301	<--
US 20030180402	A1	20030925	US 2002-104477		20020322	<--
US 7108868	B2	20060919				
US 20030216481	A1	20031120	US 2003-427746		20030430	<--
US 7514469	B2	20090407				
US 20060079467	A1	20060413	US 2005-254433		20051019	<--
US 20070135359	A1	20070614	US 2007-676528		20070220	<--
US 20080096826	A1	20080424	US 2007-927061		20071029	<--
US 20080096827	A1	20080424	US 2007-962363		20071221	<--
PRIORITY APPLN. INFO.:			US 2002-91362	A2	20020301	<--
			US 2002-104477	A2	20020322	<--
			US 2003-427746	A2	20030430	<--
			US 2003-499742P	P	20030902	<--
			US 2002-377168P	P	20020430	<--
			US 2003-450922P	P	20030226	<--
			WO 2003-US6098	W	20030228	<--
			US 2003-462030	A2	20030613	<--
			US 2003-469275	A1	20030827	<--
			US 2004-785704	A2	20040224	
			US 2004-932571	A2	20040901	
			US 2004-620163P	P	20041019	

OTHER SOURCE(S): MARPAT 142:423869

AB The invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof. The invention also includes a novel method for simultaneously inhibiting expression of pro-inflammatory cytokines, preventing ROS generation and augmenting anti-oxidant defenses. The activity of this composition is conductive to ultimately preserving cognitive function and providing a level of neuroprotection.

IC ICM A61K031-7048
ICS A61K031-353

INCL 514027000; 514456000

CC 1-11 (Pharmacology)
Section cross-reference(s): 11

ST Lasoperin freeBring flavonoid flavan mixt neuroprotectant cognition enhancer antioxidant; neurodegeneration neuroprotectant freeBring flavonoid flavan mixt learning memory cognition; aging neurodegeneration oxidative stress inflammation Lasoperin neuroprotectant cognition enhancer

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IL-1β, expression of; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IL-6, expression of; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NF-κB (nuclear factor of κ light chain gene enhancer in B-cells); formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NF-κB, expression of; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PPARγ; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Immunostimulants
(adjuvants; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Drug delivery systems
(carriers; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Drug delivery systems
(controlled-release; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Nervous system, disease
(degeneration; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Emotion
(fear, conditioning of contextual; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(for cox-1, expression of; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(for cox-2, expression of; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Acacia
Acacia auriculiformis
Acacia caesia
Acacia catechu
Acacia concinna
Acacia dealbata
Acacia farnesiana
Acacia holosericea
Acacia mangium
Acacia mearnsi
Acacia nilotica
Acacia pennata
Acacia picnantha

Acacia senegal
Acacia sinuata
Acacia speciosa
Achyrocline
Actinodaphne
Adiantaceae
Aging, animal
Alpinia
Anaphalis
Annonaceae
Antioxidants
Artocarpus
Asteraceae
Baccharis
Bignoniaceae
Brain
Burbidgea
Centaurea
Cognition
Cognition enhancers
Cognitive disorders
Colebrookea
Combretaceae
Cosmetics
Cotula
Derris (genus)
Desmos
Drugs
Embryophyta
Eupatorium
Euphorbiaceae
Fabaceae
Ficus (plant)
Flower
Glycyrrhiza
Gnaphalium
Helichrysum
Human
Inflammation
Lamiaceae
Leaf
Learning
Lindera
Memory, biological
Millettia
Monocyte
Moraceae
Neuron
Notholaena
Organic synthesis
Origanum
Oroxylum
Oxidative stress, biological
Pinaceae
Pinus
Pityrogramma
Plants
Pongamia
Pteridaceae
Root

Sapium
Scutellaria
Seed
Skin preparations (pharmaceutical)
Stachys
Stem
Tephrosia
Terminalia
Tuber (plant organ)
Ulmaceae
Ulmus
Uncaria africana
Uncaria gambier
Uncaria tomentosa
Ziziphora
(formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)

IT Cytokines
Interleukin 1β
Interleukin 6
Reactive oxygen species
Transcription factors
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)

IT Natural products
RL: NPO (Natural product occurrence); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)

IT Flavonoids
RL: NPO (Natural product occurrence); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(free-B-ring; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)

IT Brain
(hippocampus, -dependent cognitive function; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)

IT Drug delivery systems
(i.p.; formulation of free-B-ring flavonoids and flavans mixt . for use in prevention and treatment of cognitive decline and age-related memory impairments)

IT Drug delivery systems
(injections, i.m.; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)

IT Drug delivery systems
(injections, i.v.; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)

IT Drug delivery systems
(intradermal; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)

IT Drug delivery systems
(intragastric; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Memory disorders
(memory retention defect, age-related; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Memory disorders
(memory retention defect; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Cytoprotective agents
Nervous system agents
(neuroprotective agents; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Anti-inflammatory agents
(nonsteroidal; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Drug delivery systems
(oral; formulation of free-B-ring flavonoids and flavans mixt . for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Stem
(rhizome; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Plant tissue
(shoot, young; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Drug delivery systems
(suppositories; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Drug delivery systems
(topical; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(γ; formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT 506-32-1, Arachidonic acid 7782-44-7, Oxygen, biological studies 7782-44-7D, Oxygen, reactive species 9029-60-1, Lipoxygenase 39391-18-9, Cyclooxygenase 80619-02-9, 5-Lipoxygenase 82249-77-2, 15-Lipoxygenase 82391-43-3, 12-Lipoxygenase 329900-75-6, Cox-2 329967-85-3, COX-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)
IT 847597-01-7P, Lasoperin
RL: BSU (Biological study, unclassified); NPO (Natural product occurrence); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)

(formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)

IT 154-23-4, Catechin 480-11-5, Oroxylin A 480-40-0, Chrysin 490-46-0, Epicatechin 491-67-8, Baicalein 494-12-2D, Flavan, derivs. 632-85-9, Wogonin 4443-09-8, Norwogonin 21967-41-9 27740-01-8, Scutellarin 35775-49-6, Chrysin-7-glucuronide 36948-76-2 51059-44-0, Wogonin-7-glucuronide 123549-16-6
RL: NPO (Natural product occurrence); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)

IT 103-90-2, Acetaminophen 15687-27-1, Ibuprofen 169590-42-5, Celecoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)

IT 480-11-5, Oroxylin A 491-67-8, Baicalein 21967-41-9 27740-01-8, Scutellarin 36948-76-2
RL: NPO (Natural product occurrence); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(formulation of free-B-ring flavonoids and flavans mixture for use in prevention and treatment of cognitive decline and age-related memory impairments)

RN 480-11-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-6-methoxy-2-phenyl- (CA INDEX NAME)



RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 21967-41-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 27740-01-8 HCAPLUS
CN β-D-Glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 36948-76-2 HCAPLUS
CN β-D-Glucopyranosiduronic acid, 5-hydroxy-6-methoxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



L123 ANSWER 11 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:369133 HCAPLUS Full-text
DOCUMENT NUMBER: 142:435774
TITLE: Compositions treatment of chronic inflammatory diseases
INVENTOR(S): Shapiro, Howard K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 610,073, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 20050090553	A1	20050428	US 2004-924945		20040824 <--
US 20080234380	A1	20080925	US 2008-70518		20080220 <--
PRIORITY APPLN. INFO.:			US 1992-906909	B2	19920630 <--
			US 1994-241603	B2	19940511 <--
			US 1997-814291	B2	19970310 <--
			US 2000-610073	B2	20000705 <--
			US 2004-924945	A2	20040824

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 142:435774

AB This invention defines novel compns. that can be used for clin. treatment of a class of chronic inflammatory diseases. Increased generation of carbonyl substances, aldehydes and ketones, occurs at sites of chronic inflammation and is common to the etiologies of all of the clin. disorders addressed herein. Such carbonyl substances are cytotoxic and addnl. serve to perpetuate and disseminate the inflammatory process. This invention defines use of compns., the orally administered required primary agents of which are primary amine derivs. of benzoic acid capable of reacting with the carbonyl substances. P-Aminobenzoic acid (or PABA) is an example of the required primary agent of the present invention. PABA has a small mol. weight, is water soluble, has a primary amine group which reacts with carbonyl-containing substances and is tolerated by the body in relatively high dosages for extended periods. The method of the present invention includes administration of a composition comprising: (1) an orally consumed primary agent; (2) a previously known medicament co-agent recognized as effective to treat a chronic inflammatory disease addressed herein administered to the mammalian subject via the oral route, other systemic routes of administration or via the topical route; and (3) optionally 1 or more addnl. orally consumed co-agent selected from the group consisting of antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl co-agents, co-agents which may facilitate glutathione activity and nonabsorbable primary amine polymeric co-agents, so as to produce an additive or synergistic physiol. effect of an anti-inflammatory nature.

IC ICM A61K031-195
INCL 514565000; 514567000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT Drug delivery systems
(gels; compns. treatment of chronic inflammatory diseases)
IT Drug delivery systems
(injections, i.m.; compns. treatment of chronic inflammatory diseases)
IT Drug delivery systems
(injections, i.v.; compns. treatment of chronic inflammatory diseases)
IT Drug delivery systems
(lotions; compns. treatment of chronic inflammatory diseases)
IT Drug delivery systems
(oral; compns. treatment of chronic inflammatory diseases)
IT Drug delivery systems
(tablets; compns. treatment of chronic inflammatory diseases)
IT Drug delivery systems
(topical; compns. treatment of chronic inflammatory diseases)
IT 50-02-2, Dexamethasone 50-03-3, Hydrocortisone acetate 50-06-6, Phenobarbital, biological studies 50-14-6, Vitamin D2 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-33-9, Phenylbutazone, biological studies 50-34-0, Propantheline bromide 50-44-2, 6-Mercaptopurine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-53-3, Chlorpromazine, biological studies 51-06-9, Procainamide 51-34-3, Scopolamine 51-83-2, Carbachol 52-53-9, Verapamil 52-67-5, D-Penicillamine 52-90-4, L-Cysteine, biological studies 53-03-2, Prednisone 53-06-5, Cortisone 53-33-8, Paramethasone 53-36-1, Methylprednisolone acetate 53-86-1,

Indomethacin 54-05-7, Chloroquine 54-21-7, Sodium salicylate 54-35-3, Penicillin G procaine 54-47-7, Pyridoxal 5-phosphate 54-85-3, Isoniazid 54-96-6, 3,4-Diaminopyridine 55-63-0, Trinitroglycerin 56-40-6, Glycine, biological studies 57-00-1, Creatine 57-41-0, Phenytoin 57-50-1D, Sucrose, esters with fatty acids 57-96-5, Sulfinpyrazone 58-05-9, Folinic acid 58-25-3, Chlordiazepoxide 58-32-2, Dipyridamole 58-73-1, Diphenhydramine 58-85-5, Vitamin H 58-95-7, (+)-α-Tocopheryl acetate 59-02-9, α-Tocopherol 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-43-8, Vitamin B1, biological studies 59-43-8D, Thiamine, salts 59-58-5, Thiamine propyl disulfide 59-66-5, Acetazolamide 59-67-6, Nicotinic acid, biological studies 59-96-1, Phenoxybenzamine 60-23-1, Cysteamine 60-54-8, Tetracycline 61-68-7, Mefenamic acid 63-68-3, L-Methionine, biological studies 65-22-5, Pyridoxal hydrochloride 66-72-8, Pyridoxal 67-16-3, Thiamine disulfide 67-73-2, Fluocinolone acetonide 67-78-7, Triamcinolone diacetate 67-97-0, Vitamin D3 68-19-9, Vitamin B12 68-26-8, Retinol 69-46-5, Calcium acetylsalicylate 69-72-7, Salicylic acid, biological studies 70-18-8, Glutathione, biological studies 74-31-7, N,N'-Diphenyl-p-phenylenediamine 76-25-5, Triamcinolone acetonide 76-57-3, Codeine 77-37-2, Procyclidine 77-67-8, Ethosuximide 77-92-9, Citric acid, biological studies 79-83-4, Pantothenic acid 80-08-0, Dapsone 81-81-2, Warfarin 83-43-2, Methylprednisolone 83-68-1, Vitamin K6 83-69-2, Vitamin K7 83-70-5, Vitamin K5 83-88-5, Vitamin B2, biological studies 83-89-6, Quinacrine 85-87-0, Pyridoxamine 86-42-0, Amodiaquine 87-33-2, Isosorbide dinitrate 89-57-6, 5-Aminosalicylic acid 91-53-2, Ethoxyquin 91-86-1, η-Tocopherol 92-43-3, Phenidone 98-92-0, Niacinamide 99-66-1, Valproic acid 107-35-7, Taurine 113-98-4, Penicillin G potassium 114-07-8, Erythromycin 116-31-4, Vitamin A aldehyde 117-39-5, Quercetin 118-42-3, Hydroxychloroquine 118-92-3, Vitamin L1 119-13-1, δ-Tocopherol 121-79-9, Propyl gallate 124-94-7, Triamcinolone 125-33-7, Primidone 127-47-9, Retinyl acetate 128-37-0, Butylated hydroxytoluene, biological studies 129-03-3, Cyproheptadine 129-20-4, Oxyphenbutazone 130-24-5, Vitamin K5 hydrochloride 130-40-5, Riboflavin 5'-phosphate ester monosodium salt 132-17-2, Benztropine mesylate 132-98-9, Penicillin V potassium 137-08-6, Pantothenic acid calcium salt 137-58-6, Lidocaine 138-14-7, Deferoxamine mesylate 144-11-6, Trihexyphenidyl 148-03-8, β-Tocopherol 153-18-4, Rutin 298-46-4, Carbamazepine 298-50-0, Propantheline 298-81-7, Methoxsalen 302-79-4, Vitamin A acid 305-03-3, Chlorambucil 309-36-4, Methohexital sodium 315-30-0, Allopurinol 317-34-0, Aminophylline 327-97-9, Chlorogenic acid 352-97-6, Guanidinoacetic acid 356-12-7, Fluocinonide 378-44-9, Betamethasone 404-86-4, Capsaicin 432-70-2, α-Carotene 439-14-5, Diazepam 443-48-1, Metronidazole 444-27-9, Timonacic 446-72-0, Genistein 446-86-6, Azathioprine 458-37-7, Curcumin 462-20-4, Dihydrolipoic acid 472-93-5, γ-Carotene 476-66-4, Ellagic acid 480-16-0, Morin 480-17-1, Leucocyanidol 480-19-3, Isorhamnetin 481-46-9, Ginkgetin 489-35-0, Gossypetin 490-23-3, ε-Tocopherol 493-35-6, ζ2-Tocopherol 498-02-2, Apocynin 500-38-9, Nordihydroguaiaretic acid 501-30-4, Kojic acid 502-65-8, ψ-,ψ-Carotene 504-24-5, 4-Aminopyridine 511-28-4, Vitamin D4 514-65-8, Biperiden 520-18-3, Kaempferol 520-36-5, Apigenin 521-32-4, Bilobetin 522-00-9, Ethopropazine 523-68-2, N-Acetyl vitamin K5 524-36-7, Pyridoxamine dihydrochloride 525-66-6, Propranolol 528-48-3, Fisetin 529-96-4, Pyridoxamine phosphate 530-78-9, Flufenamic acid 532-11-6, Sulfarlem 532-40-1, Thiamine phosphate ester chloride 532-43-4, Thiamine mononitrate 533-31-3,

Sesamol 534-13-4, N,N'-Dimethylthiourea 540-05-6 541-15-1, L-Carnitine 548-19-6, Isoginkgetin 548-75-4, Quercetagetin-7-glucoside 552-66-9, Daidzin 552-94-3, Salsalate 564-25-0, Doxycycline 578-36-9, Potassium salicylate 599-79-1, Sulfasalazine 604-87-5 616-91-1, N-Acetylcysteine 635-97-2, Thiamine phosphoric acid ester phosphate salt 637-07-0, Clofibrate 638-23-3, S-Carboxymethylcysteine 644-62-2, Meclofenamic acid 644-62-2D, Meclofenamic acid, salts 652-78-8, Gossypin 674-38-4, Bethanechol 752-56-7, Riboflavin tetrabutyrate 768-94-5, Amantadine 841-73-6, Bucolome 846-49-1, Lorazepam 867-81-2, Pantothenic acid sodium salt 915-30-0, Diphenoxylate 992-46-1, Thiamine disulfide phosphate 1077-28-7, Thioctic acid 1115-84-0, Vitamin U 1134-47-0, Baclofen 1143-38-0, Anthralin 1166-52-5, Dodecylgallate 1398-61-4D, Chitin, derivs. 1424-27-7, Acetazolamide sodium 1505-95-9, Naphthypramide 1508-65-2, Oxybutynin chloride 1524-88-5, Flurandrenolide 1538-09-6 1553-60-2, Ibufenac 1562-74-9, 5-Thiopyridoxine 1597-82-6, Paramethasone 21-acetate 1622-61-3, Clonazepam 1721-51-3, ζ1-Tocopherol 1948-33-0, tert-Butylhydroquinone 1953-02-2, Tiopronin 2016-36-6, Choline salicylate, biological studies 2055-44-9, Perisoxal 2124-57-4, Vitamin K2(35) 2145-14-4, Paramethasone disodium phosphate 2152-44-5, Betamethasone valerate 2319-84-8, Thioctic acid sodium salt 2447-54-3, Sanguinarine 2457-80-9, Vitamin L2 2487-39-0, Vitamin K-S(II) 2766-51-0, Methylmethioninesulfonium bromide 3040-38-8, Acetyl-L-carnitine 3211-76-5, L-Selenomethionine 3286-46-2, Thiamine disulfide O,O-di-isobutyrate 3380-34-5, Triclosan 3416-24-8, Glucosamine 3475-65-8, Thiamine triphosphoric acid ester 3570-15-8, Nicotinic acid monoethanolamine salt 3930-20-9, Sotalol 4345-03-3 4394-00-7, Niflumic acid 4759-48-2, Isotretinoin 5003-48-5, Benorylate 5011-34-7, Trimetazidine 5034-76-4, Indoxole 5104-49-4, Flurbiprofen 5355-16-8, Diaveridine 5593-20-4, Betamethasone 17,21-dipropionate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. treatment of chronic inflammatory diseases)

IT 5633-20-5, Oxybutynin 5728-52-9, Felbinac 5913-70-2, Pyridoxal 5-phosphate calcium salt 5934-23-6, Vitamin K2(30) dihydro diacetate 5934-25-8, Vitamin K6 dihydrochloride 5934-26-9, Vitamin K7 hydrochloride 5949-29-1, Citric acid monohydrate 6020-87-7, Creatine monohydrate 6027-13-0, Homocysteine 6035-45-6, Folinic acid calcium salt pentahydrate 6054-98-4, Disodium azodisalicylate 6100-05-6 6223-35-4, Sodium guaiazulene-3-sulfonate 6452-71-7, Oxprenolol 6493-05-6, Pentoxifylline 7085-45-2, Biperiden lactate 7235-40-7, β-Carotene 7512-17-6, N-AcetylGlucosamine 7616-22-0, γ-Tocopherol 7683-59-2, Isoproterenol 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin B6 8069-87-2 9001-90-5D, Plasmin, streptokinase complex, acylated 9002-01-1, Streptokinase 9002-01-1D, Streptokinase, plasmin complex, acylated 9002-60-2, Corticotropin, biological studies 9002-89-5D, Poly(vinyl alcohol), derivs. 9003-39-8, Polyvinylpyrrolidone 9003-53-6D, Polystyrene, derivs. 9003-70-7D, Divinylbenzene-styrene copolymer, derivs. 9004-34-6D, Cellulose, derivs. 9004-57-3, Ethyl cellulose 9005-49-6, Heparin, biological studies 9014-67-9, Aloxiprin 9039-53-6D, Urokinase, acylated 9041-08-1, Heparin sodium 10118-90-8, Minocycline 10236-58-5, L-Selenocysteine 11032-49-8, Vitamin K2 11104-38-4, Vitamin K1 12192-57-3, Aurothioglucose 12244-57-4, Gold sodium thiomalate 13345-51-2D, Prostaglandin B1, oligomers 13422-55-4, Methyl vitamin B12 13523-86-9, Pindolol 13539-59-8, Azapropazone 13655-52-2, Alprenolol 13710-19-5, Tolfenamic acid 13739-02-1, Diacetylrhein 13993-65-2, Metiazinic acid 14402-89-2, Sodium nitroprusside 15307-86-5, Diclofenac 15475-56-6, Methotrexate sodium 15686-51-8, Clemastine 15687-27-1, Ibuprofen 15722-48-2, Olsalazine

16051-77-7, Isosorbide 5-mononitrate 17969-20-9, Fenclozic acid 18471-20-0, Ditazol 18472-51-0, Chlorhexidine gluconate 18642-10-9, Thiamine disulfide hydrochloride 18694-40-1, Epirizole 18917-89-0, Magnesium salicylate 19771-63-2, L-2-Oxothiazolidine-4-carboxylic acid 19982-08-2, Memantine 20168-99-4, Cinmetacin 20554-84-1, Parthenolide 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22494-42-4, Diflunisal 22760-18-5, Proquazone 23288-49-5, Probucol 23981-47-7, 6-Methoxy-2-naphthylacetic acid 24237-54-5, Tinoridine 25013-16-5, Butylated hydroxyanisole 25122-46-7, Clobetasol propionate 25451-15-4, Felbamate 25486-55-9, Vitamin K1 oxide 26171-23-3, Tolmetin 26589-39-9, Eudragit S 26787-78-0, Amoxicillin 26839-75-8, Timolol 27035-30-9, Oxametacin 27470-51-5, Suxibuzone 27686-36-8, Hypolaetin-8-glucoside 27696-41-9, Hypolaetin 28704-27-0, L-Alanine-L-glutamic acid-L-lysine-L-tyrosine copolymer 28841-62-5, D-myo-Inositol-1.2.6-trisphosphate 29031-19-4, Glucosamine sulfate 29098-15-5, Etoclofene 29122-68-7, Atenolol 29679-58-1, Fenoprofen 29908-03-0, S-Adenosylmethionine 30011-11-1, Bimetopyrol 30748-29-9, Feprazone 31793-07-4, Pirprofen 31842-01-0, Indoprofen 32808-51-8, Bucloxic acid 32839-30-8, Eicosapentaenoic acid 33005-95-7, Tiaprofenic acid 34031-32-8, Auranofin 34042-85-8, Sudoxicam 34148-01-1, Clidanac 34334-69-5, Cirsiliol 34461-73-9, Bumadizone calcium 34552-84-6, Isoxicam 34645-84-6, Fenclofenac 36322-90-4, Piroxicam 36330-85-5, Fenbufen 36364-49-5, Imidazole salicylate 36616-52-1, Fenclorac 36740-73-5, Flumizole 36894-69-6, Labetalol 36994-25-9, 2-(p-Bromophenyl)-9-dimethylaminopropyl-9H-imidazo[1,2-a]benzimidazole 37270-89-6, Heparin calcium 37517-30-9, Acebutolol 38194-50-2, Sulindac 38363-40-5, Penbutolol 38957-41-4, Emorfazone 40828-46-4, Suprofen 41340-25-4, Etodolac 42200-33-9, Nadolol 42399-41-7, Diltiazem 42924-53-8, Nabumetone 50270-32-1, 1-Isobutyl-3,4-diphenylpyrazole-5-acetic acid 50270-33-2, Isofezolac 51059-44-0, Oroxindin 51234-28-7, Benoxaprofen 51322-75-9, Tizanidine 51384-51-1, Metoprolol 51484-40-3, Difenpiramide 51579-82-9, Amfenac 51781-06-7, Carteolol 51803-78-2, Nimesulide 52263-84-0, (S)-(+)-Carprofen 52443-21-7, Glucametacin 53123-88-9, Rapamycin 53179-11-6D, Loperamide, diazo derivs. 53527-28-9, Scalaradial 53597-27-6, Fendosal 53716-49-7, Carprofen 54350-48-0, Etretinate 55142-85-3, Ticlopidine 55242-55-2, Propentophylline 55366-56-8, Hibifolin 55453-87-7, Isoxepac 55837-18-8, Butibufen 55985-32-5, Nicardipine 56824-20-5, Amiprilose 57132-53-3, Proglumetacin 58433-11-7, Tilomisole 58456-91-0, 2-Aminomethyl-4-tert-butyl-6-iodophenol 59122-46-2, Misoprostol 59804-37-4, Tenoxicam 59865-13-3, Cyclosporin A 59937-28-9, Malotilate 60142-96-3, Gabapentin 60940-34-3, Ebselen 61941-57-9, Ethyl 2-amino-3-benzoylphenylacetate 62571-86-2, Captopril 63329-53-3, Lobenzarit 63659-18-7, Betaxolol 64217-16-9, Phenytoin-phenobarbital mixture 64224-21-1, Oltipraz 64294-95-7, Setastine 64425-90-7, Choline magnesium trisalicylate, biological studies 65277-42-1, Ketoconazole 65666-07-1, Silymarin 66734-13-2, Alclometasone dipropionate 66934-18-7, Flunoxaprofen 68291-97-4, Zonisamide 68506-86-5, Vigabatrin 68767-14-6, Loxoprofen 69425-13-4, 2,6-Di-tert-butyl-4-[2'-thenoyl]-phenol 70360-12-2, Sideritoflavone 71125-38-7, Meloxicam 71320-77-9, Moclobemide 72509-76-3, Felodipine 74103-06-3, Ketorolac 74103-07-4, Ketorolac tromethamine 74469-00-4, Amoxicillin-clavulanate potassium mixt. 75060-92-3 75364-47-5 75695-93-1, Isradipine 75706-12-6, Leflunomide 75821-71-5, Lonazolac calcium 75847-73-3, Enalapril 76420-72-9, Enalaprilat 76547-98-3, Lisinopril 76584-70-8, Divalproex sodium 76990-56-2, Milacemide 77086-21-6, Dizocilpine 77699-47-9, Herbimycin 80474-14-2, Fluticasone propionate 80937-31-1,

6-(2,4-Difluorophenoxy)-5-methylsulfonylamino-1-indanone 81147-92-4, Esmolol 83919-23-7, Mometasone 17-(2-furoate) 84057-84-1, Lamotrigine 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 88150-42-9, Amlodipine 89149-10-0, 15-Deoxyspergualin 89796-99-6, Aceclofenac 90101-16-9, Droxicam 91418-71-2, Diacetylsplenopentin 98048-97-6, Fosinopril 98320-39-9, (10-Methoxy-4H-benzo[4,5]cyclohepta[1,2-b]thiophene-4-ylidene)acetic acid 100827-28-9, Erbstatin 103475-41-8, Tepoxalin 110101-67-2, Tirilazad mesylate 110952-54-0, 2-(2-Hydroxy-4-methylphenyl)aminothiazole hydrochloride 111406-87-2, Zileuton 117279-73-9 120072-59-5, 7-[3-(4-Acetyl-3-methoxy-2-propylphenoxy)-propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid 120210-48-2, Tenidap 122726-03-8, Vitamin K2(35) dihydro diacetate 125697-92-9, Lavendustin A 129424-08-4 131420-91-2, (Z)-3-[4-(Acetyloxy)-5-ethyl-3-methoxy-1-naphthalenyl]-2-methyl-2-propenoic acid 132392-39-3, 5-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-3-(dimethylamino)-4-thiazolidinone 132392-65-5, 5-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-3-(methylamino)-4-thiazolidinone 133332-08-8, DL-2-(4-Hexyloxyphenyl)glycine octyl ester 133763-16-3, 1-p-Chlorobenzyl-2-dimethylaminomethyl-1,2-cyclohexene 135872-94-5, 1-[(4-Chlorophenyl)methyl]-2-methyl-5-(quinolinylmethoxy)-1H-indole-3-acetic acid 136449-85-9 139639-23-9, Tissue plasminogen activator 143090-92-0, Anakinra 150977-36-9, Bromelain 151035-57-3, Quinapril-hydrochlorothiazide mixture 226721-96-6, Sodium 2-[4-(2-oxocyclopentylmethyl)phenyl]propionate dihydrate 354124-52-0, Thioctic acid ethylenediamine 700346-94-7, Nicotinic acid sodium salt sesquihydrate 762210-30-0, DL-2-[4-(5,5-Dimethylhexyloxy)phenyl]glycine octyl ester
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. treatment of chronic inflammatory diseases)

IT 850785-97-6, Diphenoxylate-atropine sulfate mixture 850785-98-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. treatment of chronic inflammatory diseases)

IT 50-18-0, Cyclophosphamide 50-44-2, 6-Mercaptopurine 58-05-9, Folinic acid 305-03-3, Chlorambucil 458-37-7, Curcumin 548-75-4, Quercetagetin-7-glucoside 2447-54-3, Sanguinarine 23288-49-5, Probucol 34334-69-5, Cirsiliol 38194-50-2, Sulindac 54350-48-0, Etretinate 65666-07-1, Silymarin 70360-12-2, Sideritoflavone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. treatment of chronic inflammatory diseases)

RN 50-18-0 HCAPLUS
CN 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (CA INDEX NAME)



RN 50-44-2 HCAPLUS
CN 6H-Purine-6-thione, 1,9-dihydro- (CA INDEX NAME)



RN 58-05-9 HCAPLUS
CN L-Glutamic acid, N-[4-[[(2-amino-5-formyl-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 305-03-3 HCAPLUS
CN Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]- (CA INDEX NAME)



RN 458-37-7 HCAPLUS
CN 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-
(CA INDEX NAME)

Double bond geometry as shown.



RN 548-75-4 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-(β-D-glucopyranosyloxy)-3,5,6-trihydroxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 2447-54-3 HCAPLUS
CN [1,3]Benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl- (CA INDEX NAME)



RN 23288-49-5 HCAPLUS
CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)- (CA INDEX NAME)



RN 34334-69-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy- (CA INDEX NAME)



RN 38194-50-2 HCAPLUS
CN 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-, (1Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 54350-48-0 HCAPLUS
CN 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, (2E,4E,6E,8E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 65666-07-1 HCAPLUS
CN Silymarin (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 70360-12-2 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7,8-trimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L123 ANSWER 12 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:123199 HCAPLUS Full-text
DOCUMENT NUMBER: 142:191239
TITLE: Botanical extract compositions comprising phytoestrogens and methods of use
INVENTOR(S): Chen, Sophie
PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 384,405, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050032882	A1	20050210	US 2003-647458	20030801 <--
EP 1808172	A2	20070718	EP 2007-9055	20030306 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.:
US 2002-362420P P 20020306 <--
US 2002-374417P P 20020422 <--
US 2003-384405 B2 20030306 <--
EP 2003-713959 A3 20030306 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 142:191239

AB A composition having phytoestrogenic and anti-cancer activity is described. The composition comprises wogonin, isoliquiritigenin, coumestrol, their pharmaceutically acceptable salts or esters, their selectively substituted analogs, or combinations thereof. The compns. may also include an anti-cancer agent and/or an immune stimulant. A method for treating or preventing cancer or an estrogen-related disorder includes administering a therapeutically effective amount of the compns. is described. The compns. are particularly useful in the treatment of hormone-related cancers.

IC ICM A61K031-353
INCL 514456000
CC 1-6 (Pharmacology)
IT Antiarthritics
Antiobesity agents
Antirheumatic agents
Antitumor agents
Bladder, neoplasm
Bone, neoplasm
Cardiovascular agents
Cardiovascular system, disease
Cognition enhancers
Cognitive disorders
Combination chemotherapy
Drug interactions
Human
Immunostimulants
Lung, neoplasm
Mammary gland, neoplasm
Menopause
Neoplasm
Obesity
Osteoarthritis
Osteoporosis
Ovary, neoplasm
Periodontium, disease
Prostate gland, neoplasm
Rheumatoid arthritis
Testis, neoplasm
Thyroid gland, neoplasm
(botanical extract compns. comprising phytoestrogens in combination with anti-cancer agents and immunostimulants for treatment of cancer and

estrogen-related disorders)
IT 57-22-7, Vincristine 60-82-2, Phloretin 64-86-8, Colchicine 94-41-7D, Chalcone, derivs. 118-34-3, Eleutheroside B 315-22-0, Monocrotaline 446-72-0, Genistein 458-37-7, Curcumin 474-58-8, Eleutheroside A 479-13-0, Coumestrol 479-41-4, Indirubin 480-44-4, Acacetin 485-72-3, Formononetin 491-70-3, Luteolin 491-80-5, Biochanin 520-36-5, Apigenin 529-53-3, Scutellarein 552-59-0, Prunetin 552-66-9, Daidzin 574-12-9D, Isoflavone, derivs. 1135-24-6, Ferulic acid 1400-76-6, Paricine 7008-42-6, Acronycine 7689-03-4, Camptothecin 9005-80-5, Inulin 9036-88-8, Mannan 15486-24-5, Eleutheroside C 15663-27-1, Cisplatin 25702-76-5, Polyfructose 26833-87-4, Homoharringtonine 28957-04-2, Oridonin 33069-62-4, Taxol 35846-53-8, Maytansine 39012-21-0, Pariphyllin 39432-56-9, Eleutheroside E 39453-41-3, β-Pachyman 53846-50-7, 8-Prenylnaringenin 56495-82-0, Irisquinone A 68236-11-3, 6,8-Diprenylnaringenin 68236-13-5, 6-Prenylnaringenin 78472-08-9, Irisquinone B 79484-75-6, Eleutheroside D 253195-19-6 757232-47-6, Irisquinone C
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(botanical extract compns. comprising phytoestrogens in combination with anti-cancer agents and immunostimulants for treatment of cancer and estrogen-related disorders)
IT 529-53-3, Scutellarein
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(botanical extract compns. comprising phytoestrogens in combination with anti-cancer agents and immunostimulants for treatment of cancer and estrogen-related disorders)
RN 529-53-3 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-(4-hydroxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L123 ANSWER 13 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:99157 HCAPLUS Full-text
DOCUMENT NUMBER: 142:170033
TITLE: Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
INVENTOR(S): Maziasz, Timothy
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 172 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20050026902	A1	20050203	US 2004-769485		20040130 <--
PRIORITY APPLN. INFO.:			US 2003-443910P	P	20030131 <--

OTHER SOURCE(S): MARPAT 142:170033

AB The present invention provides compns. and methods for the treatment of human immunodeficiency virus (HIV) infection as well as HIV associated diseases and related disorders. More particularly, the invention provides a combination therapy for the treatment of HIV infection as well as HIV associated diseases and related disorders comprising the administration to a subject of an anti-human immunodeficiency virus agent in combination with a cyclooxygenase-2 selective inhibitor or an isomer or a pharmaceutically acceptable salt, ester, or prodrug thereof.

IC ICM A61K031-55
ICS A61K031-54

INCL 514217000; 514226500

CC 1-5 (Pharmacology)

IT Antibiotics
Antioxidants
Antitumor agents
Fungicides
Immunomodulators
Neoplasm
Protozoacides
Vaccines
(in treatment regimen; methods and compns. for treatment or prevention of HIV infection and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents)

IT AIDS (disease)
Anti-AIDS agents
Combination chemotherapy
Diarrhea
Drug delivery systems
Fever and Hyperthermia
Gene therapy
Hepatitis
Human
Human immunodeficiency virus
Immunostimulation
Lymphoma
Seizures
(methods and compns. for treatment or prevention of HIV infection and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents)

IT 50-00-0, Formaldehyde, biological studies 111-30-8, Glutaral 548-04-9, Hypericin 2450-53-5, 3,5-Dicaffeoylquinic acid 6537-80-0 7770-78-7 13422-51-0, Hydroxocobalamin 19130-96-2, 1,5-Dideoxy-1,5-imino-D-glucitol 33419-42-0 79831-76-8 113852-37-2, Cidofovir 126456-36-8 126456-38-0 127749-96-6 127749-99-9 127779-20-8 138483-63-3 139694-65-8 140196-60-7 141804-42-4 142762-74-1 143224-34-4 144142-67-6 144779-91-9 146654-21-9 147318-81-8 147384-69-8 148314-61-8 149267-24-3 151867-81-1 153353-79-8 159142-13-9 159878-27-0 159878-28-1 159989-65-8 160231-42-5 161186-50-1 161277-26-5 161277-30-1 161277-32-3 164514-52-7 165591-25-3 165591-39-9 168394-24-9 168899-54-5 169273-51-2 169273-55-6 173261-21-7 173828-55-2 174484-41-4 177932-89-7 179409-87-1 180463-16-5 180902-22-1 183854-24-2 188762-00-7 192725-17-0 244641-43-8 329900-75-6, Cyclooxygenase-2 834911-92-1 834911-93-2 834911-94-3 834911-95-4

834911-96-5 834911-97-6 834911-98-7 834911-99-8 834912-00-4
834912-01-5 834912-02-6 834912-03-7 834912-04-8 834912-05-9
834912-06-0 834912-07-1 834912-08-2 834912-09-3 834912-10-6
834912-11-7 834912-12-8 834912-13-9 834912-14-0
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods and compns. for treatment or prevention of HIV infection and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents)

IT 53-43-0, 3β-Hydroxyandrost-5-en-17-one 472-15-1 534-76-9
1077-28-7, 1,2-Dithiolane-3-pentanoic acid 1093-91-0,
16-α-Bromo-3-β-hydroxyandrost-5-en-17-one 6060-06-6
21967-41-9 41135-06-2, Inophyllum B 60857-08-1,
12-Deoxyphorbol-13-acetate 76663-53-1,
13-Hydroxyingenol-3-(2,3-dimethylbutanoate)-13-dodecanoate 102674-90-8
110042-95-0, Acemannan 134332-63-1 135383-02-7 137793-81-8
137893-48-2 138667-71-7 142632-32-4, Calanolide A 142632-33-5,
Calanolide B 149572-31-6, Conocurvone 152187-38-7, Inophyllum P
155213-67-5, Ritonavir 165460-07-1 174022-42-5,
3-O-(3',3'-Dimethylsuccinyl)betulinic acid 184539-38-6
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(methods and compns. for treatment or prevention of HIV infection and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents)

IT 98-10-2D, Benzenesulfonamide, analogs and compds. 103-82-2D,
Phenylacetic acid, derivs. 127-07-1, Hydroxyurea 129-46-4
254-04-6D, 2H-1-Benzopyran, compds. 254-04-6D, Benzopyran, compds. and analogs 2054-35-5D, analogs 3056-17-5 3112-85-4D,
Methylsulfonylbenzene, analogs and compds. 3416-05-5, 3'-Deoxythymidine
4097-22-7, 2',3'-Dideoxyadenosine 4431-00-9, Aurintricarboxylic acid
7057-48-9 7481-88-1 7481-89-2, 2',3'-Dideoxycytidine 14665-52-2,
Bis(2-nitrophenyl)sulfone 25526-93-6, 3'-Fluoro-3'-deoxythymidine
29828-28-2D, Dihydronaphthalene, analogs 29968-14-7D, Dihydroquinoline, analogs 30516-87-1, 3'-Azido-3'-deoxythymidine 30516-87-1D,
3'-Azido-3'-deoxythymidine, 5'alkylglycoside carbonates 31515-43-2,
2-Nitrophenyl phenyl sulfone 36791-04-5 41107-56-6,
3'-Fluoro-2',3'-dideoxyuridine 51246-79-8,
3'-Fluoro-2',3'-dideoxycytidine 51803-78-2 53766-80-6,
2',3'-Didehydro-2',3'-dideoxyguanosine 63585-09-1, Phosphonoformic acid trisodium salt 64224-21-1 66323-44-2 66323-46-4,
3'-Azido-2',3'-dideoxyguanosine 69655-05-6, 2',3'-Dideoxyinosine
71125-38-7 78794-60-2 79872-72-3 80937-31-1 84472-85-5,
3'-Azido-2',3'-dideoxyuridine 84472-89-9, 3'-Azido-2',3'-dideoxycytidine
85236-92-6, 3'-Azido-2',3'-dideoxy-5-iodouridine 85326-06-3,
2',3'-Dideoxyguanosine 85326-07-4, 6-Methyl-2',3'-dideoxyadenosine
87190-74-7, 3'-Azido-2',3'-dideoxy-5-fluorouridine 87190-79-2
87190-80-5 87190-84-9 87418-35-7 92562-88-4,
3'-Fluoro-2',3'-dideoxyguanosine 93014-16-5,
4-(2-Methyl-4-phenyl-5-oxazolyl)benzenesulfonamide 105380-83-4,
3'-Azido-2',3'-dideoxy-5-ethyluridine 105784-82-5,
3'-Azido-2',3'-dideoxy-5-bromouridine 106060-85-9 107036-62-4,
5-Fluoro-2',3'-dideoxycytidine 107550-73-2 108441-50-5 108441-51-6,
3'-Azido-5-chloro-2',3'-dideoxyuridine 108895-46-1 109881-25-6
110142-99-9 110143-10-7 111495-90-0 111495-95-5 111495-96-6
111495-98-8 111496-01-6 114551-78-9 114753-53-6 115249-86-0,
2',3'-Dideoxy-3'-fluoro-5-bromouridine 115913-79-6 116333-41-6
119555-47-4 119644-22-3, 2',3'-Dideoxy-3'-fluoro-5-chlorouridine
119644-23-4 120443-30-3 120503-30-2,
6-Dimethylaminopurine-2',3'-dideoxyriboside 120503-34-6 120503-35-7,

N-Ethyl-2',3'-dideoxyadenosine 120826-45-1 121117-72-4 121135-52-2
121135-53-3 121353-93-3 123027-56-5 123663-49-0 124770-85-0
124903-20-4 125056-58-8 126062-18-8 126320-77-2 126347-69-1
127245-22-1 127492-31-3 127492-32-4 129618-40-2
130108-72-4 130108-73-5, 4'-Azido-2'-deoxyadenosine 130108-74-6,
4'-Azido-2'-deoxyguanosine 130108-75-7, 4'-Azido-2'-deoxyuridine
130108-76-8, 4'-Azido-2'-deoxycytidine 130108-77-9,
4'-Azido-2'-deoxyinosine 130108-82-6, 4'-Azido-3'-deoxythymidine
130797-04-5 131293-25-9 131613-15-5 132235-73-5 132774-45-9
132796-66-8 132796-67-9 132796-68-0 132970-02-6 134379-77-4
134678-17-4, Epivir 135212-57-6 135525-66-5 135525-77-8
135560-41-7 135812-04-3 135812-34-9 136160-29-7 136160-30-0
136470-78-5, Ziagen 136816-75-6 136816-76-7 136816-96-1
136817-66-8 136891-12-8 137332-54-8 137945-48-3 138192-33-3
138226-12-7 139226-28-1 139418-97-6, 4'-Azido-5-chloro-2'-deoxyuridine
139888-11-2, 4'-Cyanothymidine 141030-34-4 141030-55-9 141781-17-1
142102-79-2 143390-74-3 143491-57-0 143809-38-5 143809-39-6
144239-69-0 144433-06-7 145417-33-0 145514-01-8 145986-26-1
146739-86-8 147058-39-7 147362-57-0 147440-15-1 147584-54-1
147920-12-5 147920-13-6 147920-19-2 148311-89-1 148472-83-7,
5-Chloro-3-(phenylsulfonyl)indole-2-carboxamide 149485-30-3
149485-98-3 149950-60-7 149950-61-8 150378-17-9, Indinavir
153562-59-5 153815-93-1 154598-52-4 158959-32-1,
1-[2-(4-Fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene
158959-33-2, 1-[2-(4-Fluoro-2-methylphenyl)cyclopenten-1-yl]-4-
(methylsulfonyl)benzene 158959-34-3,
1-[2-(4-Chlorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene
158959-35-4, 1-[2-(2,4-Dichlorophenyl)cyclopenten-1-yl]-4-
(methylsulfonyl)benzene 158959-37-6,
1-[2-(4-Trifluoromethylphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene
158959-42-3, 1-[2-(4-Methylthiophenyl)cyclopenten-1-yl]-4-
(methylsulfonyl)benzene 158959-43-4,
1-[2-(4-Fluorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-
(methylsulfonyl)benzene 158959-46-7,
4-[2-(4-Fluorophenyl)cyclopenten-1-yl]benzenesulfonamide 158959-47-8,
4-[2-(4-Chlorophenyl)cyclopenten-1-yl]benzenesulfonamide 158959-56-9,
4-[2-(4-Fluorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide
159429-69-3, 1-[2-(4-Methoxyphenyl)cyclopenten-1-yl]-4-
(methylsulfonyl)benzene 159429-70-6,
1-[2-(4-Chlorophenyl)-4,4-dimethylcyclopenten-1-yl]-4-
(methylsulfonyl)benzene 159499-99-7 159519-65-0, Enfuvirtide
159989-64-7, Nelfinavir 160705-95-3 160707-69-7 160707-70-0
160707-71-1 160963-01-9 162011-90-7 162054-19-5 163303-19-3
163303-25-1 163303-29-5 163303-38-6 163303-55-7 163451-80-7
165251-89-8 165328-42-7, 1-[2-(2,3-Difluorophenyl)cyclopenten-1-yl]-4-
(methylsulfonyl)benzene 165328-49-4,
4-[2-(4-Chlorophenyl)-4,4-dimethylcyclopenten-1-yl]benzenesulfonamide
165328-51-8 168146-84-7 168299-83-0 168299-90-9 168433-84-9
169154-04-5 169154-07-8 169154-19-2 169154-24-9 169590-41-4,
4-[[5-(3-Fluoro-4-methoxyphenyl)-3-difluoromethyl]-1H-pyrazol-1-
yl]benzenesulfonamide 169590-42-5 169902-71-0,
4-[2-(3-Chloro-4-fluorophenyl)cyclopenten-1-yl]benzenesulfonamide
169902-74-3, 4-[2-(3-Fluoro-4-methoxyphenyl)cyclopenten-1-
yl]benzenesulfonamide 169902-75-4,
1-[2-(3-Chloro-4-methoxyphenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene
169951-23-9 169951-24-0 169951-25-1 169951-27-3 169951-28-4
170569-31-0 170569-42-3 170569-50-3 170569-86-5,
4-[5-(4-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
yl]benzenesulfonamide 170569-87-6,
4-[5-Phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide

170569-88-7, 4-[5-(4-Fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide 170569-91-2, 4-[5-(4-Methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide 170570-05-5 170570-25-9 170570-29-3 170570-31-7 170570-32-8 170570-33-9 170571-71-8 171888-46-3 173776-67-5 174470-77-0 175676-91-2 175676-92-3 175677-05-1 175677-06-2 175677-07-3 175677-13-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment or prevention of HIV infection and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents)

IT 548-04-9, Hypericin 33419-42-0
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods and compns. for treatment or prevention of HIV infection and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents)

RN 548-04-9 HCAPLUS
CN Phenanthro[1,10,9,8-opqra]perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-, stereoisomer (CA INDEX NAME)



RN 33419-42-0 HCAPLUS
CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4,6-O-(1R)-ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 21967-41-9
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment or prevention of HIV infection and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents)
RN 21967-41-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



IT 127-07-1, Hydroxyurea 129618-40-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment or prevention of HIV infection and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents)
RN 127-07-1 HCAPLUS
CN Urea, N-hydroxy- (CA INDEX NAME)



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[2,3-b:3',2'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- (CA INDEX NAME)



L123 ANSWER 14 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:872698 HCAPLUS Full-text
DOCUMENT NUMBER: 141:360715
TITLE: Formulation of dual cyclooxygenase (COX) and lipoxygenase (LOX) inhibitors for mammalian skin care
INVENTOR(S): Jia, Qi; Burnett, Bruce
PATENT ASSIGNEE(S): Unigen Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089392	A1	20041021	WO 2004-US10279	20040402 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004228021	A1	20041021	AU 2004-228021	20040402 <--
CA 2521429	A1	20041021	CA 2004-2521429	20040402 <--
US 20040220119	A1	20041104	US 2004-817330	20040402 <--
EP 1631304	A1	20060308	EP 2004-758816	20040402 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009179	A	20060502	BR 2004-9179	20040402 <--
JP 2006522150	T	20060928	JP 2006-509660	20040402 <--

PRIORITY APPLN. INFO.: US 2003-460736P P 20030404 <--
WO 2004-US10279 W 20040402

OTHER SOURCE(S): MARPAT 141:360715

AB The invention provides a composition of matter comprised of a mixture of two specific classes of compds., free-B-ring flavonoids and flavans, for use in the prevention and treatment of diseases and conditions associated with the skin. The composition simultaneously inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymic activity in normal, aged and damaged dermal cells and tissues. The invention further provides a method for the prevention and treatment of diseases and conditions of the skin mediated by COX and LOX. The method for preventing and treating COX-2- and 5-LOX-mediated diseases and conditions of the skin comprises topically administering to a host in need thereof a therapeutically effective amount of a composition comprising a mixture of free-B-ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants, preferably in the Scutellaria and Acacia genus of plants and pharmaceutically and/or cosmetically acceptable carriers. Finally, the invention provides a method for the prevention and treatment of COX- and LOX-mediated diseases and conditions, including but not limited to sun burns, thermal burns, acne, topical wounds, minor inflammatory conditions caused by fungal, microbial and viral infections, vitiligo, systemic lupus erythromatosus, psoriasis, carcinoma, melanoma, other mammalian skin cancers, skin damage from exposure to UV radiation, chems., heat, wind and dry environments, wrinkles, saggy skin, lines and dark circles around the eyes, dermatitis and other allergy-related conditions of the skin. Use of the composition of the invention also affords the benefit of smooth and youthful skin with improved elasticity, reduced and delayed aging, enhanced youthful appearance and texture, and increased flexibility, firmness, smoothness and suppleness.

IC ICM A61K035-78
CC 1-12 (Pharmacology)
Section cross-reference(s): 63

IT Drug delivery systems
(aerosols; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)
IT Drug delivery systems
(controlled-release; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)
IT Acacia
Acacia auriculiformis
Acacia caesia
Acacia catechu
Acacia concinna
Acacia dealbata
Acacia farnesiana
Acacia holosericea
Acacia mangium
Acacia mearnsi
Acacia nilotica
Acacia pennata
Acacia picnantha
Acacia senegal
Acacia sinuata
Acacia speciosa
Achyrocline
Acne
Actinodaphne
Allergy inhibitors
Alpinia
Anaphalis
Annonaceae
Anti-inflammatory agents
Antibacterial agents
Antitumor agents
Artocarpus
Asteraceae
Baccharis
Bignoniaceae
Burn
Carcinoma
Centaurea
Colebrookea
Combination chemotherapy
Combretaceae
Cosmetics
Cotula
Dermatitis
Derris (genus)
Desmodium sambuense
Desmos
Disinfectants
Drug delivery systems
Erythema
Eucalyptus globulus
Eupatorium
Euphorbiaceae
Fabaceae
Ficus (plant)
Glycyrrhiza
Gnaphalium
Helichrysum
Human

Inflammation
Lamiaceae
Lauraceae
Lindera
Melanoma
Millettia
Moraceae
Moraea nana
Mosla
Notholaena
Origanum
Oroxylum
Oroxylum indicum
Pinaceae
Pinus
Pityrogramma
Pongamia
Prophylaxis
Psoriasis
Pteridaceae
Radioprotectants
Sapium
Scutellaria
Scutellaria baicalensis
Scutellaria lateriflora
Scutellaria orthocalyx
Skin, disease
Skin, neoplasm
Stachys
Sunburn
Sunscreens
Tephrosia
Terminalia
Ulmaceae
Ulmus
Vitiligo
Zingiberaceae
Ziziphora
(dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)

IT Cosmetics
Drug delivery systems
(emulsions; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)

IT Cosmetics
Drug delivery systems
(gels; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)

IT Drug delivery systems
(injections, i.m.; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)

IT Drug delivery systems
(injections, i.v.; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)

IT Drug delivery systems
(intradermal; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)

IT Cosmetics
Drug delivery systems
(liqs.; dual cyclooxygenase and lipoxygenase inhibitors for mammalian

skin care)
IT Cosmetics
Drug delivery systems
(lotions; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)
IT Drug delivery systems
(ointments, creams; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)
IT Drug delivery systems
(ointments; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)
IT Drug delivery systems
(pastes; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)
IT Cosmetics
Drug delivery systems
(powders; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)
IT Drug delivery systems
(solns.; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)
IT Drug delivery systems
(suppositories; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)
IT Drug delivery systems
(tapes; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)
IT Drug delivery systems
Wound
(topical; dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)
IT 154-23-4, Catechin 480-11-5, Oroxylin A 480-40-0, Chrysin
490-46-0, Epicatechin 491-67-8, Baicalein 494-12-2D, Flavan, derivs. 632-85-9, Wogonin 4443-09-8, Norwogonin 21967-41-9, Baicalin 27740-01-8, Scutellarin 29550-13-8, 5,6-Dihydroxy-7-methoxyflavone 35775-49-6, Chrysin-7-glucuronide 36948-76-2 38183-03-8, 7,8-Dihydroxyflavone 51059-44-0, Wogonin-7-glucuronide 123549-16-6 778625-44-8, Soliprin
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)
IT 480-11-5, Oroxylin A 491-67-8, Baicalein
21967-41-9, Baicalin 27740-01-8, Scutellarin
29550-13-8, 5,6-Dihydroxy-7-methoxyflavone 36948-76-2
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dual cyclooxygenase and lipoxygenase inhibitors for mammalian skin care)
RN 480-11-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-6-methoxy-2-phenyl- (CA INDEX NAME)



RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 21967-41-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid,
5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 27740-01-8 HCAPLUS
CN β-D-Glucopyranosiduronic acid,
5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 29550-13-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6-dihydroxy-7-methoxy-2-phenyl- (CA INDEX NAME)



RN 36948-76-2 HCAPLUS
CN β-D-Glucopyranosiduronic acid,
5-hydroxy-6-methoxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L123 ANSWER 15 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:788058 HCAPLUS Full-text
DOCUMENT NUMBER: 142:169190
TITLE: Anti-tumour effects of nobiletin, a citrus flavonoid, on gastric cancer include: antiproliferative effects, induction of apoptosis and cell cycle deregulation
AUTHOR(S): Yoshimizu, N.; Otani, Y.; Saikawa, Y.; Kubota, T.; Yoshida, M.; Furukawa, T.; Kumai, K.; Kameyama, K.; Fujii, M.; Yano, M.; Sato, T.; Ito, A.; Kitajima, M.
CORPORATE SOURCE: Department of Surgery, School of Medicine, Keio University, Shinjuku, Tokyo, Japan
SOURCE: Alimentary Pharmacology and Therapeutics (2004), 20(Suppl. 1), 95-101
CODEN: APTHEN; ISSN: 0269-2813
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Aim: To demonstrate the antitumor effects of nobiletin (5,6,7.8,3',4'-hexamethoxyflavone), a citrus flavonoid extracted from Citrus depressa Hayata, on human gastric cancer cell lines TMK-1, MKN-45, MKN-74 and KATO-III. Materials and methods: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, the TdT-mediated dUTP biotin nick-end labeling (TUNEL) method and cell-cycle anal. revealed that nobiletin acted on these cells in several ways, namely by direct cytotoxicity, induction of apoptosis and modulation of cell cycle. The efficacy of combined treatment of nobiletin with a conventional anticancer drug, CDDP, was also examined Treatment with nobiletin 24 h prior to CDDP administration showed a synergistic effect compared to the control. Conclusions: Although the ED and administration route of nobiletin require further investigation, our study represents a potential successful linking of this compound with the treatment of gastric cancer.

CC 1-6 (Pharmacology)
IT Antitumor agents
Combination chemotherapy
(nobiletin followed by anticancer drug CDDP showed synergy in inducing apoptosis in human gastric cancer cell lines TMK-1 and MKN-45)
IT Drug interactions
(synergistic; combination of nobiletin with conventional anticancer drug CDDP had synergistic effect on human gastric cancer cells TMK-1 and MKN-45, suggests for gastric cancer treatment)
IT 478-01-3, Nobiletin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nobiletin showed cytotoxicity, induced apoptosis and cell cycle arrest at G0-G1, inhibited cell growth and in combination with CDDP showed synergism in inducing apoptosis in human gastric cancer cell lines)

IT 478-01-3, Nobiletin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nobiletin showed cytotoxicity, induced apoptosis and cell cycle arrest at G0-G1, inhibited cell growth and in combination with CDDP showed synergism in inducing apoptosis in human gastric cancer cell lines)

RN 478-01-3 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L123 ANSWER 16 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:633066 HCAPLUS Full-text
DOCUMENT NUMBER: 141:179610
TITLE: pharmaceutical and nutraceutical compositions containing extracts from hop and rosemary for treatment and prevention of inflammatory-related disorders
INVENTOR(S): Tripp, Matthew L.; Babish, John G.; Bland, Jeffrey S.; Darland, Gary K.; Lerman, Robert; Lukaczer, Daniel O.; Liska, Deann J.; Howell, Terrence
PATENT ASSIGNEE(S): Metaproteomics, LLC, USA
SOURCE: U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U.S. Pat. Appl. 2004 86,580.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040151792	A1	20040805	US 2003-689856	20031020 <--
US 7270835	B2	20070918		
US 20030008021	A1	20030109	US 2001-885721	20010620 <--
US 7205151	B2	20070417		
US 20040086580	A1	20040506	US 2003-464410	20030618 <--
US 20040115290	A1	20040617	US 2003-464834	20030618 <--
US 20040219240	A1	20041104	US 2004-774048	20040204 <--
AU 2004283065	A1	20050506	AU 2004-283065	20040521 <--
AU 2004283065	B2	20091126		
CA 2526804	A1	20050506	CA 2004-2526804	20040521 <--
WO 2005039483	A2	20050506	WO 2004-US16043	20040521 <--
WO 2005039483	A3	20050929		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1626731	A2	20060222	EP 2004-809400	20040521 <--
EP 1626731	B1	20090121		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

JP 2007527407	T	20070927	JP 2006-533298	20040521 <--
AT 421357	T	20090215	AT 2004-809400	20040521 <--
ES 2323708	T3	20090723	ES 2004-809400	20040521 <--
NZ 543726	A	20090828	NZ 2004-543726	20040521 <--
US 20090118373	A1	20090507	US 2004-866315	20040610 <--
US 20070202208	A1	20070830	US 2005-557293	20051118 <--
MX 2005012584	A	20060525	MX 2005-12584	20051122 <--
KR 2006105429	A	20061011	KR 2005-722350	20051122 <--
US 20070020352	A1	20070125	US 2006-326874	20060106 <--
US 20060141081	A1	20060629	US 2006-355145	20060215 <--
US 20060141082	A1	20060629	US 2006-355306	20060215 <--
US 20060177531	A1	20060810	US 2006-403016	20060412 <--
US 7431948	B2	20081007		
US 20070281045	A1	20071206	US 2006-635305	20061207 <--
US 20070166418	A1	20070719	US 2007-649584	20070104 <--
US 20070184133	A1	20070809	US 2007-729696	20070329 <--
AU 2008243262	A1	20081204	AU 2008-243262	20081114 <--
JP 2009203244	A	20090910	JP 2009-144756	20090617 <--

PRIORITY APPLN. INFO.:

US 2001-885721	A2	20010620 <--
US 2002-420383P	P	20021021 <--
US 2003-450237P	P	20030225 <--
US 2003-400293	B2	20030326 <--
US 2003-401283	B2	20030326 <--
US 2003-464410	A2	20030618 <--
US 2003-464834	A2	20030618 <--
AU 2002-310484	A3	20020620 <--
JP 2003-506631	A3	20020620 <--
US 2003-472460P	P	20030522 <--
US 2003-689856	A2	20031020 <--
US 2004-774048	A	20040204
WO 2004-US16043	W	20040521
US 2004-866315	B2	20040610
US 2005-748907P	P	20051209
US 2006-326874	A2	20060106

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:179610

AB A natural formulation of compds. that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compns. containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivs. or conjugates thereof. For example, an oral dietary

supplement containing isocohumulone, dihydroadhumulone, tetrahydroisocohumulone, hexahydroisohumulone from rosemary was found to be able to normalization the joint function after two to ten doses.

IC ICM A61K035-78
ICS A61K031-19

INCL 424745000; X42-477.8; X51-457.3

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 18

IT Drug delivery systems
(capsules; pharmaceutical and nutraceutical compns. containing exts. of hop and rosemary and triterpenes and diterpene lactones for treatment and prevention of inflammatory-related disorders)

IT Drug delivery systems
(lotions; pharmaceutical and nutraceutical compns. containing exts. of hop and rosemary and triterpenes and diterpene lactones for treatment and prevention of inflammatory-related disorders)

IT Drug delivery systems
(oral; pharmaceutical and nutraceutical compns. containing exts. of hop and rosemary and triterpenes and diterpene lactones for treatment and prevention of inflammatory-related disorders)

IT Drug delivery systems
(parenterals; pharmaceutical and nutraceutical compns. containing exts. of hop and rosemary and triterpenes and diterpene lactones for treatment and prevention of inflammatory-related disorders)

IT Anti-Alzheimer's agents
Anti-inflammatory agents
Antiarthritics
Antitumor agents
Dietary supplements
Gels
Neoplasm
Nervous system agents
Osteoarthritis
Tablets
(pharmaceutical and nutraceutical compns. containing exts. of hop and rosemary and triterpenes and diterpene lactones for treatment and prevention of inflammatory-related disorders)

IT Drug delivery systems
(rectally; pharmaceutical and nutraceutical compns. containing exts. of hop and rosemary and triterpenes and diterpene lactones for treatment and prevention of inflammatory-related disorders)

IT Drug interactions
(synergistic; pharmaceutical and nutraceutical compns. containing exts. of hop and rosemary and triterpenes and diterpene lactones for treatment and prevention of inflammatory-related disorders)

IT Drug delivery systems
(topical; pharmaceutical and nutraceutical compns. containing exts. of hop and rosemary and triterpenes and diterpene lactones for treatment and prevention of inflammatory-related disorders)

IT 67-97-0, Vitamin D3 69-72-7D, Salicylic acid, salts 76-22-2, Camphor 76-49-3, Bornyl acetate 79-92-5, Camphene 80-56-8, α-Pinene 80-57-9, Verbenone 87-44-5, Caryophyllene 89-83-8, Thymol 93-15-2, Methyl eugenol 98-55-5, α-Terpineol 99-49-0, Carvone 99-85-4, γ-Terpinene 99-86-5, α-Terpinene 99-87-6, p-Cymene 100-51-6, Benzyl alcohol, biological studies 111-02-4, Squalene 123-35-3, Myrcene 124-07-2, Octanoic acid, biological studies 124-76-5, Isoborneol 127-91-3, β-Pinene 138-86-3, Limonene 327-97-9, Chlorogenic acid 331-39-5, Caffeic acid 470-82-6, 1,8-Cineole 472-15-1, Betulinic acid 473-98-3, Betulin 491-09-8,

Piperitenone 491-70-3, Luteolin 499-75-2, Carvacrol 507-70-0, Borneol 520-11-6, 6-Methoxyluteolin 520-26-3, Hesperidin 520-34-3, Diosmetin 520-36-5, Apigenin 546-80-5, α-Thujone 559-70-6, β-Amyrin 562-74-3, Terpinen-4-ol 569-90-4, 6-Methoxy luteolin-7-glucoside 578-74-5 586-62-9, Terpinolene 638-95-9, α-Amyrin 638-97-1, β-Amyrenone 644-30-4, Curcumene 906-33-2, Neo-chlorogenic acid 1139-30-6, Caryophyllene oxide 1197-07-5, trans-Carveol 3387-41-5, Sabinene 3650-11-1, Rosmaricine 4180-23-8, trans-Anethole 4339-72-4, 3-O-Acetyloleanolic acid 4821-04-9 5373-11-5, Luteolin-7-glucoside 5957-80-2, Carnosol 6753-98-6, α-Humulene 7372-30-7, 3-O-Acetylursolic acid 10366-91-3, Salicylic acid-2-β-D-glucoside 13849-91-7, 19α-Hydroxy ursolic acid 20283-92-5 23028-17-3, α-Hydroxyhydrocaffeic acid 23510-81-8, Humulone 25269-20-9, Isocohumulone 25422-83-7, Isoadhumulone 25522-96-7, Isohumulone 26472-41-3 26707-60-8, 2β-Hydroxy oleanolic acid 27210-57-7, Rosmariquinone 33880-83-0, β-Elemene 34334-69-5 34421-27-7, Tetrahydroisocohumulone 53527-42-7, Luteolin-3'-O-β-D-glucuronide 53833-85-5, Sabinyl acetate 80225-53-2, Rosmanol 91729-95-2, Rosmaridiphenol 111200-01-2, 7-Ethoxy-rosmanol 113085-62-4, 7-Methoxy rosmanol 142628-20-4, Cohumulone 142628-21-5, Adhumulone 147714-64-5 147714-67-8 160598-97-0 160598-98-1 685110-35-4, Dihydroisohumulone 685110-36-5, TetrahydroAdhumulone 685110-37-6, Hexahydroisocohumulone 685110-38-7, HexahydroAdhumulone 685141-03-1, Rosmarinol
RL: FFD (Food or feed use); NPO (Natural product occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(pharmaceutical and nutraceutical compns. containing exts. of hop and rosemary and triterpenes and diterpene lactones for treatment and prevention of inflammatory-related disorders)

IT 520-11-6, 6-Methoxyluteolin 569-90-4, 6-Methoxy luteolin-7-glucoside 34334-69-5
RL: FFD (Food or feed use); NPO (Natural product occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(pharmaceutical and nutraceutical compns. containing exts. of hop and rosemary and triterpenes and diterpene lactones for treatment and prevention of inflammatory-related disorders)

RN 520-11-6 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxy- (CA INDEX NAME)



RN 569-90-4 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-(β-D-glucopyranosyloxy)-5-hydroxy-6-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 34334-69-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L123 ANSWER 17 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:627486 HCAPLUS Full-text
DOCUMENT NUMBER: 142:85904
TITLE: In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
AUTHOR(S): Chen, F.; Chan, K. H.; Jiang, Y.; Kao, R. Y. T.; Lu, H. T.; Fan, K. W.; Cheng, V. C. C.; Tsui, W. H. W.; Hung, I. F. N.; Lee, T. S. W.; Guan, Y.; Peiris, J. S. M.; Yuen, K. Y.
CORPORATE SOURCE: Centre for Research in Plant Drugs Development, Department of Botany, The University of Hong Kong, Hong Kong
SOURCE: Journal of Clinical Virology (2004), 31(1), 69-75
CODEN: JCVIFB; ISSN: 1386-6532
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Com. antiviral agents and pure chemical compds. extracted from traditional Chinese medicinal herbs were screened against 10 clin. isolates of SARS coronavirus by neutralization tests with confirmation by plaque reduction assays. Interferon-beta-1a, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clin. and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomized placebo controlled trials in future epidemics.

CC 1-5 (Pharmacology)
IT Artemisia apiacea
Combination chemotherapy
Glycyrrhiza uralensis
Human
Leukocyte
Prophylaxis
SARS coronavirus
Scutellaria baicalensis
(in vitro susceptibility of 10 clin. isolates of SARS coronavirus to selected antiviral compds.)
IT Drug interactions
(synergistic; in vitro susceptibility of 10 clin. isolates of SARS coronavirus to selected antiviral compds.)
IT 21967-41-9P, Baicalin
RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(baicalin had inhibitory activity against severe acute respiratory syndrome causing prototype corona virus grown in fRHK-4 cell line and less effective in Vero cell line)
IT 21967-41-9P, Baicalin
RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(baicalin had inhibitory activity against severe acute respiratory syndrome causing prototype corona virus grown in fRHK-4 cell line and less effective in Vero cell line)
RN 21967-41-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 46 THERE ARE 46 CAPLUS RECORDS THAT CITE THIS RECORD (47 CITINGS)
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L123 ANSWER 18 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:368873 HCAPLUS Full-text
DOCUMENT NUMBER: 140:368677
TITLE: Compositions using hops- and rosemary-derived components, triterpenes, and other compounds for the treatment of pathological conditions associated with inflammatory response
INVENTOR(S): Tripp, Matthew L.; Babish, John G.; Bland, Jeffrey S.; Darland, Gary; Lerman, Robert; Lukaczer, Daniel O.; Liska, Deann J.; Howell, Terrence
PATENT ASSIGNEE(S): Metaproteomics, LLC, USA

SOURCE: PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037180	A2	20040506	WO 2003-US33362	20031020 <--
WO 2004037180	A3	20040930		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040086580	A1	20040506	US 2003-464410	20030618 <--
US 20040115290	A1	20040617	US 2003-464834	20030618 <--
CA 2503196	A1	20040506	CA 2003-2503196	20031020 <--
AU 2003286549	A1	20040513	AU 2003-286549	20031020 <--
AU 2003286549	B2	20061130		
EP 1558271	A2	20050803	EP 2003-777751	20031020 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006508182	T	20060309	JP 2005-501640	20031020 <--
NZ 539642	A	20070126	NZ 2003-539642	20031020 <--
MX 2005004288	A	20050802	MX 2005-4288	20050421 <--
US 20070160692	A1	20070712	US 2007-532388	20070321 <--
AU 2008243262	A1	20081204	AU 2008-243262	20081114 <--

PRIORITY APPLN. INFO.:

US 2002-420383P	P	20021021 <--
US 2003-450237P	P	20030225 <--
US 2003-400293	A	20030326 <--
US 2003-401283	A	20030326 <--
US 2003-464410	A	20030618 <--
US 2003-464834	A	20030618 <--
US 2001-885721	A2	20010620 <--
AU 2002-310484	A3	20020620 <--
WO 2003-US33362	W	20031020 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 140:368677

AB A natural formulation of compds. for modulating inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compns. contain at least one fraction isolated or derived from hops. Other embodiments disclose combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivs. or conjugates thereof.

IC ICM A61K
CC 1-7 (Pharmacology)
Section cross-reference(s): 63
IT AIDS (disease)
Allergy inhibitors
Anti-AIDS agents

Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Antiobesity agents
Antitumor agents
Antiviral agents
Arthritis
Asthma
Atherosclerosis
Autoimmune disease
Cardiovascular agents
Cardiovascular system, disease
Common cold
Digestive tract, disease
Drug delivery systems
Eye, disease
Gastrointestinal agents
Human
Human immunodeficiency virus 1
Humulus lupulus
Immunomodulators
Inflammation
Influenza
Macrophage
Neoplasm
Nervous system, disease
Nervous system agents
Obesity
Respiratory distress syndrome
Rosmarinus officinalis
Skin, disease
(hops- and rosemary-derived components, triterpenes, and other compds. for treatment of diseases associated with inflammatory response)

IT Drug delivery systems
(oral; hops- and rosemary-derived components, triterpenes, and other compds. for treatment of diseases associated with inflammatory response)

IT Drug delivery systems
(parenterals; hops- and rosemary-derived components, triterpenes, and other compds. for treatment of diseases associated with inflammatory response)

IT Drug delivery systems
(rectal; hops- and rosemary-derived components, triterpenes, and other compds. for treatment of diseases associated with inflammatory response)

IT Drug interactions
(synergistic; hops- and rosemary-derived components, triterpenes, and other compds. for treatment of diseases associated with inflammatory response)

IT Drug delivery systems
(topical; hops- and rosemary-derived components, triterpenes, and other compds. for treatment of diseases associated with inflammatory response)

IT 64-19-7, Acetic acid, biological studies 69-72-7D, Salicylic acid, salicylates, biological studies 70-18-8, Glutathione, biological studies 76-22-2, Camphor 76-49-3, Bornyl-acetate 77-52-1, Ursolic acid 79-92-5, Camphene 80-26-2 80-56-8, α-Pinene 80-57-9 83-46-5, β-Sitosterol 87-44-5, Caryophyllene 89-83-8, Thymol 93-15-2, Methyl-eugenol 98-55-5, α-Terpineol 99-49-0, Carvone 99-85-4, γ-Terpinene 99-86-5, α-Terpinene 99-87-6, p-Cymene 100-51-6, Benzyl-alcohol, biological studies 110-15-6, Succinic acid, biological studies 111-02-4, Squalene 123-35-3, Myrcene 124-07-2,

Octanoic acid, biological studies 124-76-5, Isoborneol 127-91-3, β-Pinene 138-86-3, Limonene 327-97-9, Chlorogenic acid 331-39-5, Caffeicacid 466-05-7, Pinicolic acid A 470-82-6, 1,8-Cineole 471-53-4 472-15-1, Betulinic acid 473-98-3, Betulin 491-09-8, Piperitenone 491-70-3, Luteolin 495-60-3, Zingiberene 499-75-2, Carvacrol 507-70-0, Borneol 508-01-0, Soyasapogenol A 508-02-1, Oleanolic acid 508-24-7, Tumulosic acid 511-25-1, Cohumulone 520-11-6, 6-Methoxyluteolin 520-26-3, Hesperidin 520-34-3, Diosmetin 520-36-5, Apigenin 545-46-0, Uvaol 546-80-5, α-Thujone 559-70-6, β-Amyrin 559-74-0, Friedelin 560-66-7, Eburicoicacid 562-74-3, Terpinen-4-ol 569-90-4, 6-Methoxy-luteolin-7-glucoside 578-74-5 586-62-9, Terpinolene 595-15-3, Soyasapogenol B 638-95-9, α-Amyrin 638-97-1, β-Amyrenone 639-14-5, Gypsogenin 644-30-4, Curcumene 906-33-2, Neo-chlorogenic acid 989-30-0 1139-30-6, Caryophyllene-oxide 1197-07-5, trans-Carveol 1405-86-3, Glycyrrhizin 1449-05-4 3387-41-5, Sabinene 3416-24-8, Glucosamine 3650-09-7, Carnosic acid 3650-11-1, Rosmaricine 4180-23-8, trans-Anethole 4339-72-4, 3-O-Acetyloleanolicacid 5373-11-5, Luteolin-7-glucoside 5957-80-2, Carnosol 6246-46-4 6246-46-4D, derivs. 6753-98-6, α-Humulene 6822-47-5, Sophoradiol 7372-30-7, 3-O-Acetylursolic acid 13220-57-0, Tryptanthrin 13849-91-7 20243-59-8D, derivs. 20283-92-5, Rosemaric acid 22748-58-9 23028-17-3, α-Hydroxyhydrocaffeic acid 24149-26-6D, derivs. 25269-20-9, Isocohumulone 25422-83-7, Isoadhumulone 25522-96-7, Isohumulone 26472-41-3, Humulone 26707-60-8 27210-57-7, Rosmariquinone 28815-20-5, Tetrahydro-isohumulone 29070-92-6, Pachymic acid 31769-65-0, Adhumulone 33880-83-0 34157-83-0, Celastrol 34421-27-7, Tetrahydro-isocohumulone 38602-20-9 53527-42-7 53833-85-5, Sabinylacetate 74285-86-2, Triptophenolide 80225-53-2, Rosmanol 91729-95-2, Rosmaridiphenol 111200-01-2, 7-Ethoxy-rosmanol 113085-62-4, 7-Methoxy-rosmanol 160598-97-0 160598-98-1 312925-21-6D, derivs. 685141-03-1, Rosmarinol
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hops- and rosemary-derived components, triterpenes, and other compds. for treatment of diseases associated with inflammatory response)

IT 520-11-6, 6-Methoxyluteolin 569-90-4, 6-Methoxy-luteolin-7-glucoside
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hops- and rosemary-derived components, triterpenes, and other compds. for treatment of diseases associated with inflammatory response)

RN 520-11-6 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxy- (CA INDEX NAME)



RN 569-90-4 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-(β-D-glucopyranosyloxy)-5-hydroxy-6-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L123 ANSWER 19 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:242560 HCAPLUS Full-text
DOCUMENT NUMBER: 140:331764
TITLE: Significant decrease of cyclosporine bioavailability in rats caused by a decoction of the roots of Scutellaria baicalensis
AUTHOR(S): Lai, Miao-Ying; Hsiu, Su-Lan; Hou, Yu-Chi; Tsai, Sang-Yuan; Chao, Pei-Dawn Lee
CORPORATE SOURCE: Graduate Institute of Chinese Pharmaceutical Sciences, Department of Pharmacy, China Medical University, Taichung, 404, Taiwan
SOURCE: Planta Medica (2004), 70(2), 132-137
CODEN: PLMEAA; ISSN: 0032-0943
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Scutellariae Radix (SR), the root of Scutellaria baicalensis (Labiatae), is widely used in clin. Chinese medicine. To investigate the effect of SR on the absorption and disposition of cyclosporine, rats were administered with cyclosporine orally (in the form of the microemulsion Neoral) and i.v. with and without coadministration of SR decoction in randomized cross-over designs, resp. Furthermore, the effects of the major constituents, e.g., baicalin and its aglycon baicalein on cyclosporine pharmacokinetics were also investigated in rats. A specific monoclonal fluorescence polarization immunoassay was used to determine the blood concentration of cyclosporine. Our results indicated that coadministration of SR decoction at doses of 1 g/kg and 2 g/kg significantly decreased the Cmax of cyclosporine by 62.9% and 79.6% and reduced the AUC0-540 by 55.2% and 82.0%, resp. On the contrary, coadministration of baicalin and baicalein at doses of 112 μmol/kg markedly elevated the Cmax of cyclosporine by 408.1% and 87.5% and increased the AUC0-540 by 685.3% and 150.2%, resp. Nevertheless, SR decoction did not alter the pharmacokinetics of i.v. cyclosporine. These results indicate that a profound interaction between SR decoction and cyclosporine occurred at the absorption site. To ensure the efficacy and safety of cyclosporine, the coadministration of SR and its prepns. with oral cyclosporine should be avoided.

CC 1-2 (Pharmacology)
IT Drug bioavailability
Scutellaria baicalensis
(decrease of cyclosporine bioavailability in rats caused by a decoction of roots of Scutellaria baicalensis)
IT Drug interactions
(pharmacokinetic; decrease of cyclosporine bioavailability in rats caused by a decoction of roots of Scutellaria baicalensis)

IT 491-67-8, Baicalein 21967-41-9, Baicalin
RL: NPO (Natural product occurrence); PAC (Pharmacological activity); BIOL (Biological study); OCCU (Occurrence)
(decrease of cyclosporine bioavailability in rats caused by a decoction of roots of Scutellaria baicalensis)

IT 491-67-8, Baicalein 21967-41-9, Baicalin
RL: NPO (Natural product occurrence); PAC (Pharmacological activity); BIOL (Biological study); OCCU (Occurrence)
(decrease of cyclosporine bioavailability in rats caused by a decoction of roots of Scutellaria baicalensis)

RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 21967-41-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L123 ANSWER 20 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:892548 HCAPLUS Full-text
DOCUMENT NUMBER: 139:386470
TITLE: Formulation of a mixture of Free-B-ring flavonoids and flavans for treatment of diseases mediated by the COX-2 and 5-LO pathways
INVENTOR(S): Jia, Qi
PATENT ASSIGNEE(S): Unigen Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003092599	A2	20031113	WO 2003-US13463	20030430 <--

```
     WO 2003092599          A3    20040311
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2484192             A1    20031113    CA 2003-2484192         20030430 <--
     AU 2003228777          A1    20031117    AU 2003-228777          20030430 <--
     AU 2003228777          B2    20090226
     EP 1503778             A2    20050209    EP 2003-726548          20030430 <--
     EP 1503778             B1    20090805
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     NZ 535988              A     20050930    NZ 2003-535988          20030430 <--
     JP 2005529898          T     20051006    JP 2004-500784          20030430 <--
     AT 438393              T     20090815    AT 2003-726548          20030430 <--
     EP 2108370             A1    20091014    EP 2009-167112          20030430 <--
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR
     ES 2330097             T3    20091204    ES 2003-726548          20030430 <--
     RU 2379031             C2    20100120    RU 2004-135069          20030430 <--
     IN 2004KN01614         A     20060714    IN 2004-KN1614          20041029 <--
     BR 2004006279          A     20060613    BR 2004-6279            20041108 <--
     US 20070135359         A1    20070614    US 2007-676528          20070220 <--
PRIORITY APPLN. INFO.:                         US 2002-377168P     P   20020430 <--
                                               WO 2003-US6098      W   20030228 <--
                                               EP 2003-726548      A3  20030430 <--
                                               WO 2003-US13463     W   20030430 <--
                                               US 2003-469275      A1  20030827 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S):         MARPAT 139:386470
AB    The present invention provides a novel composition of matter comprised of a
      mixture of two specific classes of compds., Free-B-ring flavonoids and flavans
      for the prevention and treatment of diseases and conditions mediated by the
      cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) pathways, including but not
      limited to the relief joint discomfort and pain associated with conditions
      such as osteoarthritis, rheumatoid arthritis, and other injuries that result
      from overuse.  The present invention further provides a novel method for
      simultaneously inhibiting the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-
      LO) enzymes, and reducing COX-2 mRNA production  Finally, the present
      invention includes a method for weight loss and blood glucose control.  The
      methods of this invention are comprised of administering to a host in need
      thereof an effective amount of the composition of this invention together with
      a pharmaceutically acceptable carrier.  Examples are given for preparation of
      organic and aqueous exts. from Acacia and Scutellaria, inhibition of COX-2
      peroxidase activity by various plant species, and isolation of flavonoids for
      Scutellaria exts.
IC    ICM  A61K
CC    63-7 (Pharmaceuticals)
      Section cross-reference(s): 1
IT    Acacia catechu
      Antiarthritics
      Desmodium sambuense
        Drug delivery systems
      Eucalyptus globulus
```

Myrica nana
Scutellaria baicalensis
Scutellaria lateriflora
Scutellaria orthocalyx
(formulation of a mixture of free-B-ring flavonoids and flavans for treatment of diseases mediated by the COX-2 and 5-LO pathways)

IT Flavonoids
RL: NPO (Natural product occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(formulation of a mixture of free-B-ring flavonoids and flavans for treatment of diseases mediated by the COX-2 and 5-LO pathways)

IT 329900-75-6, COX-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(COX-2, inhibitors; formulation of a mixture of free-B-ring flavonoids and flavans for treatment of diseases mediated by the COX-2 and 5-LO pathways)

IT 154-23-4, Catechin 480-11-5, Oroxylin A 480-40-0, Chrysin
490-46-0, Epicatechin 491-67-8, Baicalein 632-85-9, Wogonin
4443-09-8, Norwogonin 21967-41-9, Baicalin
27740-01-8, Scutellarin 35775-49-6, Chrysin 7-glucuronide
36948-76-2 51059-44-0, Wogonin 7-glucuronide 123549-16-6
RL: NPO (Natural product occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(formulation of a mixture of free-B-ring flavonoids and flavans for treatment of diseases mediated by the COX-2 and 5-LO pathways)

IT 80619-02-9, 5-Lipoxygenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; formulation of a mixture of free-B-ring flavonoids and flavans for treatment of diseases mediated by the COX-2 and 5-LO pathways)

IT 480-11-5, Oroxylin A 491-67-8, Baicalein
21967-41-9, Baicalin 27740-01-8, Scutellarin
36948-76-2
RL: NPO (Natural product occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(formulation of a mixture of free-B-ring flavonoids and flavans for treatment of diseases mediated by the COX-2 and 5-LO pathways)

RN 480-11-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-6-methoxy-2-phenyl- (CA INDEX NAME)



RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 21967-41-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid,
5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 27740-01-8 HCAPLUS
CN β-D-Glucopyranosiduronic acid,
5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 36948-76-2 HCAPLUS
CN β-D-Glucopyranosiduronic acid,
5-hydroxy-6-methoxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L123 ANSWER 21 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:728651 HCAPLUS Full-text
DOCUMENT NUMBER: 138:265150
TITLE: Combination use of kampo-medicines and drugs affecting intestinal bacterial flora
AUTHOR(S): Ishihara, Miya; Homma, Masato; Kuno, Eiko; Watanabe,

Machiko; Kohda, Yukinao
CORPORATE SOURCE: Department of Pharmacy, Tsukuba University Hospital, Tsukuba, Ibaraki, 305-8575, Japan
SOURCE: Yakugaku Zasshi (2002), 122(9), 695-701
CODEN: YKKZAJ; ISSN: 0031-6903
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
AB The intestinal bacteria, Eubacterium sp. and Bifidobacterium sp., participate in the metabolism of active kampo-ingredients, glycyrrhizin (GL), sennoside (SEN) and baicalin (BL). Since antibiotics and bacterial prepns., Bifidobacterium longum (LAC-B), Clostridium butyricum (MIYA-BM), and Streptococcus faecalis (BIOFERMIN), affect the bacterial population in intestinal bacterial flora, metabolism of the active kampo-ingredients in the bacterial flora may be altered by their combined administration. We investigated 1199 prescriptions including kampo-medicines for 308 patients. Combination use of kampo-medicines with antibiotics and bacterial prepns. occurred with 7% and 10% of the kampo-prescription, resp. Most antibiotics have activity against intestinal bacteria, except that cephems and macrolides are not active against to E. coli. This means that antibiotics may lower the metabolism of GL, SEN and BL when administered in combination. It is also highly possible that bacterial prepns. increase the number of Eubacterium sp. and Bifidobacterium sp., resulting in enhanced metabolism of GL and SEN when they are used concomitantly with kampo-medicines. The present results suggested that the drug interactions of kampo-medicines with antibiotics and bacterial prepns. should be confirmed in clin. studies.
CC 1-4 (Pharmacology)
IT Antibiotics
Bifidobacterium
Bifidobacterium longum
Clostridium butyricum
Drug interactions
Enterococcus faecalis
Eubacterium
Human
Intestinal bacteria
(combination use of kampo-medicines and drugs affecting intestinal bacterial flora)
IT Natural products, pharmaceutical
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination use of kampo-medicines and drugs affecting intestinal bacterial flora)
IT 517-43-1, Sennoside 1405-86-3, Glycyrrhizin 21967-41-9, Baicalin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination use of kampo-medicines and drugs affecting intestinal bacterial flora)
IT 21967-41-9, Baicalin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination use of kampo-medicines and drugs affecting intestinal bacterial flora)
RN 21967-41-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)

L123 ANSWER 22 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:695764 HCAPLUS Full-text
DOCUMENT NUMBER: 137:210932
TITLE: Combination therapy for reduction of toxicity of chemotherapeutic agents
INVENTOR(S): Prendergast, Patrick T.
PATENT ASSIGNEE(S): Ire.
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069949	A2	20020912	WO 2002-IB632	20020305 <--
WO 2002069949	A3	20030605		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002238799	A1	20020919	AU 2002-238799	20020305 <--
US 20020169140	A1	20021114	US 2002-91855	20020306 <--
US 20080139496	A1	20080612	US 2008-34289	20080220 <--
PRIORITY APPLN. INFO.:			IE 2001-209 A	20010306 <--
			WO 2002-IB632 W	20020305 <--
			US 2002-91855 B1	20020306 <--

AB Provided in the present invention are compds. suitable for treating neoplasms and tumors, viral, bacterial and parasite infections and combination therapy with these agents to lower the adverse side effects.

IC ICM A61K031-00
ICS A61K031-352; A61K031-12; A61K031-235; A61K009-127; A61K009-32; A61K009-16; A61K009-36; A61P035-00; A61P031-00; A61P031-04; A61P031-12; A61P031-18; A61P033-00; A61P037-06; A61K039-395; A61K039-42; A61K039-44; A61K031-7068; A61K031-7072

CC 1-6 (Pharmacology)
Section cross-reference(s): 63

IT Anti-AIDS agents
Antibacterial agents
Antimalarials

Antitumor agents
Antiviral agents
Drug delivery systems
Drug delivery systems
Neoplasm
Radiotherapy
Surgery
(combination therapy for reduction of toxicity of chemotherapeutic agents)

IT Drug delivery systems
(enteric, enteric coating; combination therapy for reduction of toxicity of chemotherapeutic agents)

IT Drug delivery systems
(immunoconjugates; combination therapy for reduction of toxicity of chemotherapeutic agents)

IT Drug delivery systems
(liposomes; combination therapy for reduction of toxicity of chemotherapeutic agents)

IT Drug interactions
(synergistic; combination therapy for reduction of toxicity of chemotherapeutic agents)

IT 50-44-2, 6-Mercaptopurine 50-89-5, Thymidine, biological studies 50-91-9, Floxuridine 51-21-8, 5-Fluorouracil 54-05-7, Chloroquine 54-42-2, 5-Iodo-2'-deoxyuridine 58-96-8, Uridine 60-54-8, Tetracycline 68-94-0, Hypoxanthine 69-93-2, Uric acid, biological studies 70-00-8, Trifluorothymidine 73-24-5, Adenine, biological studies 80-08-0, Dapsone 83-89-6, Quinacrine 90-34-6, Primaquine 100-33-4, Pentamidine 130-95-0, Quinine 147-94-4, Cytosine arabinoside 154-42-7, 6-Thioguanine 320-67-2, Azacytidine 342-69-8, 6-MMPR 443-48-1, Metronidazole 446-86-6, Azathioprine 500-92-5, Proguanil 518-28-5, Podophyllotoxin 605-23-2 1397-89-3, Amphotericin B 2365-40-4 3056-17-5, Stavudine 3416-05-5 3736-81-0, Diloxanide furoate 4291-63-8, Cladribine 4294-16-0, Benzyladenosine 4338-47-0, Furfuryladenosine 5536-17-4, Vidarabine 6025-53-2 7481-89-2, Ddc 7724-76-7 8064-90-2 13484-66-7 13484-67-8 15176-29-1, 5-Ethyl-2'-deoxyuridine 15185-43-0, DOTC 16412-36-5 18417-89-5, Sangivamycin 19387-91-8, Tinidazole 20268-93-3 20859-00-1 21679-14-1, Fludarabine 23169-37-1, 9-(4-Hydroxybutyl)guanine 23205-42-7, 3-Deazauridine 23256-30-6, Nifurtimox 30516-87-1, 3'-Azido-3'-deoxythymidine 30561-97-8 31441-78-8, Mercaptopurine 31698-14-3, Cyclocytidine 32115-08-5 34334-69-5, Cirsiliol 35943-35-2, Triciribine 36791-04-5, Ribavirin 37338-39-9 39809-25-1, Penciclovir 39960-81-1 51145-79-0 53230-10-7, Mefloquine 53910-25-1 53928-14-6 54532-47-7 55274-37-8 55582-99-5, N6-Adamantyladenosine 55583-00-1 59277-89-3, ACV 60084-10-8, Tiazofurin 62488-57-7, 5,6-Dihydro-5-azacytidine 63968-64-9D, Artemisinin, derivs. 65886-71-7, Ara-AC 69304-47-8 69304-48-9 69655-05-6, Dideoxyinosine 69756-53-2, Halofantrine 74886-33-2 77181-69-2 82410-32-0, Ganciclovir 84408-37-7, 6-Deoxyacyclovir 85087-20-3, Doxycline 86304-28-1, Buciclovir 87535-95-3 90301-59-0 92999-29-6 95058-81-4, Gemcitabine 95233-18-4, Atovaquone 97389-88-3 100817-46-7, Stibogluconic acid 101511-50-6 104227-87-4, Famciclovir 106941-25-7, PMEA 108436-80-2 113852-36-1 113852-37-2, Cidofovir 114088-58-3, PMEG 124832-26-4, Valacyclovir 127475-49-4 127759-89-1, Lobucavir 132216-69-4 132216-70-7 132240-40-5 134678-17-4, Lamivudine 136470-78-5, Abacavir 141204-94-6, Co-artemether 142340-99-6 143491-57-0, BW 1592 145514-04-1, DAPD 162600-97-7 168146-84-7, 1592U89 Succinate
RL: PAC (Pharmacological activity); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)
(combination therapy for reduction of toxicity of chemotherapeutic agents)

IT 50-44-2, 6-Mercaptopurine 50-91-9, Floxuridine
51-21-8, 5-Fluorouracil 54-42-2,
5-Iodo-2'-deoxyuridine 100-33-4, Pentamidine
147-94-4, Cytosine arabinoside 154-42-7, 6-Thioguanine
518-28-5, Podophyllotoxin 4291-63-8, Cladribine
5536-17-4, Vidarabine 21679-14-1, Fludarabine
34834-69-5, Cirsiliol 51145-79-0 82410-32-0
, Ganciclovir 95058-81-4, Gemcitabine 97389-88-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy for reduction of toxicity of chemotherapeutic agents)

RN 50-44-2 HCAPLUS
CN 6H-Purine-6-thione, 1,9-dihydro- (CA INDEX NAME)



RN 50-91-9 HCAPLUS
CN Uridine, 2'-deoxy-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 51-21-8 HCAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-fluoro- (CA INDEX NAME)



RN 54-42-2 HCAPLUS
CN Uridine, 2'-deoxy-5-iodo- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 100-33-4 HCAPLUS
CN Benzenecarboximidamide, 4,4'-[1,5-pentanediylbis(oxy)]bis- (CA INDEX NAME)



RN 147-94-4 HCAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-β-D-arabinofuranosyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 154-42-7 HCAPLUS
CN 6H-Purine-6-thione, 2-amino-1,9-dihydro- (CA INDEX NAME)



RN 518-28-5 HCAPLUS
CN Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5R,5aR,8aR,9R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 4291-63-8 HCAPLUS
CN Adenosine, 2-chloro-2'-deoxy- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 5536-17-4 HCAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 21679-14-1 HCAPLUS
CN 9H-Purin-6-amine, 9-β-D-arabinofuranosyl-2-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 34334-69-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy- (CA INDEX NAME)



RN 51145-79-0 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,6,7-trimethoxy- (CA INDEX NAME)



RN 82410-32-0 HCAPLUS
CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]- (CA INDEX NAME)



RN 95058-81-4 HCAPLUS
CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 97389-88-3 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-[3,4-bis(acetyloxy)phenyl]-5,6,7-trimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L123 ANSWER 23 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:107102 HCAPLUS Full-text
DOCUMENT NUMBER: 136:145285
TITLE: Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
INVENTOR(S): Berg, Kurt Frimann
PATENT ASSIGNEE(S): Immupharm Aps, Den.
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009699	A2	20020207	WO 2001-DK515	20010723 <--
WO 2002009699	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2416899	A1	20020207	CA 2001-2416899	20010723 <--
EP 1307189	A2	20030507	EP 2001-957764	20010723 <--
EP 1307189	B1	20060510		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004505046	T	20040219	JP 2002-515252	20010723 <--
BR 2001012818	A	20041019	BR 2001-12818	20010723 <--
NZ 524121	A	20050930	NZ 2001-524121	20010723 <--
AT 325612	T	20060615	AT 2001-957764	20010723 <--
AU 2001279587	B2	20060817	AU 2001-279587	20010723 <--
ES 2263643	T3	20061216	ES 2001-957764	20010723 <--
IL 154144	A	20070724	IL 2001-154144	20010723 <--
CN 100411617	C	20080820	CN 2001-816572	20010723 <--
NO 2003000337	A	20030321	NO 2003-337	20030122 <--
ZA 2003000723	A	20040428	ZA 2003-723	20030127 <--
KR 824075	B1	20080422	KR 2003-701218	20030127 <--
MX 2003000848	A	20041213	MX 2003-848	20030128 <--
US 20040053858	A1	20040318	US 2003-363430	20030922 <--
US 7166640	B2	20070123		
HK 1057330	A1	20061222	HK 2003-108112	20031107 <--

US 20050245467 A1 20051103 US 2005-172878 20050705 <--
PRIORITY APPLN. INFO.: DK 2000-1152 A 20000728 <--
DK 2000-1316 A 20000904 <--
DK 2000-1935 A 20001223 <--
DK 2001-7 A 20010103 <--
DK 2001-827 A 20010522 <--
WO 2001-DK515 W 20010723 <--
US 2003-363430 A1 20030922 <--
OTHER SOURCE(S): MARPAT 136:145285

AB The present invention relates to methods of treating conditions and/or symptoms related to common cold of the upper and/or lower respiratory tract and/or eyes. In particular the invention relates to the methods of treating conditions and/or symptoms related to common cold comprising administration of a flavonoid or administration of a flavonoid in combination with a metal. The invention furthermore describes compns. comprising a metal and a flavonoid useful for the treatment of conditions and/or symptoms relates to common cold.

IC ICM A61K031-35
CC 1-12 (Pharmacology)
Section cross-reference(s): 63
IT Drug delivery systems
(aerosols; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)
IT Drug delivery systems
(bioadhesive; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)
IT Drug delivery systems
(chewing gums; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)
IT Drug delivery systems
(emulsions; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)
IT Drug delivery systems
(gels; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)
IT Drug delivery systems
(inhalants; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)
IT Drug delivery systems
(insufflators; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)
IT Drug delivery systems
(liqs., dispersions; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)
IT Drug delivery systems
(liqs.; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)
IT Drug delivery systems
(lollipops; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)
IT Drug delivery systems

(lozenges; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)

IT Antiasthmatics
Antipyretics
Antitussives
Antiviral agents
Common cold
Drug delivery systems
Drug interactions
Fever and Hyperthermia
Hay fever
Headache
Human
Influenza A virus
Influenza B virus
(method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)

IT Drug delivery systems
(microspheres; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)

IT Drug delivery systems
(powders; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)

IT Drug delivery systems
(solns.; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)

IT Drug delivery systems
(sprays; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)

IT Drug delivery systems
(suspensions; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)

IT Drug delivery systems
(tablets, chewable; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)

IT Drug delivery systems
(tapes, buccal; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)

IT Drug delivery systems
(topical; method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)

IT 117-39-5, Quercetin 153-18-4, Rutin 153-18-4D, Rutin, flavonoids, ethylhydroxy derivs. 154-23-4, Catechin 446-72-0, Genistein 478-01-3, Nobiletin 480-16-0, Morin 480-17-1, Leucocyanidol 480-18-2, Taxifolin 480-40-0, Chrysin 480-41-1, Naringenin 481-53-8, Tangeritin 491-67-8, Baicalein 491-70-3, Luteolin 520-18-3, Kaempferol 520-33-2, Hesperitin 520-36-5, Apigenin 525-82-6, Flavone 528-48-3, Fisetin 548-75-4, Quercetagetin 7-O-glucoside 548-83-4, Galangin 552-58-9, Eriodictyol 557-34-6, Zinc acetate 577-85-5, 3-Hydroxyflavone 652-78-8, Gossypin

863-03-6, Epicatechin gallate 989-51-5, Epigallocatechin gallate 1617-53-4, Amentoflavone 4468-02-4, Zinc gluconate 7085-55-4, Troxerutin 7440-66-6, Zinc, biological studies 10236-47-2, Naringin 13392-28-4, Rimantadine 23713-49-7D, Zinc ion (Zn+2), chelates with amines and amino acids, biological studies 32427-55-7, Tambuletin 40816-51-1 51059-44-0, Oroxindin 55965-63-4, Venoruton 56324-52-8, Hypolaetin 8-O-glucuronide 64364-41-6 70360-12-2, Sideritoflavone 107667-60-7, PolaPreZinc 153168-05-9, Picovir 204255-11-8, Tamiflu
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)

IT 478-01-3, Nobiletin 480-41-1, Naringenin 481-53-8, Tangeritin 491-67-8, Baicalein 548-75-4, Quercetagetin 7-O-glucoside 70360-12-2, Sideritoflavone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of treating symptoms of common cold and allergic rhinitis and infections relating to respiratory tract with flavonoids in combination with metals and other agents)

RN 478-01-3 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy- (CA INDEX NAME)



RN 480-41-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 481-53-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)- (CA INDEX NAME)



RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 548-75-4 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-(β-D-glucopyranosyloxy)-3,5,6-trihydroxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 70360-12-2 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7,8-trimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L123 ANSWER 24 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:71884 HCAPLUS Full-text
DOCUMENT NUMBER: 136:112639
TITLE: Nutraceutical natural product composition for cancer treatment

INVENTOR(S): Clayton, Paul Rodney; Rooperai, Harcharan; Dexter, David
PATENT ASSIGNEE(S): Forum Bioscience, UK
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005827	A2	20020124	WO 2001-GB3150	20010718 <--
WO 2002005827	A3	20020718		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
GB 2000-17620 A 20000718 <--
GB 2000-23574 A 20000926 <--
GB 2000-26600 A 20001031 <--

AB A program of micronutrients designed specifically to modify all the known steps in the cancer sequence comprises administering an effective amount of one or more flavonoids, one or more lectins, one or more isoflavones, one or more carotenoids, betaine and selenium to a mammal suffering from cancer as a combination therapy in which the components are administered together, concurrently or sequentially.

IC ICM A61K035-00
CC 1-6 (Pharmacology)
Section cross-reference(s): 63
IT Antitumor agents
(brain; nutraceutical natural product composition for cancer treatment)
IT Antitumor agents
(glioblastoma multiforme; nutraceutical natural product composition for cancer treatment)
IT Antitumor agents
(metastasis; nutraceutical natural product composition for cancer treatment)
IT Antitumor agents
Apoptosis
Aronia
Berry
Drug interactions
Vaccinium myrtillus
(nutraceutical natural product composition for cancer treatment)
IT Drug delivery systems
(nutraceutical; nutraceutical natural product composition for cancer treatment)
IT 50-35-1, Thalidomide 50-81-7, Vitamin C, biological studies 107-43-7, Betaine 127-40-2, Lutein 144-68-3, Zeaxanthin 303-49-1, Clomipramine 432-70-2, α-Carotene 472-61-7, Astaxanthin 472-70-8, Cryptoxanthin 481-53-8, Tangeretin 502-65-8, Lycopene 1406-16-2, Vitamin D 1406-18-4, Vitamin E 7235-40-7, β-Carotene 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7782-49-2, Selenium, biological studies 11103-57-4, Vitamin A

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nutraceutical natural product composition for cancer treatment)

IT 481-53-8, Tangeretin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nutraceutical natural product composition for cancer treatment)

RN 481-53-8 HCAPLUS

CN 4H-1-Benzopyran-4-one, 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L123 ANSWER 25 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:392055 HCAPLUS Full-text

DOCUMENT NUMBER: 135:10008

TITLE: Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols

INVENTOR(S): Guthrie, Najla; Kurowska, Elzbieta Maria

PATENT ASSIGNEE(S): KGK Synergize, Can.

SOURCE: U.S., 7 pp., Cont.-in-part of U.S. Ser. No. 938,640, abandoned.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6239114	B1	20010529	US 2000-481963	20000112 <--
US 6251400	B1	20010626	US 1997-938640	19970926 <--
WO 2001051043	A2	20010719	WO 2001-IB186	20010112 <--
WO 2001051043	A3	20020530		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1997-938640 B2 19970926 <--
US 2000-481963 A 20000112 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Compns. and methods for the prevention and treatment of neoplastic diseases using a synergistic combination of triterpenes are described. Individuals at a high risk of developing or having neoplasia undergoing conventional therapies may be treated with an ED of triterpene derivs., i.e., limonoids (1-500 mg/day), flavonoids (200-5000 mg/day), tocotrienols (1-1200 mg/day) or a combination of these agents. For example, in the DU 145 prostatic tumor cell line, tangeretin alone or nobitelin alone inhibited these cells most effectively followed by nomilin when the test agents were given alone. When given as combinations, the most effective combination was nomilin + hesperitin + α-tocotrienol, followed by limolin + nobelitin + α-tocotrienol and nomilin + naringenin, followed by nomilin + hesperitin + α-tocotrienol and limonin + tangeretin + α-tocopherol, followed by nomilin + tangeretin and limonin + tangeretin, followed by limonin + naringenin.

IC ICM A61K031-70

INCL 514032000

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

IT Antitumor agents
(Ewing's sarcoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)

IT Antitumor agents
(Kaposi's sarcoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)

IT Antitumor agents
(Waldenstroem's macroglobulinemia; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)

IT Antitumor agents
(Wilms' tumor; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)

IT Antitumor agents
(acoustic neuroma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)

IT Antitumor agents
(acute lymphocytic leukemia; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)

IT Antitumor agents
(acute myelocytic polycythemia vera; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)

IT Antitumor agents
(adenocarcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)

IT Antitumor agents
(astrocytoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)

IT Antitumor agents
(basal cell carcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)

IT Antitumor agents
(bile duct carcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)

IT Antitumor agents
(bladder carcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)

IT Antitumor agents
(bronchi carcinoma; compns. of synergistic combinations of limonoids,

flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Drug delivery systems
(capsules; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(carcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(cervix; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(chondrosarcoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(chordoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(choriocarcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(colon carcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(colon; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(craniopharyngioma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(cystadenocarcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(embryonal carcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Drug delivery systems
(emulsions; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(ependymoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(fibrosarcoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(glioma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(hemangioblastoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(hemangiosarcoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(hepatoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Drug delivery systems
(inhalants; compns. of synergistic combinations of limonoids,

flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Drug delivery systems
(injections, i.m.; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Drug delivery systems
(injections, i.p.; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Drug delivery systems
(injections, i.v.; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Drug delivery systems
(injections, intrathecal; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Drug delivery systems
(injections, s.c.; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(leiomyosarcoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(leukemia; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(liposarcoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(lung small-cell carcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(lung; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(lymphangioendotheliosarcoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(lymphangiosarcoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(lymphoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(mammary gland; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(medullary carcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(medulloblastoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(melanoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(meningioma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(mesothelioma; compns. of synergistic combinations of limonoids,

flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(multiple myeloma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(myosarcoma inhibitors; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(neuroblastoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(oligodendroglioma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Drug delivery systems
(oral; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(osteosarcoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(ovary; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(pancreas; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(pinealoma inhibitors; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(prostate gland; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Drug delivery systems
(rectal; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(renal cell carcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(retinoblastoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(rhabdomyosarcoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(sebaceous gland carcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(seminoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Drug delivery systems
(solns.; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(squamous cell carcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)

IT Drug delivery systems
(suspensions; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(sweat gland; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Drug interactions
(synergistic; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(synovial membrane tumor inhibitors; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Drug delivery systems
(tablets; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(thyroid gland papillary adenocarcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Antitumor agents
(thyroid gland papillary carcinoma; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT Drug delivery systems
(topical; compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT 478-01-3, Nobiletin 480-41-1, Naringenin
481-53-8, Tangeretin 520-33-2, Hesperetin 1063-77-0, Nomilin
1180-71-8, Limonin 1721-51-3, α-Tocotrienol 6829-55-6,
Tocotrienol 14101-61-2, γ-Tocotrienol 25612-59-3,
δ-Tocotrienol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
IT 478-01-3, Nobiletin 480-41-1, Naringenin
481-53-8, Tangeretin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. of synergistic combinations of limonoids, flavonoids and tocotrienols for treatment of neoplastic diseases)
RN 478-01-3 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy- (CA INDEX NAME)



RN 480-41-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-,

(2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 481-53-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L123 ANSWER 26 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:53374 HCAPLUS Full-text
DOCUMENT NUMBER: 134:95504
TITLE: Compositions comprising L-DOPA renal cell transfer-blocking compounds suitable for the treatment of Parkinson's disease with L-DOPA
INVENTOR(S): Soares-Da-Silva, Patricio
PATENT ASSIGNEE(S): Port.
SOURCE: Brit. UK Pat. Appl., 23 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2348371	A	20001004	GB 2000-6063	20000314 <--
GB 2348371	B	20010404		
CA 2402712	A1	20010920	CA 2001-2402712	20010313 <--
CA 2402712	C	20050517		
WO 2001068065	A2	20010920	WO 2001-EP2896	20010313 <--
WO 2001068065	A3	20020221		
WO 2001068065	A9	20020718		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1267853	A2	20030102	EP 2001-931528		20010313 <--
EP 1267853	B1	20040908			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001009220	A	20030318	BR 2001-9220		20010313 <--
HU 2003000130	A2	20030528	HU 2003-130		20010313 <--
HU 2003000130	A3	20051128			
JP 2003526658	T	20030909	JP 2001-566629		20010313 <--
JP 3677002	B2	20050727			
AT 275397	T	20040915	AT 2001-931528		20010313 <--
PT 1267853	E	20041231	PT 2001-931528		20010313 <--
ES 2228858	T3	20050416	ES 2001-931528		20010313 <--
AU 781280	B2	20050512	AU 2001-58283		20010313 <--
RU 2266111	C2	20051220	RU 2002-127782		20010313 <--
CN 1262269	C	20060705	CN 2001-809375		20010313 <--
CZ 297123	B6	20060913	CZ 2002-3348		20010313 <--
MX 2002009043	A	20040819	MX 2002-9043		20020913 <--
US 20040242503	A1	20041202	US 2003-221496		20030108 <--
PRIORITY APPLN. INFO.:			GB 2000-6063	A	20000314 <--
			WO 2001-EP2896	W	20010313 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 134:95504

AB A pharmaceutical composition for the treatment of Parkinson's disease comprises L-DOPA and at least one compound capable of blocking the L-DOPA renal cell outward transfer pathway, the blocking compound being chosen from (a) a flavonoid Ph benzopyran derivative; (b) a trans-stilbene derivative; or (c) phloretin. The composition may also comprise an inhibitor of amino acid decarboxylase, e.g. carbidopa or benserazide, and/or an inhibitor of catechol-O-methyltransferase, e.g. entacapone or tolcapone. The composition is preferably administered in solid form and the L-DOPA may be administered simultaneously or sequentially with the L-DOPA renal cell outward transfer-blocking compound

IC ICM A61K031-198
ICA A61K045-06; A61P025-16
ICI A61K031-198, A61K031-12, A61K031-352
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
IT Antiparkinsonian agents
Drug bioavailability
Drug delivery systems
Kidney
(DOPA renal cell transfer-blocking compds. suitable for treatment of Parkinson's disease with DOPA)
IT 60-82-2, Phloretin 90-18-6, Quercetagetin 103-30-0D, trans-Stilbene, derivs. 117-39-5, Quercetin 322-35-0, Benserazide 446-72-0, Genistein 480-16-0, Morin 480-40-0, Chrysin 480-44-4, Acacetin 490-46-0, (-)-Epicatechin 491-67-8, Baicalein 501-36-0, Resveratrol 520-18-3, Kaempferol 520-36-5, Apigenin 528-48-3, Fisetin 529-44-2, Myricetin 3440-24-2 10083-24-6, Piceatannol 28860-95-9, Carbidopa 130929-57-6, Entacapone 132594-09-3 134308-13-7, Tolcapone 146132-95-8 208186-81-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(DOPA renal cell transfer-blocking compds. suitable for treatment of Parkinson's disease with DOPA)

IT 90-18-6, Quercetagetin 491-67-8, Baicalein
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DOPA renal cell transfer-blocking compds. suitable for treatment of Parkinson's disease with DOPA)

RN 90-18-6 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,6,7-tetrahydroxy- (CA INDEX NAME)



RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L123 ANSWER 27 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:231499 HCAPLUS Full-text
DOCUMENT NUMBER: 130:262145
TITLE: Use of citrus limonoids and flavonoids as well as tocotrienols for the treatment of cancer and hypercholesterolemia
INVENTOR(S): Carrol, Kenneth Kitchener; Kurowska, Elzbieta Maria
PATENT ASSIGNEE(S): KGK Synergize Inc., Can.; Carroll, Margaret Aileen; Guthrie, Najla
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915167	A2	19990401	WO 1998-IB1721	19980924 <--
WO 9915167	A3	19990701		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6251400	B1	20010626	US 1997-938640		19970926 <--
CA 2304202	A1	19990401	CA 1998-2304202		19980924 <--
AU 9894557	A	19990412	AU 1998-94557		19980924 <--
EP 1049464	A2	20001108	EP 1998-947740		19980924 <--
R: AT, DE, FR, GB, IT, NL					
JP 2003510240	T	20030318	JP 2000-512536		19980924 <--
PRIORITY APPLN. INFO.:			US 1997-938640	A	19970926 <--
			WO 1998-IB1721	W	19980924 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Compns. and methods for the prevention and treatment of neoplastic diseases and hypercholesterolemia are described. Individuals at a high risk of developing or having neoplasia or hypercholesterolemia undergoing conventional therapies may be treated with an ED of triterpene derivs. in citrus limonoids, polyphenolic flavonoid citrus compds., tocotrienols or a combination of these agents.

IC ICM A61K031-365
ICS A61K031-35; A61K031-355

CC 1-12 (Pharmacology)
Section cross-reference(s): 63

IT Antitumor agents
Antitumor agents
(Ewing's sarcoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)

IT Antitumor agents
Antitumor agents
(Kaposi's sarcoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)

IT Antitumor agents
Antitumor agents
(Wilms' tumor; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)

IT Antitumor agents
Antitumor agents
(acoustic neuroma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)

IT Antitumor agents
Antitumor agents
(acute lymphocytic leukemia; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)

IT Antitumor agents
(acute myelogenous leukemia; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)

IT Antitumor agents
(adenocarcinoma, papillary and others; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)

IT Antitumor agents
Antitumor agents
(astrocytoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)

IT Antitumor agents
Antitumor agents
(basal cell carcinoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)

IT Antitumor agents
Antitumor agents
(bile duct carcinoma; citrus limonoids and flavonoids as well as

tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(bladder carcinoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
Antitumor agents
(bronchi carcinoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(carcinoma, papillary and others; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(cervix; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(chondrosarcoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
(choriocarcinoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Anticholesteremic agents
Antitumor agents
Chemotherapy
Citrus
Drug delivery systems
Drug interactions
Grapefruit juice
Orange juice
(citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(colon carcinoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(cordoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
(craniopharyngioma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
(ependymoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(fibrosarcoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(glioma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
(hemangiosarcoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(hepatoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents

(leiomyosarcoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(leukemia; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
(liposarcoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(lung carcinoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(lung small-cell carcinoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(lymphangiosarcoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(lymphoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(mammary gland; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
(medulloblastoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(melanoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
Antitumor agents
(meningioma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
(mesothelioma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(multiple myeloma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(neuroblastoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(oligodendroglioma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(ovary; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
(pancreas; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(pinealoma inhibitors; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents

(prostate gland; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
(renal cell carcinoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
(retinoblastoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
(rhabdomyosarcoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(sarcoma, myxosarcoma and others; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
(sebaceous gland carcinoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(seminoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(squamous cell carcinoma; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(sweat gland; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
(synovial membrane tumor inhibitors; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT Antitumor agents
Antitumor agents
(testis; citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT 478-01-3, Nobiletin 480-41-1, Naringenin
481-53-8, Tangeretin 520-33-2, Hesperetin 1063-77-0, Nomilin
1180-71-8, Limonin 1721-51-3, α-Tocotrienol 6829-55-6,
Tocotrienol 10540-29-1, Tamoxifen 14101-61-2,
γ-Tocotrienol 25612-59-3, δ-Tocotrienol 123564-61-4,
Limonin glucoside 123564-62-5, Nomilin glucoside 123564-64-7,
Obacunone glucoside 125107-15-5, Nomilinic acid glucoside 125107-16-6,
Deacetylnomilinic acid glucoside 129477-06-1, Deacetylnomilin glucoside
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
IT 478-01-3, Nobiletin 480-41-1, Naringenin
481-53-8, Tangeretin 10540-29-1, Tamoxifen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(citrus limonoids and flavonoids as well as tocotrienols for treatment of cancer and hypercholesterolemia)
RN 478-01-3 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy- (CA INDEX NAME)



RN 480-41-1 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 481-53-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)- (CA INDEX NAME)



RN 10540-29-1 HCAPLUS
CN Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L123 ANSWER 28 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1998:706097 HCAPLUS Full-text
DOCUMENT NUMBER: 129:310877
ORIGINAL REFERENCE NO.: 129:63297a,63300a
TITLE: Biflavanoids and their derivatives as antiviral agents, alone or in combination with at least one known antiviral agent
INVENTOR(S): Zembower, David E.; Lin, Yuh-Meei; Flavin, Michael T.; Schure, Ralph; Zhao, Geng-Xian
PATENT ASSIGNEE(S): Medichem Research, Inc., USA
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9846238	A1	19981022	WO 1998-US7649	19980415 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9871243	A	19981111	AU 1998-71243	19980415 <--
US 6399654	B1	20020604	US 1998-60839	19980415 <--
PRIORITY APPLN. INFO.:			US 1997-842625 A2	19970415 <--
			US 1998-60839 A	19980415 <--
			US 1995-465P P	19950623 <--
			US 1996-668284 A2	19960621 <--
			WO 1998-US7649 W	19980415 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Substantially purified antiviral biflavanoids robustaflavone, hinokflavone, amentoflavone, agathisflavone, volkensiflavone, morelloflavone, rhusflavanone, succedaneaflavanone, GB-1a, and GB-2a are provided. Antiviral biflavanoid derivs. and salt forms thereof, e.g., robustaflavone tetrasulfate potassium salt, and methods for preparing the same are also disclosed. Pharmaceutical compns. which include the antiviral biflavanoids, derivs. of salts thereof are also provided alone or in combination with at least one antiviral agent such as 3TC. Also disclosed is an improved method for obtaining substantially pure robustaflavone from plant material. The biflavanoid compds., derivs. or salts thereof of the invention may be used in a method for treating and/or preventing viral infections caused by viral agents such as influenza, e.g., influenza A and B; hepatitis, e.g., hepatitis B; human immunodeficiency virus, e.g., HIV-1; Herpes viruses (HSV-1 and HSV-2); Varicella Zoster virus (VZV); and measles. For instance, semi-synthetic hexa-O-acetate and hexa-O-Me ether derivs. of robustaflavone have been found to be effective in a method for treating or preventing hepatitis B viral infections. Compns. which include these robustaflavone derivs. along with methods for preparing and using the same are also provided. These compns. may be used alone or in combination with at least one antiviral agent such as 3TC.

IC ICM A61K031-70
ICS A61K031-52
CC 1-5 (Pharmacology)
Section cross-reference(s): 11, 26, 63
IT Antibacterial agents

Antibiotics
Antiviral agents
Drug delivery systems
Drug interactions
Fungicides
Hepatitis B virus
Hepatitis virus
Herpesviridae
Human adenovirus 5
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 5
Human immunodeficiency virus
Human immunodeficiency virus 1
Human parainfluenza virus 3
Immunomodulators
Immunostimulants
Influenza A virus
Influenza B virus
Influenza virus
Measles virus
Respiratory syncytial virus
Retroviridae
Rhus succedanea
(biflavanoids and derivs., alone or in combination with other antiviral agents, for viral infection prevention or treatment, and biflavanoid isolation and preparation)

IT Drug interactions
(synergistic; biflavanoids and derivs., alone or in combination with other antiviral agents, for viral infection prevention or treatment, and biflavanoid isolation and preparation)

IT 480-41-1, Naringenin 520-36-5, Apigenin 56663-56-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(biflavanoids and derivs., alone or in combination with other antiviral agents, for viral infection prevention or treatment, and biflavanoid isolation and preparation)

IT 1617-53-4, Amentoflavone 1617-53-4D, Amentoflavone, derivs. 3056-17-5, D4T 7481-89-2, DdC 16851-21-1, Morelloflavone 16851-21-1D, Morelloflavone, derivs. 18412-96-9, GB-2a 18412-96-9D, GB-2a, derivs. 19202-36-9, Hinokiflavone 19202-36-9D, Hinokiflavone, derivs. 19360-72-6D, GB-1a, derivs. 27542-37-6, Volkensiflavone 27542-37-6D, Volkensiflavone, derivs. 28441-98-7, Agathisflavone 28441-98-7D, Agathisflavone, derivs. 30516-87-1, AZT 39809-25-1, Penciclovir 49620-13-5D, Robustaflavone, derivs. 53060-72-3D, Rhusflavanone, derivs. 57291-00-6D, Succedaneaflavanone, derivs. 59277-89-3, Acyclovir 69655-05-6, DdI 82410-32-0, Ganciclovir 126320-77-2D, TIBO, derivs. 127779-20-8, Saquinavir 129618-40-2, Nevirapine 134678-17-4, Lamivudine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biflavanoids and derivs., alone or in combination with other antiviral agents, for viral infection prevention or treatment, and biflavanoid isolation and preparation)

IT 480-41-1, Naringenin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(biflavanoids and derivs., alone or in combination with other antiviral

agents, for viral infection prevention or treatment, and biflavanoid isolation and preparation)

RN 480-41-1 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 19202-36-9, Hinokiflavone 19202-36-9D, Hinokiflavone, derivs. 82410-32-0, Ganciclovir 129618-40-2, Nevirapine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(biflavanoids and derivs., alone or in combination with other antiviral agents, for viral infection prevention or treatment, and biflavanoid isolation and preparation)

RN 19202-36-9 HCAPLUS

CN 4H-1-Benzopyran-4-one, 6-[4-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)phenoxy]-5,7-dihydroxy-2-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 19202-36-9 HCAPLUS

CN 4H-1-Benzopyran-4-one, 6-[4-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)phenoxy]-5,7-dihydroxy-2-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 82410-32-0 HCAPLUS

CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]- (CA INDEX NAME)



RN 129618-40-2 HCAPLUS
CN 6H-Dipyrido[2,3-b:3',2'-e][1,4]diazepin-6-one,
11-cyclopropyl-5,11-dihydro-4-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L123 ANSWER 29 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1997:639911 HCAPLUS Full-text
DOCUMENT NUMBER: 127:302886
ORIGINAL REFERENCE NO.: 127:59035a,59038a
TITLE: Study on baths with crude drug. III. The effect of Ligustici chuanxiong rhizoma extract on the percutaneous absorption of some natural compounds
AUTHOR(S): Sekiya, Kouji; Kadota, Shigetoshi; Katayama, Kazunori; Koizumi, Tamotsu; Namba, Tsuneo
CORPORATE SOURCE: Research Institute for Wakan-Yaku (Traditional Sino-Japanese Medicines), Toyama Medical and Pharmaceutical University 2630-Sugitani, Toyama, 930-01, Japan
SOURCE: Biological & Pharmaceutical Bulletin (1997), 20(9), 983-987
CODEN: BPBLEO; ISSN: 0918-6158
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
AB To investigate the permeability of natural compds. through hairless mouse skin, compds. having a range of lipophilicity, i.e., ginsenoside-Re, baicalin, glycyrrhizin, baicalein, wogonin, honokiol, magnolol, bergapten, shikonin and sinomenine were used. These compds. permeated through the skin a little, however, they were generally accumulated into the skin. The uptake amount into the skin of each compound related to their lipophilicities in the in vitro experiment Furthermore, Ligustici Chuanxiong Rhizoma (Senkyu) ether extract (SEE) enhanced their permeability into the skin; especially, it exhibited an effect on the skin permeability of moderately lipophilic compds. such as baicalein and bergapten. The effect of SEE in vivo was similar to that obtained in the in vitro experiment The results indicated that natural compds. having high lipophilicity sufficiently permeated into the hairless

mouse skin due to their accumulative property, and SEE enhanced the permeability of the moderately lipophilic compds. into the skin.

CC 1-2 (Pharmacology)
Section cross-reference(s): 63

IT Absorption
Drug bioavailability
Ligusticum chuanxiong
Lipophilicity
Skin
(baths with crude drug and effect of Ligustici chuanxiong rhizoma extract on percutaneous absorption of natural compds. in relation to lipophilicity)

IT Drug delivery systems
(topical; baths with crude drug and effect of Ligustici chuanxiong rhizoma extract on percutaneous absorption of natural compds. in relation to lipophilicity)

IT 115-53-7, Sinomenine 484-20-8, Bergapten 491-67-8, Baicalein 517-89-5, Shikonin 528-43-8, Magnolol 632-85-9, Wogonin 1405-86-3, Glycyrrhizin 21967-41-9, Baicalin 35354-74-6, Honokiol 52286-59-6, Ginsenoside-Re
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(baths with crude drug and effect of Ligustici chuanxiong rhizoma extract on percutaneous absorption of natural compds. in relation to lipophilicity)

IT 491-67-8, Baicalein 21967-41-9, Baicalin
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(baths with crude drug and effect of Ligustici chuanxiong rhizoma extract on percutaneous absorption of natural compds. in relation to lipophilicity)

RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



RN 21967-41-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L123 ANSWER 30 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1997:174992 HCAPLUS Full-text
DOCUMENT NUMBER: 126:166479
ORIGINAL REFERENCE NO.: 126:32053a,32056a
TITLE: Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders
INVENTOR(S): Isakson, Peter C.; Anderson, Gary D.; Gregory, Susan A.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9641626	A1	19961227	WO 1996-US10106	19960611 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2224517	A1	19961227	CA 1996-2224517	19960611 <--
AU 9661117	A	19970109	AU 1996-61117	19960611 <--
EP 833622	A1	19980408	EP 1996-918465	19960611 <--
EP 833622	B1	20050810		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 11507670	T	19990706	JP 1997-503273	19960611 <--
AT 301457	T	20050815	AT 1996-918465	19960611 <--
ES 2247604	T3	20060301	ES 1996-918465	19960611 <--
PRIORITY APPLN. INFO.:			US 1995-489472 A	19950612 <--
			WO 1996-US10106 W	19960611 <--

OTHER SOURCE(S): MARPAT 126:166479

AB Combinations of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor are described for treatment of inflammation and inflammation-related disorders. Preparation of e.g. 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl]benzenesulfonamide is described., as are pharmaceutical formulations and activity against collagen-induced arthritis in mice.

IC ICM A61K031-00
ICS A61K031-10; A61K031-18
CC 1-7 (Pharmacology)
Section cross-reference(s): 28, 63
IT Anti-inflammatory agents
Antiarthritics
Drug delivery systems
(cyclooxygenase-2 inhibitor combination with 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders, compound preparation, antiarthritic activity and pharmaceutical compns.)
IT Drugs
(for inflammation-associated disorders; cyclooxygenase-2 inhibitor combination with 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders, compound preparation,

antiarthritic activity and pharmaceutical compns.)
IT 141579-54-6, A 76745
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(A 76745; cyclooxygenase-2 inhibitor combination with 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders, compound preparation, antiarthritic activity
and pharmaceutical compns.)
IT 168434-89-7, CT 3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CT 3; cyclooxygenase-2 inhibitor combination with 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders, compound preparation, antiarthritic activity
and pharmaceutical compns.)
IT 187112-47-6, R 840 (Pharmaceutical)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(R 840; cyclooxygenase-2 inhibitor combination with 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders, compound preparation, antiarthritic activity
and pharmaceutical compns.)
IT 170569-86-5P 186887-83-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cyclooxygenase-2 inhibitor combination with 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders, compound preparation, antiarthritic activity and pharmaceutical compns.)
IT 341-88-8, KF-8940 4737-26-2, Isoflavan 27686-84-6, Masoprocol 34334-69-5, Cirsiliol 36441-32-4, DuP-654 46721-85-1, CBS-1114 50847-11-5, Ibudilast 60284-71-1, AHR-5333 71125-38-7, Meloxicam 75139-38-7, Carbazomycin B 78794-60-2 79916-77-1, Forsythiaside 80809-81-0, Docebenone 87660-25-1, ONO 5349 91431-42-4, Lonapalene 92532-05-3, Rev 5367 93211-49-5, L-651392 96314-49-7, TEI-8005 96920-48-8, TMK 992 96928-53-9, TMK-919 99107-52-5, Bunaprolast 99134-29-9, L-651896 99318-09-9, QA-208-199 100035-75-4, Evandamine 101335-99-3, Eprovafen 101618-31-9, TMK 789 101619-08-3, TMK 781 101619-11-8, TMK-777 101910-24-1, PF-5901 102612-16-8, L-656224 103141-09-9, FPL 62064 103475-41-8, Tepoxalin 104007-80-9, TZI-41127 104153-37-9, Rilopirox 105357-17-3, SC-41661A 107008-29-7, L-652343 107746-52-1, E 5110 107889-32-7, LY 178002 108073-62-7, Carbazomycin C 110033-17-5, WY 47288 110406-33-2 110501-66-1, TMK-688 110545-79-4, SCH 40120 111406-87-2, Zileuton 111525-11-2, A 63162 111908-94-2, SK&F-104351 111908-95-3, SK&F-104493 111974-60-8, Wy-48252 112344-52-2, Flobufen 114832-13-2, CGS-8515 114917-95-2, BMY-30094 115255-10-2, ONO-LP 219 115255-23-7, ONO-LP 269 115816-05-2, BI-L-93BS 117574-40-0, CV-6504 118414-82-7, L 663536 118420-47-6, AL-3264 119256-94-9, FR 110302 120164-49-0, E-6080 120210-48-2, Tenidap 120602-97-3, RG-6866 121135-51-1, 210-610 121412-39-3, CGS-21595 121502-05-4, PD-127443 122454-69-7, SK&F-105809 122610-85-9, A-65260 123016-21-7, Wy-50295 123606-23-5, A-69412 123653-11-2, NS-398 125578-25-8 125721-82-6, BIL 226XX 125722-16-9, Enofelast 127245-22-1, BF-389 127378-46-5, CI 987 127481-38-3, L-674636 128253-31-6, Bay-x-1005 129424-08-4, ICI-211965 130116-16-4, CI-986 130838-15-2, Y-19432 131817-86-2, CGS 22745 132392-65-5, LY-269415 132734-43-1, LY-233569 132956-22-0, Enazadrem phosphate 133174-26-2, L-670630 133430-69-0, ETH-615 134470-36-3, BW-B 218C 134470-38-5, BW-B 70C 134822-78-9, CGS-23885 134823-10-2, CGS 24891 135133-84-5,

SC-45662 135872-69-4, WAY 120739 135872-94-5, WAY 121520
138331-04-1, R-68151 139149-55-6, SB-202235 139340-56-0, CI 1004
140841-32-3, ZD-2138 141579-67-1, A-78773 141579-87-5, A-79175
143809-38-5 143809-39-6 143964-80-1, F-1322 145096-30-6, E 3040
146935-39-9, Epocarbazolin A 147030-01-1, MK-591 147317-96-2,
Nitrosoxacin A 147432-77-7, Ontazolast 147497-10-7, CGS 26529
147936-06-9, L-699333 148915-76-8, BU 4601A 149539-02-6, BI-L-357
150693-65-5, Lagunamycin 152784-11-7, WILD20 153950-29-9, A 121798
154214-70-7, R-85355 154355-76-7, ABT 761 155944-23-3, ZM 230487
156897-06-2, ML-3000 157630-13-2, MER W8020 158930-07-5, L 739010
158959-32-1 158959-33-2 158959-34-3 158959-35-4 158959-37-6
158959-42-3 158959-43-4 158959-46-7 158959-47-8 158959-56-9
159429-69-3 159429-70-6 161435-44-5, CGS-25997 162011-90-7, MK 966
162054-19-5 162738-34-3 163303-19-3 163303-25-1 163303-29-5
163303-38-6 165251-89-8 165328-42-7 165328-49-4 165328-51-8
165328-52-9 168299-83-0 168299-90-9 168433-84-9 169154-04-5
169154-07-8 169154-19-2 169154-24-9 169590-41-4 169590-42-5
169902-71-0 169902-74-3 169902-75-4 169951-23-9 169951-24-0
169951-25-1 169951-27-3 169951-28-4 170569-31-0 170569-42-3
170569-50-3 170569-87-6 170569-88-7 170569-91-2 170570-05-5
170570-25-9 170570-29-3 170570-31-7 170570-32-8 170570-33-9
170571-71-8 171095-65-1, CMI 568 171888-46-3 173776-67-5
174454-52-5 174470-77-0 175676-91-2 175676-92-3 175677-05-1
175677-06-2 175677-07-3 175677-13-1 175677-14-2 175883-05-3
175883-36-0 177560-19-9 177560-23-5 177560-29-1 177560-30-4
177560-34-8 177560-36-0 177560-38-2 177560-61-1 177660-54-7
177660-55-8 177660-56-9 177660-67-2 177660-72-9 177660-73-0
177660-76-3 177660-77-4 177660-78-5 177660-81-0 177660-85-4
177660-89-8 177660-92-3 177660-94-5 177661-00-6 177661-01-7
177661-02-8 177661-04-0 177661-06-2 177661-15-3 177661-17-5
177661-18-6 177661-19-7 177661-49-3 177662-22-5 177754-42-6
181627-94-1 181627-96-3 181627-98-5 181628-00-2 181695-72-7
181695-81-8 181695-85-2 181696-18-4 181696-33-3 181809-58-5
181809-60-9 181809-63-2 185344-55-2 186804-93-3 186887-75-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase-2 inhibitor combination with 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders, compound preparation, antiarthritic activity and pharmaceutical compns.)

IT 186912-76-5, L 752860 187112-03-4, A 72694 187112-04-5, A 80263
187112-09-0, Bay-q 1531 187112-10-3, BF 397 187112-11-4, BW 4C
187112-12-5, BW 70C 187112-17-0, CHF 1909 187112-22-7, EF 40
187112-23-8, EN 105 187112-24-9, Floculide 187112-26-1, FPL 64170
187112-28-3, GR 80907 187112-29-4, HP 977 187112-30-7, HX 0386
187112-32-9, L 691816 187112-33-0, Linazolast 187112-35-2, LY 280810
187112-36-3, MM 7002 187112-41-0, P 8892 187112-42-1, P 8977
187112-43-2, PD 136005 187112-44-3, PD 145246 187112-50-1, RU 46057
187112-51-2, RU 54808 187112-52-3, SL 81-0433 187112-54-5, SS 81OH
187112-56-7, Tanabe 757 187112-57-8, Tanabe 799 187112-58-9, TMK 685
187112-59-0, TZI 2721 187112-62-5, WAY 125007 187112-64-7, ZD 7717
187112-65-8, ZM 216800 193739-23-0, CMI 392
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase-2 inhibitor combination with 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders, compound preparation, antiarthritic activity and pharmaceutical compns.)

IT 39391-18-9 80619-02-9, 5-Lipoxygenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; cyclooxygenase-2 inhibitor combination with 5-lipoxygenase inhibitor for treatment of inflammation and

inflammation-related disorders, compound preparation, antiarthritic activity
and pharmaceutical compns.)
IT 455-91-4P 18931-60-7P 170570-77-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction; cyclooxygenase-2 inhibitor combination with 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders, compound preparation, antiarthritic activity
and pharmaceutical compns.)
IT 99-91-2, 4'-Chloroacetophenone 321-28-8, 2-Fluoroanisole 383-63-1, Ethyl trifluoroacetate 454-31-9, Ethyl difluoroacetate 27918-19-0, 4-Sulfonamidophenylhydrazine hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; cyclooxygenase-2 inhibitor combination with 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders, compound preparation, antiarthritic activity
and pharmaceutical compns.)
IT 34334-69-5, Cirsiliol 123653-11-2, NS-398
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase-2 inhibitor combination with 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders, compound preparation, antiarthritic activity and pharmaceutical compns.)
RN 34334-69-5 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy- (CA INDEX NAME)



RN 123653-11-2 HCAPLUS
CN Methanesulfonamide, N-[2-(cyclohexyloxy)-4-nitrophenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L123 ANSWER 31 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1993:81675 HCAPLUS Full-text

DOCUMENT NUMBER: 118:81675
ORIGINAL REFERENCE NO.: 118:14389a,14392a
TITLE: Inhibition of scale adhesion in the polymerization of ethylenic monomers
INVENTOR(S): Watanabe, Mikio; Ueno, Susumu; Usu, Masahiro; Yono, Masayoshi
PATENT ASSIGNEE(S): Shin-Etsu Chemical Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04266903	A	19920922	JP 1991-28940	19910222 <--

PRIORITY APPLN. INFO.: JP 1991-28940 19910222 <--

AB Scale formation is prevented in the polymerization of CH2:CR1R2 [R1 = H, Me; R2 = H, CnH2n+1, CO2M (M = alkali metal, NH4+), CO2CnH2n+1, CN, Ph, C6H4R3 (R3 = H, OH, Me, CH:CH2), OCOCnH2n+1, OCnH2n+1, CH:CH2] by using polymerizers, in which the monomer-contacting parts are covered with films containing flavonoid-type natural colorants and PVA [saponification degree (A) ≥70 mol%]. Thus, carthamin and Kuraray PVA-140 (PVA, A 99 ± 0.5 mol%) were dissolved in a 50:50 mixture of H2O and MeOH at a 100/900 weight ratio to 1.0% concentration, adjusted to pH 9.0 with NaOH then the resulted solution was sprayed onto monomer-containing parts of a stainless steel polymerizer, dried at 50° for 10 min, and washed. Then, 125 kg styrene was polymerized with 50 kg acrylonitrile at 70° for 3 h in H2O in the presence of SBR latex, an emulsifier, NaOH, tert-C12H25SH, and K2S2O8 in the polymerizer to obtain a polymer with scale adhesion 9 g/m2-the inside wall.

IC ICM C08F002-00
CC 35-10 (Chemistry of Synthetic High Polymers)
Section cross-reference(s): 39
IT Coating materials
(blends of flavonoids and PVA, scale inhibitors, for polymerizing ethylenic monomers)
IT 12597-68-1, Stainless steel, uses
RL: USES (Uses)
(polymerizers, for ethylenic monomers, scale inhibitor for, blends of flavonoids and PVA as)
IT 117-39-5, Quercetin 480-15-9, Datiscetin 480-16-0, Morin 487-52-5, Butein 490-31-3, Robinetin 491-67-8, Baicalein 519-39-1, Isocarthamin 520-18-3, Kaempferol 520-36-5, Apigenin 528-48-3, Fisetin 529-44-2, Myricetin 548-58-3, Primetin 632-85-9, Wogonin 5064-02-8, Pedicinin 36338-96-2, Carthamin
RL: USES (Uses)
(scale inhibitors containing PVA and, for polymerizing ethylenic monomers)
IT 491-67-8, Baicalein
RL: USES (Uses)
(scale inhibitors containing PVA and, for polymerizing ethylenic monomers)
RN 491-67-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl- (CA INDEX NAME)



L123 ANSWER 32 OF 32 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1984:505515 HCAPLUS Full-text
DOCUMENT NUMBER: 101:105515
ORIGINAL REFERENCE NO.: 101:16029a,16032a
TITLE: Inhibition of aflatoxin B1 carcinogenesis in rainbow trout by flavone and indole compounds
AUTHOR(S): Nixon, Joseph E.; Hendricks, Jerry D.; Pawlowski, Norman E.; Pereira, Cliff B.; Sinnhuber, Russell O.; Bailey, George S.
CORPORATE SOURCE: Dep. Food Sci. Technol., Oregon State Univ., Corvallis, OR, 97331, USA
SOURCE: Carcinogenesis (1984), 5(5), 615-19
CODEN: CRNGDP; ISSN: 0143-3334
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The following compds.: 50 and 500 ppm β-naphthoflavone (BNF) [6051-87-2], 1000 ppm flavone [525-82-6], 1000 ppm of a tangeretin [481-53-8] nobiletin [478-01-3] mixture, 1000 ppm β-ionone [79-77-6], 1000 ppm indole-3-carbinol (I3C) [700-06-1] and 2000 ppm quercetin [117-39-5] were examined for protection against aflatoxin B1 (AFB1)(I) [1162-65-8] hepatocarcinogenesis, induction of the mixed-function oxidase (MFO) [9040-60-2] system and metabolism of AFB1 in rainbow trout (Salmo gairdneri). These compds. were fed to fingerling rainbow trout for 8 wk. At that time the activity of several MFO enzymes and cytochrome P 450 [9035-51-2] content were measured and the trout were exposed for 2 wk to 20 ppb AFB1 in the same diets. After feeding the test diets without AFB1 for another 6 wk and basal diet for another 52 wk, the tumor incidence was determined The effect of BNF and I3C on in vivo binding of AFB1 to DNA was also measured in sep. groups of trout. BNF induced the trout MFO system in a dose-dependent manner, tangeretin-nobiletin was less effective, and I3C did not induce. BNF showed significant alterations in the metabolism of AFB1 to aflatoxicol [29611-03-8] and aflatoxin M1 [6795-23-9] using cell fractions from pretreated fish. None of the other compds., including I3C showed such an effect. Despite the apparent lack of in vitro effect of I3C, both BNF and I3C reduced AFB1-DNA binding in vivo. I3C and BNF provided marked protection against AFB1-induced hepatocarcinogenesis, whereas the other compds. were less effective. The 58 wk tumor incidences were 4% for I3C, 6%

for BNF, and 18% for BNF, compared to 38% for the AFB1-pos. control. These data demonstrate that gross induction of the MFO system was not necessarily required for alterations in DNA adduct formation in vivo or protection against AFB1 carcinogenesis. Both BNF and I3C provided marked protection but only BNF induced the MFO system.

CC 4-6 (Toxicology)
Section cross-reference(s): 1, 17

IT 79-77-6 117-39-5 478-01-3 481-53-8 525-82-6
700-06-1 6051-87-2
RL: BIOL (Biological study)
(aflatoxin-induced liver neoplasm response to, in rainbow trout, mixed-function oxidases in relation to)

IT 478-01-3 481-53-8 700-06-1
RL: BIOL (Biological study)
(aflatoxin-induced liver neoplasm response to, in rainbow trout, mixed-function oxidases in relation to)

RN 478-01-3 HCAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy- (CA INDEX NAME)



RN 481-53-8 HCAPLUS
CN 4H-1-Benzopyran-4-one, 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)- (CA INDEX NAME)



RN 700-06-1 HCAPLUS
CN 1H-Indole-3-methanol (CA INDEX NAME)



OS.CITING REF COUNT: 43 THERE ARE 43 CAPLUS RECORDS THAT CITE THIS RECORD (43 CITINGS)

FILE 'HOME' ENTERED AT 16:54:47 ON 29 JAN 2010

SEARCH HISTORY

```
=> d stat que l4; d his nofile
L2              STR
```




```
VAR G8=H/OH/22/25/26/X
NODE ATTRIBUTES:
NSPEC   IS RC     AT  17
NSPEC   IS RC     AT  21
NSPEC   IS RC     AT  24
CONNECT IS E1  RC AT  25
CONNECT IS E1  RC AT  27
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  28

STEREO ATTRIBUTES: NONE
L4         3009 SEA FILE=REGISTRY SSS FUL L2

100.0% PROCESSED   55925 ITERATIONS                          3009 ANSWERS
SEARCH TIME: 00.00.02


     (FILE 'HOME' ENTERED AT 15:37:56 ON 29 JAN 2010)

     FILE 'CAPLUS' ENTERED AT 15:38:10 ON 29 JAN 2010
                E US2006-586822/APPS
L1              1 SEA SPE=ON  ABB=ON  US2006-586822/AP
                D SCA

     FILE 'ZCAPLUS' ENTERED AT 15:38:45 ON 29 JAN 2010
                E DRUG BIOAVAILABILITY+ALL/CT
                E E9+ALL
                E DRUG METABOLISM+ALL/CT
                E DRUG DESIGN+ALL/CT
                E ANTITUMOR AGENTS+ALL/CT
                E  COMBINATION CHEMOTHERAPY+ALL/CT
                E E10+ALL

     FILE 'REGISTRY' ENTERED AT 15:43:55 ON 29 JAN 2010
L2              STR
L3             50 SEA SSS SAM L2
L4           3009 SEA SSS FUL L2
```

```
                SAVE TEMP L4 KWO822FULL/A

     FILE 'STNGUIDE' ENTERED AT 15:48:07 ON 29 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 15:51:21 ON 29 JAN 2010
L5          9000 SEA SPE=ON  ABB=ON  L4
L6             1 SEA SPE=ON  ABB=ON  US2006-586822/AP
L7         11455 SEA SPE=ON  ABB=ON  CHENG Y?/AU
L8         36775 SEA SPE=ON  ABB=ON  LEE Y?/AU
L9           285 SEA SPE=ON  ABB=ON  YEO H?/AU
L10        28697 SEA SPE=ON  ABB=ON  DRUG BIOAVAILABILITY/CT
L11       342049 SEA SPE=ON  ABB=ON  DRUG DELIVERY SYSTEMS+NT,OLD/CT
L12       495141 SEA SPE=ON  ABB=ON  ANTITUMOR AGENTS+NT,OLD,RTCS/CT
L13        50670 SEA SPE=ON  ABB=ON  DRUG INTERACTIONS+OLD/CT
L14        11152 SEA SPE=ON  ABB=ON  COMB?/OBI(L)PHARMAC?/OBI
L15        45792 SEA SPE=ON  ABB=ON  COMBINATION CHEMOTHERAPY/CT
L16        12971 SEA SPE=ON  ABB=ON  CODRUG#/OBI OR COADMIN?/OBI OR CONCOMITANT?
                 /OBI OR CONCURRENT?/OBI
L17         1784 SEA SPE=ON  ABB=ON  CO/OBI(W)(DRUG#/OBI OR ADMIN?/OBI)
L18       203485 SEA SPE=ON  ABB=ON  BLEND?/OBI
L19       462118 SEA SPE=ON  ABB=ON  MIXTURE#/OBI
L20           64 SEA SPE=ON  ABB=ON  L1 OR ((L7 OR L8 OR L9) AND L5 AND (L10 OR
                 L11 OR L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19))
                 OR ((L7 AND (L8 OR L9)) OR (L8 AND L9))
L21           32 SEA SPE=ON  ABB=ON  L1 OR ((L7 OR L8 OR L9) AND L5 AND (L10 OR
                 L11 OR L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19))
                 OR (L7 AND L8 AND L9)
L22            3 SEA SPE=ON  ABB=ON  L7 AND L8 AND L9
L23            7 SEA SPE=ON  ABB=ON  ((L7 OR L8 OR L9) AND L5 AND L12 AND (L10
                 OR L11 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19)) OR
                 (((L7 AND (L8 OR L9)) OR (L8 AND L9)) AND L5 AND (L10 OR L11
                 OR L12 OR L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19))
L24            8 SEA SPE=ON  ABB=ON  (L6 OR L22 OR L23)
L25           83 SEA SPE=ON  ABB=ON  L5 AND L10
L26            1 SEA SPE=ON  ABB=ON  L6 AND L5
                 D SC
                 D SCA
L27         1289 SEA SPE=ON  ABB=ON  L5 AND L11
L28         2223 SEA SPE=ON  ABB=ON  L5 AND L12
L29          129 SEA SPE=ON  ABB=ON  L5 AND L13
L30           38 SEA SPE=ON  ABB=ON  L5 AND L14
L31           77 SEA SPE=ON  ABB=ON  L5 AND L15
L32            1 SEA SPE=ON  ABB=ON  L5 AND L16
L33            2 SEA SPE=ON  ABB=ON  L5 AND L17
L34            4 SEA SPE=ON  ABB=ON  L5 AND L18
L35           68 SEA SPE=ON  ABB=ON  L5 AND L19
L36            7 SEA SPE=ON  ABB=ON  L5 AND (L16 OR L17 OR L18)
L37           70 SEA SPE=ON  ABB=ON  L5 AND L10 AND (L11 OR L12 OR L13 OR L14
                 OR L15 OR L19)
L38           34 SEA SPE=ON  ABB=ON  L5 AND L10 AND L12
L39           31 SEA SPE=ON  ABB=ON  L5(L)L19
L40           17 SEA SPE=ON  ABB=ON  L5(L)L19 AND (L10 OR L11 OR L12 OR L13 OR
                 L14 OR L15 OR L16 OR L17 OR L18)
L41            6 SEA SPE=ON  ABB=ON  L40 AND (RHUBARB OR HPLC)/TI
                 D SCA TI HITIND
L42         1343 SEA SPE=ON  ABB=ON  L5(L)ANT/RL
L43           10 SEA SPE=ON  ABB=ON  L40 NOT L42
L44          321 SEA SPE=ON  ABB=ON  L5 AND (L10 OR L11 OR L13 OR L14 OR L15 OR
                 L16 OR L17 OR L18 OR L19) AND L12 NOT L42
L45            6 SEA SPE=ON  ABB=ON  L5 AND L10 AND (L13 OR L14 OR L15 OR L16
```

```
                OR L17 OR L18 OR L19) AND L12 NOT L42

     FILE 'STNGUIDE' ENTERED AT 16:02:54 ON 29 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 16:34:16 ON 29 JAN 2010
L46           17 SEA SPE=ON  ABB=ON  L5 AND L10 AND L11 AND L12 NOT L42
L47        22246 SEA SPE=ON  ABB=ON  (L10 AND (L11 OR L12 OR L13 OR L14 OR L15
                OR L16 OR L17 OR L18 OR L19))
L48        72117 SEA SPE=ON  ABB=ON  L11 AND (L12 OR L13 OR L14 OR L15 OR L16
                OR L17 OR L18 OR L19)
L49        38344 SEA SPE=ON  ABB=ON  L12 AND (L13 OR L14 OR L15 OR L16 OR L17
                OR L18 OR L19)
L50        10606 SEA SPE=ON  ABB=ON  L13 AND (L14 OR L15 OR L16 OR L17 OR L18
                OR L19)
L51         4284 SEA SPE=ON  ABB=ON  L14 AND (L15 OR L16 OR L17 OR L18 OR L19)
L52         3593 SEA SPE=ON  ABB=ON  L15 AND (L16 OR L17 OR L18 OR L19)
L53          298 SEA SPE=ON  ABB=ON  L16 AND (L17 OR L18 OR L19)
L54           15 SEA SPE=ON  ABB=ON  L17 AND (L18 OR L19)
L55         7815 SEA SPE=ON  ABB=ON  L18 AND L19
L56            1 SEA SPE=ON  ABB=ON  L5 AND L53
L57            1 SEA SPE=ON  ABB=ON  L5 AND (L53 OR L54)
L58           70 SEA SPE=ON  ABB=ON  L5 AND L47
L59          313 SEA SPE=ON  ABB=ON  L5 AND L48
L60          131 SEA SPE=ON  ABB=ON  L5 AND L49
L61           35 SEA SPE=ON  ABB=ON  L5 AND L50
L62           12 SEA SPE=ON  ABB=ON  L5 AND L51
L63            5 SEA SPE=ON  ABB=ON  L5 AND L52
L64            0 SEA SPE=ON  ABB=ON  L5 AND L55
L65           22 SEA SPE=ON  ABB=ON  L5 AND L47 AND (L48 OR L49)
L66           28 SEA SPE=ON  ABB=ON  L5 AND L50 AND (L47 OR L48 OR L49)
L67            0 SEA SPE=ON  ABB=ON  L65 AND L66
L68           47 SEA SPE=ON  ABB=ON  (L65 OR L66) NOT L42
L69        11425 SEA SPE=ON  ABB=ON  L48 AND (L49 OR L50 OR L51 OR L52 OR L55)
L70         7577 SEA SPE=ON  ABB=ON  L49 AND (L50 OR L51 OR L52 OR L55)
L71         1622 SEA SPE=ON  ABB=ON  L50 AND (L51 OR L52 OR L55)
L72          348 SEA SPE=ON  ABB=ON  L51 AND (L52 OR L55)
L73            0 SEA SPE=ON  ABB=ON  L52 AND L55
L74            3 SEA SPE=ON  ABB=ON  L72 AND L5
L75           29 SEA SPE=ON  ABB=ON  (L70 OR L71) AND L5
L76         3135 SEA SPE=ON  ABB=ON  L69 AND (L70 OR L71)
L77          633 SEA SPE=ON  ABB=ON  L70 AND L71
L78           15 SEA SPE=ON  ABB=ON  (L76 OR L77) AND L5
L79           13 SEA SPE=ON  ABB=ON  (L76 OR L77) AND L5 NOT L42
L80         3283 SEA SPE=ON  ABB=ON  L5(L)(THU OR BAC OR PAC OR PKT OR DMA)/RL
L81           59 SEA SPE=ON  ABB=ON  L80 AND L47
L82          271 SEA SPE=ON  ABB=ON  L80 AND L48
L83          111 SEA SPE=ON  ABB=ON  L80 AND L49
L84           32 SEA SPE=ON  ABB=ON  L80 AND L50
L85           12 SEA SPE=ON  ABB=ON  L80 AND L51
L86            5 SEA SPE=ON  ABB=ON  L80 AND L52
L87            1 SEA SPE=ON  ABB=ON  L80 AND L53
L88            0 SEA SPE=ON  ABB=ON  L80 AND L54
L89            0 SEA SPE=ON  ABB=ON  L80 AND L55
L90         1214 SEA SPE=ON  ABB=ON  L5 AND PATENT/DT
L91           80 SEA SPE=ON  ABB=ON  L5 AND REVIEW/DT
L92         7786 SEA SPE=ON  ABB=ON  L5 NOT L90
L93         5065 SEA SPE=ON  ABB=ON  L92 AND PY<2005
L94          452 SEA SPE=ON  ABB=ON  L90 AND (PD<20040203 OR AD<20040203 OR
                PRD<20040203)
L95         5105 SEA SPE=ON  ABB=ON  (L94 OR L93 OR L91) NOT L42
```

```
L96          19 SEA SPE=ON  ABB=ON  L95 AND L47
L97          92 SEA SPE=ON  ABB=ON  L95 AND L48
L98          53 SEA SPE=ON  ABB=ON  L95 AND L49
L99           5 SEA SPE=ON  ABB=ON  L95 AND L50
L100          2 SEA SPE=ON  ABB=ON  L95 AND L51
L101          0 SEA SPE=ON  ABB=ON  L95 AND L52
L102          0 SEA SPE=ON  ABB=ON  L95 AND L53
L103          0 SEA SPE=ON  ABB=ON  L95 AND L54
L104          0 SEA SPE=ON  ABB=ON  L95 AND L55
L105          6 SEA SPE=ON  ABB=ON  L95 AND (L50 OR L51)
L106          7 SEA SPE=ON  ABB=ON  L95 AND L47 AND (L48 OR L49)
L107         21 SEA SPE=ON  ABB=ON  L95 AND L48 AND L49
L108        266 SEA SPE=ON  ABB=ON  L5 AND (L13 OR L14 OR L15 OR L16 OR L17 OR
                L18 OR L19)
L109          9 SEA SPE=ON  ABB=ON  L108 AND L10
L110        131 SEA SPE=ON  ABB=ON  L108 AND L12
L111        111 SEA SPE=ON  ABB=ON  L108 AND L12 AND L80
L112         42 SEA SPE=ON  ABB=ON  L108 AND L12 AND L80 AND L11
L113         20 SEA SPE=ON  ABB=ON  L112 AND L95
L114         13 SEA SPE=ON  ABB=ON  (L36 OR L43 OR L45 OR L46 OR L57 OR L63 OR
                L62 OR L74 OR L79 OR L109) AND L95

     FILE 'REGISTRY' ENTERED AT 16:49:18 ON 29 JAN 2010

     FILE 'HCAPLUS' ENTERED AT 16:49:30 ON 29 JAN 2010
                D QUE NOS L24
                D IBIB ABS HITIND HITSTR L24 1-8

     FILE 'REGISTRY' ENTERED AT 16:50:08 ON 29 JAN 2010
                D STAT QUE L4

     FILE 'HCAPLUS' ENTERED AT 16:51:46 ON 29 JAN 2010
                D QUE NOS L36
                D QUE NOS L43
                D QUE NOS L109
                D QUE NOS L45
                D QUE NOS L46
                D QUE NOS L57
                D QUE NOS L63
                D QUE NOS L62
                D QUE NOS L74
                D QUE NOS L79
L115         54 SEA SPE=ON  ABB=ON  (L36 OR L43 OR L45 OR L46 OR L57 OR L63 OR
                L62 OR L74 OR L79 OR L109) NOT L24
L116         36 SEA SPE=ON  ABB=ON  L115 AND PATENT/DT
L117          1 SEA SPE=ON  ABB=ON  L115 AND REVIEW/DT
L118         18 SEA SPE=ON  ABB=ON  L115 NOT L116
L119          6 SEA SPE=ON  ABB=ON  L118 AND PY<2005
L120         10 SEA SPE=ON  ABB=ON  L116 AND (PD<20040203 OR AD<20040203 OR
                PRD<20040203)
L121         17 SEA SPE=ON  ABB=ON  (L117 OR L119 OR L120)
L122         13 SEA SPE=ON  ABB=ON  L121 NOT L5(L)ANT/RL
                D QUE NOS L105
                D QUE NOS L106
                D QUE NOS L113
L123         32 SEA SPE=ON  ABB=ON  ((L105 OR L106 OR L113) NOT L24) OR L122
                D IBIB ABS HITIND HITSTR L123 1-32

     FILE 'HOME' ENTERED AT 16:54:47 ON 29 JAN 2010
                D STAT QUE L4
```